var title_f21_2_21536="2D TTE Suprasternal notch view aorta";
var content_f21_2_21536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the suprasternal notch view showing the aorta and major branch vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 498px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHyAQADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrfD/hAeOfiB8QG1TxF4mtUsNUEEEVhqTwxqpjBxt5HX0rqP8AhSml/wDQ2eN//By3+FJ8Hv8Ake/il/2Gk/8ARQr1WgDyv/hSml/9DZ43/wDBy3+FH/ClNL/6Gzxv/wCDlv8ACvVKKAPK/wDhSml/9DZ43/8ABy3+FH/ClNL/AOhs8b/+Dlv8K9UooA8r/wCFKaX/ANDZ43/8HLf4Uf8AClNL/wChs8b/APg5b/CvVKKAPK/+FKaX/wBDZ43/APBy3+FH/ClNL/6Gzxv/AODlv8K9UooA8r/4Uppf/Q2eN/8Awct/hR/wpTS/+hs8b/8Ag5b/AAr1SigDyv8A4Uppf/Q2eN//AAct/hR/wpTS/wDobPG//g5b/CvVKKAPK/8AhSml/wDQ2eN//By3+FIPgrpZJA8WeNsj/qNN/hXpep3D2mnXM8Sh5I4yyIT95scD8TisfU/L0qzSa5ikcYT7XeREqy8gb8DqATk+ig9cVMnYpK5xv/ClNL/6Gzxv/wCDlv8ACj/hSml/9DZ43/8ABy3+FejW1tBJ5dxFPJMpwyuspZWHrwcEVeqiTyv/AIUppf8A0Nnjf/wct/hR/wAKU0v/AKGzxv8A+Dlv8K9UooA8r/4Uppf/AENnjf8A8HLf4Uf8KU0v/obPG/8A4OW/wr1SigDyv/hSml/9DZ43/wDBy3+FH/ClNL/6Gzxv/wCDlv8ACvVKKAPK/wDhSml/9DZ43/8ABy3+FH/ClNL/AOhs8b/+Dlv8K9UooA8r/wCFKaX/ANDZ43/8HLf4Uf8AClNL/wChs8b/APg5b/CvVKKAPK/+FKaX/wBDZ43/APBy3+FJ/wAKU0v/AKGzxv8A+Dlv8K9VooA8r/4Uppf/AENnjf8A8HLf4VxnxT8BJ4I0PTtX0jxP4sluf7UtICl1qryRlXkAIIwM8V9D15X+0h/yImn/APYasf8A0aKAE+D/APyPnxS/7DKf+ihXqteVfB7/AJHv4pf9hpP/AEUK9VoAw/GPivRPBuj/ANqeJb5bKx8xYvMMbvlznACoCT0PbtWxbzR3NvFPA6yQyqHR1OQykZBH4V5t8VfAerePNd0iBb61stBsre4eQyQ+e0s8i+UAYyQMKjOQ2eCelb/wp0fWfD3gTTNG8RSQTXmnqbZJYWLB4VJEZ5AwQm0Y9qAOuooooAKKKKACiiigAooooAKKKzdYeWVYLS0uBDLPKEd1ILomCxwPU7cZ7ZzSbsBFOZtYsXW1MKW7SDZK3ziRAQSQBjGSODk8c1rEBlwwBBGCOxqlo+lWej2FvZafF5VvBGsUa5JwoGByetXqaAbHGkSBI1CoOgAwBTqKKACiiigAooooAKKKKACiiigAooooAKKKKACvK/2kP+RE0/8A7DVj/wCjRXqleV/tIf8AIiaf/wBhqx/9GigBPg9/yPfxS/7DSf8AooV6rXlXwe/5Hv4pf9hpP/RQr1WgAooooAKKKKACiiigAooooAKr6heQafZyXN0+2JBk4GST2AHUk9gOTVisiOQahrs8bBTDpxXA65lZc5/BWGP94+1JsaLMKy31vHJP5lurEOsattYDnAYj8Mj8Oafa6dZ2s8s1tbRRTSnLuq4LH3q3RTQrhRRRQAUUUUAFFFFABRRSDOBkYNAC0UjuqIWdgqgZJJwBXP6nqN1dSyWWnIyMXWMTKw3Hn5yODtAHc9e3Y0m7Dsad1q2m2koiu9QtIJDn5JZlU8DJ4Jq9XNTeGrSLTLxpESW5NpJAjlf9WjLyq9+SM+presZPOsreX+/GrfmM0J9wsT0Z5x3oopiCiiigAryv9pD/AJETT/8AsNWP/o0V6pXlf7SH/Iiaf/2GrH/0aKAE+D3/ACPfxS/7DSf+ihXqteVfB7/ke/il/wBhpP8A0UK9VoAKKKKACiiigAooooAKKKKACsvTXhTWNWt1XZOZI7h8n76tGqhvp+7I/wCA1qVkX1sI/EmmX6Z3uktm4A4KsBICfoYiB/vmkxo16KKKYgopodT0YHnHXv6U6gAooooAKKKKACoLy6itIWklJOASFXlmx2A71XvtQSB1jj2tISck52oBjOSO/IwvU1Qt7Nb2L7VfoDHMvKup3Op6KQfurznb27nrSb7DSEkN1qkx2OYIYxkEqCoY5AP+0w44+6D6441NOiigi8uAMQCcux3Mx7kmkdDKVUgoqt8qr+f9DVpFWNAqAKgHAHAFJDY4gEEHoaoaBn+wtOz1+zR5/wC+RV+qmj8aTZgDGIUH6Cn1F0LdFFFMQUUUUAFeV/tIf8iJp/8A2GrH/wBGivVK8r/aQ/5ETT/+w1Y/+jRQAnwe/wCR7+KX/YaT/wBFCvVa8q+D3/I9/FL/ALDSf+ihXqtABRRRQAUUUUAFFFFABRRRQAVBdAEwjv5gI/X+manrP1MkXuk4OM3LD6/uZaTGjQqC+uBa2skxG4qPlX+8ewH1OBU9Z99cBbkDaGjt0Mz/AO9yFX6nn8hQwQ2xjkM4V2UrASX2jhpW5OPYBv19q0qhs42jt1EmPMOWfb03E5OPxNTUIGFFFQ3dylrC0jhmIGQiDLN7AdzTESsyopZyFUdST0rJvL24l3x2alSJFRSCN0nPJGfurwwyfQ47ZR2lvrryxkCMbxxlFPzAZP8AE3TjoKuW8KQIyoSXZiXkbqx9f6Cp3KSILLT1tmRpG3ugKxqPuxjAz9TkdTzzV4RncWPUj8v85ogAC8Z+pp5bBA701YG2JxGvOT/M0z5nK9vUf5/KnhOSSeTTwMUCuIoCqAOg4qtpQ26dbr6LirVV7EYtgPRmH5MaOodCxRRRTEFFFFABXlf7SH/Iiaf/ANhqx/8ARor1SvK/2kP+RE0//sNWP/o0UAJ8Hv8Ake/il/2Gk/8ARQr1WvKvg9/yPfxS/wCw0n/ooV6rQAUUUUAFFFFABRRRQAUUUUAFZevy/Z1sLggHy7yJef8ApofK/wDalalc38QJJIvD0ZhOJDqNgqn3N5CP60nsNbnSVkweRO8OFDG5ka5Jx95VwFb/ANF4+lWdYZxp8iRf6yUrCp9NxC5/DOfwoskJurmUgKi7YYgP7qjk/wDfRI/AUnuNaIu0U12VF3OwUepOKy7u9llRxbhwoI2hCN83f5c9AfmGfbjtTbsJK5Zur4RzLBDtaU9WbhE5xyfXOOOpqlbQNdBri4G2N+rYO+VOoGP4V5YbeuAOeTU1pYmF4zI5cRjbFEPux8Yye7H3P4YzWgFO7J6kdPSl1HohgQCMIihY1HygcdOn8ql2gg56HtQAB1606nYTY3k5HQetKBSbjuwBx606gQUE4pCewpAMH1pgOHNV7E5gbP8Az1k/9DarFQWYxC3/AF0k/wDQzSGT0UUUxBRRRQAV5X+0h/yImn/9hqx/9GivVK8r/aQ/5ETT/wDsNWP/AKNFACfB7/ke/il/2Gk/9FCvVa8q+D3/ACPfxS/7DSf+ihXqtABRRRQAUUUUAFFFFABRRRQAVyvxGhludG0+2t0LyS6tYHA/upcxyMfwVGP4V1VZuqxPJe6OV5WO7Lv9PJlA/UikxozNe8X+H9J1a1sNT1ixtbstvMUsoUhdjEE+nSsjwt8RtI1ua6trCC/kaOaVEk8jCXBDE4jJPzcHOeBjvXjnx51C+0u78X3GnywfarKWzvIGeFZM20gMMq8g/dmRfpuxXjnwl8Z38vxi0DUNbv5GSe4FtKxbaqpIvl4AHAHzDpUu+9wT6NH3RvnvZ41IywLPkcxRY4HP8TZ/DrV61jWNmEQLMTlpW6t3/rVmCJIIUihQJGgCqo6ACngAdBTsFxqIFHr7mlzyAKXnPtSAVQhcU2Q7ULHJCjOB1OKdRQBCm8vv3YjZR8hHK9ef5flUhNL0GBSj3pDAdKKDQKYgqK2/1bf77/8AoRqWorc8SD0c0gJaKKKYBRRRQAV5X+0h/wAiJp//AGGrH/0aK9Uryv8AaQ/5ETT/APsNWP8A6NFACfB7/ke/il/2Gk/9FCvVa8q+D3/I9/FL/sNJ/wCihXqtABRRRQAUUUUAFFFFABRRUFzcpBhcF5W+7GvVuQM/Tkc0XAkkkSJdzsFHvWTe3D3JkQrItvsO1IuJ5CQRkdNo9Dwc+lO3T3EsOcG5AYsOsUJwPpuI6fienSrscCW7PIoLzyY3OfvMOcD8MnFTuitjzP4l+EIdXuNNhu9kcep2t1ojIuAqB08+I56kiS3Tr3Y+tfBbpPp+oPHIGhubeUqwPBR1P8wRX6JfGH7TB4DuNUtYzJdaRcQamqLzkQyq7j/vgOK+HPjdaQ2fxY8TC1Ia3muzdRsOjLKBKCPb5+KfUR9/+BtZPiHwboesPt8y+sop329A7ICwH0Oa3K8k/ZZ1oax8HdLjLAy6fJLZvg+jbl/8dZa9boWwgoqncalaW9x9nkmU3GwyeSvzPtHfA5qKK7vLiWEw2Xl27cs8z4YDH90d8+9F0x2drmjTWdVUs7BVHJJOMVSW2vXeQzXu1STtWKMDA+pyc1HFott5e26aW85zm5cv+QPSjUNCzDfWs7H7PdQy44IjcNj8qLjULS2bFzcRw8bsyHaMfU8VJb2sFsu23hjjX0VQKW4t4bmF4riJJY3GGVxkEU+pOth6lWAdSCCMgg8EU6saXTbnT7eQ6FIoK8pazEmLgY2jugPt09DSR65ClhayauyaXcSHZJHK3yhx1UOQAR6HuPSle25Vr7G1Ve1bMl0P7suP/HVP9alidJI1eJ1dGGVZTkEeoNVrH/j61D/ruP8A0UlAFyiiimIKKKKACvK/2kP+RE0//sNWP/o0V6pXlf7SH/Iiaf8A9hqx/wDRooAT4Pf8j38Uv+w0n/ooV6rXlXwe/wCR7+KX/YaT/wBFCvVaACiiigAooqtqN9babZyXd9MsNvGPmdvc4A9SSSAAOTQA+6uYLSEzXU0cMQIBeRgoyTgDJ7kkCsu7v9RuJvJ0i0VUKbhd3IIjBz93ZkMT+X41HYRm/todT1hJIiSZIrSXAEKk/LuUdXwAT1wSQKuXMskomEqslvtOxEP72TGc/QcDH64qXqtSkikk+ox24+0X9qZFcCWYRbYkAIyOT16jrwfpirVvbu8kxQvFGzZeZvvy8L0/ujjH4dqsxWolRDOgCBtyw8bV5OM+p6H61aGTncOOwpu73C66EVtEkEKQwDbEihV/CpgACTS0h6gfrTEQ3lvFeWk9rOm+GZGjkU91IwR+tfn18cbK2sPEWn2cc0j6lZWSWF9E6kFHgJijPuGiWNhj1r7+ubwm5W0tBvmyPMbGViXrz7+g9x2ry743/Byz8fWIvdP8uDxJEFVbhztWZc8h8e3Q44xjpSSuxPQ86/Yrj1caX4maIIumNJCEaRSQZxndj/gOM/8AAa+lLnT5bpds97OIyuGSIhM++RyPzrnPhD4NXwJ4EsNFZke6UtNcuhyHlY5OPYDA/CuzosgTZU03TrXTbaOCzhWNIxtHc/iepq3RRTAKKKKACiiigAqOeCK4jMc8aSIeCrDIqSigDlI/A2m2GpPqOgtLpV8/DvAco6/3WQ5XH4ZHan6NPrtnqlzBrVnHcRSgSJe2YwnCgYZGOQeO2R9K6iik0F7FGXU7eGMvKJ1UHHELN+gBpbbVbC6uTbQXkD3QXc0AceYo9SnUfiKu1SvNKsrti81uhlK7fMAw4Hsw5pgvMu0VnhJtPEQV5bi34QhvmdB03Z6n3zk1ejdZEV0OVYZBpJgOryv9pD/kRNP/AOw1Y/8Ao0V6pXlf7SH/ACImn/8AYasf/RopgJ8Hv+R7+KX/AGGk/wDRQr1WvKvg9/yPfxS/7DSf+ihXqtABRRRQAVy98Tq3iNYJ4lfT9PKzRxkZNxcDPP8Aux5Xn+8f9mt6a5zxCRhT88jD5VAxnn1x/wDXqtp9qsHmJaqyK0jSyTsBmRmOWx7Z/wDrVL12KWm4u6SV4ydr3Az8mcpE2Oc+pAIH+FW4LZY3MrnfOyhWkPUj09hT4YlgiEcY4Hqck+5Pc1JTSE2FFFFMQVWu5WUxwQMFmlztJGdoHVsfl+JFTSyLEjO5wo61S0u3cvLfXCstzcADa3/LNBnan1GST7k+1Ia7lq1t0t4yqZJZi7MerEnJNTVR1TVrLSxF9uuI4PNOEMhwO2eeg6isfXdaRrqysbK7MM0jCSd1Tc0MO1m3EHpuK7B6luM4OFzJaBZvU6Yd6KwdM1xRp1tPrDLaSXD7UR/4WwTsJ6Z+V8fQevO6CD0NNO4haKKZLIkMTyyuqRoCzOxwFA6kntTBa6IfSBgc4IODjis3T9atNS+0HTzJcJCMiREOyTrwjHhunUcVzVha69p8t19piklt711vJBaEB4nIIeNSzeoQ5GBw3rWbqWtbU66eEcuZTfK1bR6X/pHcUVU0k3J023N9xclAXBxkH3xxmrdWnc5pR5ZOPYKKKKZIUUUUAFFFFABVaGN4Z3UcwPlwMfdbPI+hzn86s0E4x70AFeV/tIf8iJp//Yasf/Ror1SvK/2kP+RE0/8A7DVj/wCjRQAnwe/5Hv4pf9hpP/RQr1WvKvg9/wAj38Uv+w0n/ooV6dPcJFlF+ebbuEank/4fWgCSWRIo2eRgqjqTVR2lmeQS5it+ibSd746/QU0tvkUtia4QjMQb5Yye599p7/1qxDbBZBLKfMnxjd2GcZAHYcCluVsRwwmSNBKgSI/dhxwBz196uUEDP0ooE3cKKKKYgooqC9maC3Z413ynhE/vMegoAUgyTAYHlpyfdu1TVFbRtHAiyNvfqzAYyTyePrSXl1DZ27T3MgjiUgFj6k4AHqSSAB3JxS2Gcn8UGW10ay1N4llGn3sM5Rl3BkZhDIMd/wB3K5HuBWZoeg2um67qkFgUtoZblJX3sWcqqYU85yAwOBwoHPOcVcgubvxX4jWNIXi0XT5N80rEfvp0f5YQPRSAWP8AeUDsc2fFOg+GL6eLUtbs7Wa4RxA0jttXJxkNzzjaODUpc2rHtoZclrPqOow3caINB09VSyVjvM8wAPm/7o2IgPcs56Yqxa313N46SdC40O3tPstu+4/vpNytKduOcAIM54Kvx3rQHiCa3nnt7TRjc2UAVYWtZUYMoHZc8elPXVtI1tbfTUuJrG9kVmhjKmKQEKQ3lkjBIBOdpOM81EZKXw9Cmmnr1LureJLSzaa3s1bUdTRciytiGfJ6bj0Qe5/WqK6Fd+ILWJ/FTjyi4l/s2LiJcdFc9X9wfl9qTQNNg8KS/YYkY2km6XzymTnC53v1JJycnsPaurByOKFBz+P7un/BOl4iFHTDqz/me/y7fn5jIYo4IUihRY40G1VUYAHoKfRRWxxN31YUUUUAFFFFABRRRQAUUUUAFFFFABXlf7SH/Iiaf/2GrH/0aK9Uryv9pD/kRNP/AOw1Y/8Ao0UAJ8Hv+R7+KX/YaT/0UK9DWCSOWV0uGXfJhsopK56YOPcda88+D3/I9/FL/sNJ/wCihXplwpKzIhxI67kPuP8ADikxxJYYkhTCfUk8kn3qSmo29FYDG4ZwadTEA70UUUAFFFFABVZWM10cA+VF0OOrcg/l/Wlv3mS3ItgDO5CJnoCe/wCAyce1SwRiGJUUkgdyck+5pD2H1xnxc1mXw/4G1HVbVFe5s4zPErgFd/CoSD1wzq34V2dYHjjSLbXPDN9pt83l213E1u8mM+XuGA2PZtp/CiWwLcpaFZQ+HvB8cNqPs8rlBLJI24mVyql2Pqcg/WrMXh/Tbd0e4MkzRjbGkjlsbcnIHc85J9areD5JdU8MW1r4gij+3srpdIv3WmjkKSEf8CUEexFaMt6UkS0vcJcsfMVscMgdQ3Pvux+NTd7lWTVjn7tNAvbuKzWyCI6fajOj+W2FIKtgHcQTjP8A9esLx9pmp6xBNawz6Y6W6tdQeUZFnj8sEjJDfKW5U+uT6Vy3hHwxq8+qajqt1qMTeKYC1sbZpCF3gbiWPeN12EKBtAx0PFejajr0Gi6Fd3mpaNLY3EiMzyKokikfaxUbl5wcAZYAc1nKWjU3/XZnXho1H71KKb2s9X6pb/cVdFvvFuueHNL1ISaMI7pI51WSOQMpbHynDc4zj3rWtR4zNtEUk0LbsGP3UvTH+9UngRVXwLokLbJEjgiVXiYMr7FB3e3K8+hrp7aPyreKPOdiBfyFNU9Fq/vG8Y46OnH/AMBOZ2+NP+euhf8AfqX/AOKq14it9RufDtvApjN801sJSgbZ/rE38Zztxnv0roKKr2as1d6mf1x88ZqMVyu+iscrJaXbeHdMt7jKyrKRPwzquFfoByVzjHtitjw5HNDolnFclmljTYWbOWwSAeeRkYODWlRTjCzuTVxLqQ5Wut/z/wAwoooqzmCiiigAooooAKKKKACvK/2kP+RE0/8A7DVj/wCjRXqleV/tIf8AIiaf/wBhqx/9GigBPg9/yPfxS/7DSf8AooV6mfvqce2a8s+D3/I9/FL/ALDSf+ihXqb9AfQ0AhIsbAB2yPyOKfUcZG+ReeDn8x/+upKENhRRRQIKKKgvGkEQWHAlkYICe3qfwAJpMEQwCS4vpJnx5EXyRKD1bkMx/kPofWrtMijWKNY0GFUYAp9CBhTXUMu1gCp4INOopgcMyJ4a8bxTiRYdM1X9zOHPC3WAImB/20UqfdB3Na2qahcjW1sn0eWWEKXhu1cEbsDcCMcDDY9/StDxBotnr2nPZahGHgfG4EA5wQe/uAc9qn0yxWxg8tXdwDxvcsR2HJJPQCocXsik1uSi1h3BjGu/IJOO/rUOsabbaxpk+n3yF7WddkiA43LnkfQ9Ku0VZJz0vhPT0E7aYZtMnmOWktH2c88lfunqeo71BaTeJdKlaLUIItXslHyXFviO4PX7yHCnsMgiuopMnPTis3TV7x0OtYybTjVSmvPf5Pf8beRjab4m0u/v2sEnMOoKMta3CmOTv0B+90PIzW0Tis7WNF07WYPJ1K0inXOQWXkHnkHqOpqXTbBNPhaKKWeSPPyiWQvsGOgJ7U4860kRV9g1zU7p9nr9z0+63zYlnqtje28s9rcxyxRDLsp+6MZ5/Dmkt9WsLiBZ4buJomkWENux87Ywv1ORj6iue8O+HbzTNJv7SYxO9xZxxrJvJKsIyhTp90HkH/bPpTbzwlJPpkNlBObUFBLNMpDubhERYyNwPA2k+uQKjnna9jreHwiqOPtNLqz8rXf+R2NFQWJuDZW5vAguvLXzQhyofHzYPpnNJe3K2iJJIP3ZkVGb+7uOAfzIrW+lzzWrOxYooopiCiiigAooooAK8r/aQ/5ETT/+w1Y/+jRXqleV/tIf8iJp/wD2GrH/ANGigBPg9/yPfxS/7DSf+ihXqjDKkeoryv4Pf8j38Uv+w0n/AKKFeq0ARqCJFJ6lcH8P8mpKjPVD6Nz+v+IqSkhsKKDRTEFVU3TXrPjEUI2L/tMep/Dp+Jqa5lMMDyBS5A4UdWPYUWyNHAiuQXA+Yju3c/nSH0uSUUUUxBQKKAMDAoAKKKKACiiigAooooAKKKKACiiigAqO4hjuIJIZ0DxSKVZT0IPUVJRQBDaBlhwzlyGYbj1wGOP0wM1NUNqTscN94SPn/vokfoRU1JDe4UUUUxBRRRQAV5X+0h/yImn/APYasf8A0aK9Uryv9pD/AJETT/8AsNWP/o0UAJ8Hv+R7+KX/AGGk/wDRQr1WvKvg9/yPfxS/7DSf+ihXqtAEMudr4zkYfjqcf/qqbqOKQ/eFCfdGO3FIfQWkzmloJwOeBTEQStvuI4hnI/eN9O36/wAqnqC1IeMzA5835gf9nt+lT0kN9gooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigCCIqt1PH/Edsn4EY/wDZanqCb5Z4X9yhPsR/iBU9JDYUUUUxBRRRQAV5X+0h/wAiJp//AGGrH/0aK9Uryv8AaQ/5ETT/APsNWP8A6NFACfB7/ke/il/2Gk/9FCvVa8q+D3/I9/FL/sNJ/wCihXqtACN2+tA7+xoIyMUDrn1FAxar3sbTRrEDhXcB/depH44x+NWKiDFrpk28IgOfqT/hSYIlHHSiiimIKKKKACiiigAooooAKKjG8ytnAQfdA7/WnNkDIycdh3oAdRVZppAxCqrEnAByPenKJnUb2VDuB+TnI9OaVx2J6KKKYgooooAKKKKAI7iMywsqna3VW9COQfzpYn8yNWxgnqPQ+lPrO0+5uHv9RguLUwwxSj7NJuyJkKKWPthyw/CkM0aKKKYgoooBzQAV5X+0h/yImn/9hqx/9GivVK8r/aQ/5ETT/wDsNWP/AKNFACfB7/ke/il/2Gk/9FCvVa8q+D3/ACPfxS/7DSf+ihXqtABSelLTeeee/FADqhWVftkkWPmCK/1ySP6VNVeSL/ToZweiNGR65wR+W0/nSY0WKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACoZixj3RKGdTwDx7H9M1NSAAZx35oAEYOispyrDIPtS0igKMAYFLQAUUUUAFeV/tIf8AIiaf/wBhqx/9GivVK8r/AGkP+RE0/wD7DVj/AOjRQBzmi65rXgjx547aTwT4m1W21PUhcQXFhbBoyoQDqSM8+ldH/wALY1T/AKJn43/8A1/+Krm/j18aNY+HPi6z0nS9O0+6hnsUui9yHLbjJIuBtYcYQfnXmn/DVHinGf7D0XH0l/8Ai6BpNnt//C2NU/6Jn43/APANf/iqT/hbGp5z/wAKz8b/APgGn/xVeHH9qrxT/wBAPRM/SX/4ukH7VfinP/ID0T8pf/i6LA4tHuf/AAtjVP8Aomfjf/wDX/4qkPxY1Mkf8Wz8b8f9Oa//ABVeGn9qvxUCR/YWice0v/xdSRftUeKpDj+w9EH4S/8AxdDCx7f/AMLY1T/omfjf/wAA1/8AiqP+Fsap/wBEz8b/APgGv/xVeK/8NSeJ/wDoB6N+Uv8A8XTh+1H4nIyND0b/AMi//FUk7hY9o/4Wxqn/AETPxv8A+Aa//FUf8LY1T/omfjf/AMA1/wDiq8YP7UXibcB/Ymi88dJf/i6H/ai8TKcf2Jo2fpL/APF0wsez/wDC2NU/6Jn43/8AANf/AIqj/hbGqf8ARM/G/wD4Br/8VXiv/DUnifP/ACBNF/KX/wCLo/4ak8Tj/mCaL+Uv/wAXSuI9q/4Wxqn/AETPxv8A+Aa//FUf8LY1T/omfjf/AMA1/wDiq8V/4ak8UZP/ABJNFx24l/8Ai6kj/af8UOM/2JouO/Ev/wAXTA9m/wCFsap/0TPxv/4Br/8AFUf8LY1T/omfjf8A8A1/+KrzjSP2htfuZ4hdaVpKwsfmKeYCBn3auqHx1iNzFGbSABiMnJ4/WlzIVzd/4Wxqn/RM/G//AIBr/wDFUf8AC2NU/wCiZ+N//ANf/iqqeI/ipfWeni60q2sZhsziQOefwIrzG4/aU8TQSsjaNo+R7Sf/ABdF0Fz1n/hbGqf9Ez8b/wDgGv8A8VR/wtjVP+iZ+N//AADX/wCKrxuX9p7xMmMaJo23pkiX/wCLpD+0/wCJgMnRNGHp/rf/AIumM9l/4Wxqn/RM/G//AIBr/wDFUf8AC2NU/wCiZ+N//ANf/iq8a/4af8T+WGOiaMPwl/8Ai6lX9pvxMVBOjaNg+0v/AMXQ9Aeh7B/wtjVP+iZ+N/8AwDX/AOKo/wCFsap/0TPxv/4Br/8AFV5In7S3iVumi6R+Un/xdSR/tKeInIU6NpIPf/Wf/FUrger/APC2NU/6Jn43/wDANf8A4qj/AIWxqn/RM/G//gGv/wAVXlUn7SmvR/f0jSR/38/+KpU/aT8QOPl0jSemekn/AMVRdAeqf8LY1T/omfjf/wAA1/8AiqP+Fsap/wBEz8b/APgGv/xVM+EHxOvfHVxcQ3VnawtEobMO7v8AUmuo1jxnHoepPBqsYWD+GRM/rQ3bUVzmv+Fsap/0TPxv/wCAa/8AxVH/AAtjVP8Aomfjf/wDX/4qu80TxJpWtkrp14kzgZKjORWwTgEnoKE7jPK/+Fsap/0TPxv/AOAa/wDxVcj8S/E+u+OdH0/SLP4f+LLJxqVrcNNdWgEaqkgJyQSelbvjH4uXmh3zwW9rZSgMVBff/Q1leA/jXq3iX4i6H4fm0/T47TUDOHlj3712Qu4xlsclQPpmhSTA8u/bKI/4Wjpak9dGi/8AR09fPzTsGbpXv/7ZjbfinpZ4/wCQNF/6Pnr57l/1r/U0WKeiHGVjjIHFN3k9hTKKYuZj9/sKesxUHAHNQ0UBdln7U4/hFXE44PJrKrREgLHr06UnpsCLHmDqOCR+VMPQ881GsgZsAE013IYYPHXpQ3cdmyT/ABpenfimqdwzjGad0PzA4NSSKhAb2+lelfC34e3XjG5VbaaJAOu72rzRSRjODx+ddn4J8Y6l4auA+nyiPnJHNVfQHex7PrngO28J2CpdeXLMg6rxg/nXm/iBYHQvb/LJ2GOlJ4i8farrML/aZTIW6nP/ANeuNl1K4MjMZCAfU1GrJSsax1G+WPyGmcoeMZrOvLceUXYnefUelQzXsjkMCA/c+/rUP2iWduTk5wOadhqxnXKFX5PB7U6NPOAVBh+n1rQuNNu2tzMYv3Q5z7UujRn+0LbI/wCWikj8aq40zRTwVr6xCVtKu2TG4ARk5GOuKNO8M6vqAMlrp1zJHGcMVQ8eor6NDWz/ABVsYP7fuYpWjiZbEZCE+UMDr3qt4h1mG306ODVYb7Rw1/cPBdWLAIx8xsqwpNkt3sfPdtpN7PdCxjtp3uw20whDvBHUY61XkglhuZEeNonQlWVhgqe4x2r6H0HSL2x8ca14guruzzHZxtDcshRGeRVwSP72Ov1rz/48aR9g8RprFuyPaaxCLhHi+7vAAfH48/jSuNM8zKMZcOAwHYjrUP8AqmOGyQeR2IqMufU5ximbjJuHTtmgLnqnwh8fjwVfXE5i81JUCFQcGtL4h/E5/E8waOIoozwDXjgdhjnpSpIefmPpRa4ro7DS/FF9pt0Jra4ljfsVbFdndfGDxFfWoga8lAHHUDPFeRRvuULHyw6e9SGSTHGE4GMc0WKsdDf6nPezO9xIXDtncxFdP8CmD/G/wiR2a7H/AJKzV5+hJRd/X0rvfgH/AMlr8J+m+6/9JZqEJMs/tpnHxT0o9v7Gi/8AR89fPx6mvoH9tT/kqWl4/wCgNF/6PnrwAAHOTWhWr0GV9P8A7OHiC10n4ZQQyXlqj/8ACUGS6il1WGz2WptkVpZFfmWMH/lmMFiBz8pr5kKqADkmjYOMZ59aLBYv+Jkto/EmqpYXCXVot3KIZ0TYsqbztcL2BGDjtmsyn7ef50oQd80rBysjq6gVVznLZxVYICwA+lSE7etFioonRsuP4Qo/z/OpCucg4weRVf7w64yP5Uudo6HcOPwpWG12JgGwo3AkHB57U7ILYB6DmoHRlY+gNKqt8vXDelKwmizGqkjJwTV9QDnaB68VnYHJzjBxW34OgjuvEmlwTqGiluY42B7qWAoSvoZvYrK7I2VOfQU1iXVt/qc19P3fw68M3mo+ObI20Vo6S28FlKBgQO6rg/QsQD9a8y8W+B49A+Gn2i/tvK1q31Z7aZh/c2ggfQ8EUm7aiV2eVAMAwHzD29amhEkKq2M5JA96rwTCJgV69ea27TUoJI1haBS54B7iqaZVmb/hK11HXnNpCipbAZeWTiNBjuf6V1VzZW/h7R5U0DTjdag+UfUXTgDPRF5H41o/DHwJqevr5ccskOnSsN6hiFOPUV9PeG/C1jo+jRWLQxTBRhiyg5osT1Pg6817WY9eXVJrqYahEVKzYG4bRtH6Vq2PxF8RWzzeZfeessjSskqqwDsclgCODXrH7Q/gOHT7qTUdPjSCKcg/KMBfX9a4/wCFHhizvfD2uahc6R/bF3bNGscA9GPJ/CpWoNHGav4213VbO4t7y+keG4lErKMYyOB+AFUNR1/Ub/SrPTbq5kls7UkwxHkIT1xXtms/DLTdai0BrexfQ9Svp3jltWbOIlVm3gdjx+tcZreneCD/AGhpdj9rtb603LBdyvuSVlOCCPfnFGgl2PLjkHknBP5VFFL5RBXlsda9futK8F+FxZ6b4hs7u6vprdJbqeN8CLeNw2j2zXluvw2drql3DpUpns1kYW8rDlk7E+9Un0KizOd8yArkD+dOSbl8rz60xVznd09KVMZwenrVWLsiUSsH/wBnmpUlLYznj1qFihQgsOmKIipGSTkjGfapdtyXsaWWjVXGWzzgn/PvXov7P4x8afCnOcvdH/yVmrzMHIByRx6+lejfs7k/8Lq8LZOcPc/h/ok1JIDR/bT/AOSp6WP+oLF/6PnrwHoDmvff21P+Sp6X2/4k0X/o+evAc5781QbBnnmjJ70DAo7elArgfyo55NFJ1FCHcUU4fd/GkX3pACelUNaFiFQWxnApyNsJyM/41Ar4xjrilDZFJo00ZcDZGTgj0HNPUEsFA59K6T4b6XHqGp7rq2aa2RhuIGcVseM9O0+01IfYFKjqAV6Goehm97HG3enzWscbzL8rjPSpfD1//Zms2N8y71gnSUpnqFYHH6UajqNzOpimbcq8Cs4HuMdcUbC9T2rxL8W7XVIPF6Q2UsMusyQSRMH5h8vb/wDE1m+Mviivib4d6bol3byf2lbzeZNc5GJgBgE++MD8K8oLcEnqKmtIGuZ1RMZJosgVkCsC+MZB/nXSeE2t31OCKaFD5jhQxPA5/lVO4sILeIh2xcD+EV6R8EPAdz4m1dLjbGLaJssXp77CbPqz4Y2MVl4TtVj2EnJJWtjXtcs9EtjNeNgAcAEc1R03RhoOkyeTIcxoWIBOCcV82fErxve32s3FmSXKuVA3cVMpW0BaI7Px/q48eWs8UMgtbS3OXnlHyKB2HqeelePr4sg8N6Fr+kaU0zNcyxCG5B2nCnLfnzXUeD9F8Q+Ib6wsboMtgvIj3DafcjPvXpHxE+DuknwvJcWUax3kSgk9AT3o5bJiTuzynRvjBHaab4bF1bTXGo6VcSO8jN/rYmDArn8R+VZs+teCrbUNS1m2+03c13HKIbCWEBYWc9d2e2TivO7jSrj+2V09NqytKIgSehJwP51NqXhnUdP8WS+HyBPfxzLF8nRmOCMfnTSuOyW53moeIvCHiC603VdaN7b31tDHDdQRxh1uNgwDnPHAFeceNdZtdV8S399p9t9ls55MxxKPuLgAD9P1rtn+Gtq2qPox8Q2q68iktAY2CbgMlN3rVGH4cw2Wi2Oo+JNZg01b7d5ERRnYhTgscds0XBWPO1k3Scfe6fWlE7EDg5zitTxdoEnh7WJbI3EVyFUOk0XKupGQR6fSsVVO7lgPY0XNEkSgNyCQeetOQ+/45pjDcuMgH270qDJIwSPrQiS0s52le+OSTXpn7OLE/G3wsecFrnr7Ws1eWjBAAr0/9mw5+NvhYZzzckD0/wBFmqrBY2f21f8Akqelf9gWL/0fPXgLHOK9+/bV/wCSp6V/2Bov/R89eAUCCiiigAo5oooAd2oppo5oEP8Ap9adGCzBQOTxgVGMnp2ro/DGg3WpI9zamM+UcFSMk8UDT5Tq/h1q58NFpXbdE55XHOKk8W+JYdauyYIVB6e+c1yl3bt5rJJJsYclRnBrR0K2htNQhmncfLICVPOeah+YtNz0/wCGPghPEFrcI+nxzSdmdSMcfSub8cfCrW9Evyv2JjE3KvGjEfyr65+Fg0+Xw/HdWCxhpAA20Yrspo45FxMiMo/vDNXoJJnw/wCGPgn4g1oxOIRDE5+9IrAD9KveLPhbeeDbQSzTQGTbux0zX1vq/inQ9Dhc3l7DEEGdgr5Y+N/xDg8RarILCT/REAUZzUymnoirM8am81r0GVznIBJIr6w/ZnvdOttHkh8xUlYnliADXyZPdxs/mD64P9a3dK8ZXun2Rt7Z2VcHDA8j9aHfoDTZ9kfF7x1Y6D4euYIJ1e7lT5fLYHA/Ovk7R9bZ/ETTyRm4md+nBrm77xDdX84NxLJJnA+dia9U+Bvg/wD4SPWUlK7UALliM4ApKLbuwbsj6N+F1k7aXDfXSBJGQBV29B61l/FbXb1dGntlt2gUymPcWBDAHhs+4wcf4V6PptoljYw28f3Y1C5rxX4yeILd9ZjspsvbRODIEONw68fjTnbYSvY8csPB10dXGr6hOltYQyrI0xGdzZ4C56+/pXVeKfDl3pvxHuvGcdzpk+mwTrd7Fuh5joEXOB6+2a6zwpZ2XjlXsLjMcJU+VCv3Y1HTj1968r+M3w9vPCM7ulzJLaSH5OT0xS1Wwlq9Sxqfh/R9Q8U3fiq7121/sO4le78lX/0kBufL2+uTjrUes22nfEPQtD/sfVLWwm0qFrSWHUH2ZXcSjKecnHWvNPBuhT+KPEtjo0M6xSXL7Az5wOCTT9L8MXuoeMT4ctJFN2blrYPnAJBIz9OKOV7DaW7YvxFXSLbWY7bQpHlit4VimlPIeUDlhz0rjixGGwBivSNa8A2qWOqTaVrlve3GnAm4tyhRsA4JGTzg1DoHw31LWPBGoeIoWQpbAssBHzyKv3mH0yPzpxaKTUUcAJjtBwOKQMeucnIolKLxjFRM+CCOPpVJFqxcJ2jJOBjpXp37NH/JcfC+QQc3PB/69Zq8oDNIcFhj3r1P9maRm+OnhhWx8puR/wCSstKxLjY6L9tX/kqelf8AYGi/9Hz14DXv37av/JU9K/7A0X/o+evAKYgoFJRQIWikooAWiijtQMVevPSvTPBF3Yz2hjtX+yXieoyH/GvM6nsbl7S5SSMkEEH60mrisdD4muH/ALQYPhXBPI7ms1tVdiokAbacZ6VNr+pw6gyPGhVgOfesMmkkM9b8E/FO88PApHPLsJBChuBWl4s+OmvauWS2uZoIcYwp6/jXiYb60oJ6nmk4JvUFY6HVvE+o6jIz3NzLIx67mrGku3ckFmOT61XJB56UdqqyQN22JBM3Qn9auaPbyX19BBHyXYL+dZ2QT0q5pl69lew3EXDRsCKeg76WPqLwL+zxHf6TbX2qXqh5RuKKp6V7p4I8LQeFYEs7O3QIq4Mg718y+HP2i9T0vTYLSWBZPLG3cea73w5+0baXKs+pW/l8HGDUup0sRy9Wz1r4oXNxZ+HJZoLloTnGF6mvjfxLdanPrU087Syx7ie9db8Rvi5ea/fOYVZbNT8qZwCK5zQ0uvEQkma5jiiYfd9Klau9hvQ9m+BOqpaQFktWM5TbkmmfHzxAuq6aNPFuTcbhggZwfb866X4O6Amk6Mbq5VnOzO9u/pXjXxN8fTad4+uJtNjgdomZFEibgCRjOPUdqcuiJiVvAfhuLwd4r8Oarr2oQW91NOrra90RgcmQ/wAP0xSa74Rj0nxneeILvX7FdNkvnkRrKfdPGGY7SF9s+tSah8OdV8U+FP8AhKTe+fPIPMkBJJP+cV4hqImtbmSKRzlWweTim7lJJ3Poq4uIbPQNWbxzqGkanaSQMlpLaEee0p+6SBj8eTVqx+Jvhnwnd+H9ANh9sgtLRIJ7qOUBCZVHmZXv2r5feZ24LNj0JpGkZhyxyKVn3CyNnxjbQWXiXU7eylWa2juXWJ06Mm47SPwrEHJzn86TLHnJNLVp2Q7jw5UZ/CvUv2Xju+OfhnPrdf8ApLNXlQ7V6p+y9/yXXwx/28/+ks1O4czZ1P7av/JU9K/7AsX/AKPnrwDFe/8A7a3/ACVPSv8AsCxf+j568ApCEpaSigAooooAWikpaACiijpQMduyMEZ9KTPHSkooEFehfCf4eSeO5b3zL1bC0tQi+cy53SyMFRfxJFee1694P+Jtr4L+HNlpWmWNpe6jc3j3d4bmPcE2kCID3G3P40m7BZvYx9E+HEmfEd34huGs9N8PsFuzGm6R2LYVUB9Tjn0pbjwfoes+FdY1zwpf3AOkoklzZXiDcULBd6sPc9MV3Gu/E3w/4kTWbS/BtbfxNZQPcyRJ/wAel5EcbiO6kKOnrXJ/2v4d8IeC/EOk6VfPq+razEsDXCpsihiDBiMHktxS5ugWPLcY+lGecikzk80VQWF3H1qeCYpzuPHSolCkHcSOOKZQMvS6hPINrucYxXbfC+9jstYhlvG3W65yCa88q7YS4fmQxoAc4NJoW6sfcbfEHTh4Wjgs0wzRYGCMCvkb4g3SzeJ7udDuLSZ+uRVD+1b+OIrDdSvEgG35zgisC9uJZp2eQsWz3qUtbsFoen+GPiJqlppseltO8do2EYA9vpXK+O9KS2ulubebzY5fnz6ZrKsLOaeyknGQuM5P9K9H+HGkWuv6dNY6ywSJVyj45z9adrA3bU8eo7VueLdBl0LU5ISGMG4+W5H3h61h1QCjjqKAdoYYHIpKKACvVf2XP+S6+Gf+3r/0llryqvVP2XP+S7eGf+3r/wBJZaAOr/bV/wCSp6V/2Bov/R89eAV7/wDtrf8AJU9K/wCwLF/6Pnr5/oAKKKKAClHPcCkp207C3GAcdf8APpQA2nxkK6kgEA9DTKWgDvdGi0HVdNMMsKw3KgkMSBnjjvXG6nbC1u3jBBUcjBzVdXK/dJB9qazFySxyT3NAJDaWkpaAJZXRlG1cN0PvUVFFABRT0jdyAqk/QVetNF1C7kCQWszsemEJoAzqK7jTfhj4qv4xJBo1yyE8ZAGf1rO1zwP4g0eVlvtLuYuem3OPxFPlYlJM5iirr6XfKDm1mwP9g1VkjeM4kRlI7EUrDI6UHFKQcnjFGCOooAsrezBAqnCgYwKryMWYk9TzSdh0pKALsOo3CWv2ZX/deld74R1ACzQSP5UK457k+lea1qaOGkmCM5VBz14pPYDv9f1SLxTA1rNLHAtuu5HfHPtXl0q7JGXOcEjI71q6pMi3HlRNu2H73rVx9IbUrL7RZR5ZFyyjmhaBsc5RSspVirDBHBFJTAOleqfsuf8AJdvDP/b1/wCksteV16p+y5/yXbwz/wBvX/pLLQB1f7a3/JU9K/7A0X/o+evn+voD9tb/AJKnpX/YFi/9Hz18/wBABRRRQAUUUUAFFFFABS0lFAC0lLSqQDyM0ACgk4AzXc+EfhxrPiBYZbaHEMjYyareA9ZttMuw11paXaEjJJ6Cvp3wF420a4MMaaebOPIHUYHv0oukTJy6Efwu+C8NnFBLrVnA5DFjxXqfifQtN0jw9v02GHT5BPBEJ0QZjDzIrH8mNdLpF/Z3NqjWsyMuOmeaTXLWK/08QySqiCaKUkjP3JFfH47cUN9gUThbjULrRtbsrSy1o6mZo5pJYZEX92iRMwfIH94KKzPDmtXOoeH9D1a81f7VcXhhD2klqFiO9gCN23gAEnOe1dF4stbbVNRsLq1YRS2XnAsq/wCsWSNkKnHbkH8K57RrG9TwlbeGL/U7BbKGBLdpVgZZSgPUHdgHjris9bjurWPRZPDOjybidOtsn/YFfPHxw8GwJeSSQaQojBx5iKcdOOgr6LGuaeu1FukLYwOvNY3ibztasJba3ij8sjPmNzxVtt7Csj4U1jRoIp958lRkbkLHPT6Vz+p3ULqY4ooxjjIrtfiv4dn0zxHdo8oZd/avPLm38vDOc5PTNKOpasVjjPPSgY60rbQRimEjP9KoTHcU7cwXAJx1pqEbgD071Z+0osIRUycY5pgitnDZOTW9ofiSfRvNNsATIAvPYVz+eaTqaQEtzKZ53lI5dix/GoqKmkt5Y4lkdCEbo3rQBDXqv7Ln/JdfDP8A28/+ksteVV6p+y5/yXbwz/29f+kstAHV/trf8lT0r/sCxf8Ao+evn+voD9tX/kqelf8AYFi/9Hz18/0AFFFFABRRRQAUUUUAFFFLQAdqBSUUAb/h+dElVfNKbm74x/Ou+XxzFpu1FjSbBwMfT615GOtes6h8P/Duk6lpWnahqmqG5vraC48yGAFE80ZHbnFJ9xPcmj+LmoWsyvaZTB6AV6F4O+Ld5fRBLyRmTPzDGM1xus/B7S/DNreXWveI5FhivzZRmC237v3auGPPHDdPaptB+Fi3HiaG3stdb+x5bJL2O/MOwFncxohUnglxip5U3ZMG1a56/L4+YROLJVZuQCeB061zk3iY6pIZLpR5uQCoPBrx9NfPhrUL3S9Wt3FzBM8bhmxyDir2ha/axXb3dnKgA5EcrHH0pWv1E1Y930Hxro9lZC3NhK1xkAcHrVjW/Hcum6XLPEpjZh909j1rx2T4y/ZQqf2JbyMjE7lPXHSue8S+O9V8WW7RQaQ0KMd2EJotcdjm/HXiC413Vrq5mmYB33fpXFSMWYkkmtbVLO+tULXNpNGp6swOOfesc1aVir3Cg0lFMQtSwFAwZ+3NQ0UAWp5Yiv7pCG65Paq1JRQAVPJcyyRLE7kxr0HpUFLQAuDXqn7Lv/JdvDP/AG8/+ksteVliQM16p+y5/wAl28M/9vX/AKSy0DOq/bW/5KnpX/YFi/8AR89fP9fQH7a3/JU9K/7AsX/o+evn+gQUUUUAFKPzpKKAH7cgY5NNoBxSsMY96AG0pOaKSgAroPC/h/8Atx3Xz/KIIAGM5rBA5HNelfDfTXMiiK5jwzjHHINHoJ6FTU/hhqlpA80TrLGo3AYOTXc618Wr/RvFPhqHTLsDSLS0s0uongUncoAkGSM9K9WtLac2JiGyUkbV+XJFeDfEjwjqLapNPHp7BWwMhcZ96Wr0JTT3Oz8X/E7TNM8MarF4Qu4pJp9eluUWaMSZhaJOfmz/ABZFY9t8YUh8GLHq1nb61q19c+bcibMawxxY8lVCY77m/GvIJtEv4mKvbSg+69a2dF8FX+pRCQgxpnBJHSly6WbLbXY1vi5rdn4z8T2uvacqQyX1nEbqAHAimUFCPyUH8a4tImV1jkcICeobOK09d8OvpJO+XPGelc/mmhrTY7zwrYWJvY1e+XZnq2P8a9ksvEXhfw3pzBAlxKE7c5NfOeh6bdahOFtQ2c4yK6s+Fby1R5LidAF4IJzTaZErX1N74geLpPEenzw2sKRRfeAABJxXkNegWwjgV0dlMgHA9a4jUoxFfzoOgc4pIaK1FFKAScDrTGKoJ6CkNWYbSWTttWnw2MssjDaQqnDN2FAFKirN5HFFIUiYvj+Kq1ABS0lFAC16t+y8Qfjt4YwMf8fP/pLLXlNeq/suf8l28M/9vX/pLLQB1X7a3/JU9K/7AsX/AKPnr5/r6A/bW/5KnpX/AGBYv/R89fP9ABRRRQAUUUo60AJUsLhThhkGl/duFABVieSTxUeMNj8KANMxW1wcxybW29COlRSabIpO05XGd2ODVeS3kQBgCRjOQKt2NxMWjjEoxuHDUagrFKSB0IyrDPqK3fC90thqEU8+4IDkc4rtNP8ACg8QIfs1xCGTgsB3NOufhhe2cZae4Ro0BK7QOf1pO1iedHqXhD4l6Nb2Q8wDeGAwWGa9k8K6lpfiuxXPlbWJHUEnFfIdp4TgZR/pIjkPDLkdfzrb0ue/0GEG2vnXyyWHP+BqPh1THo+h9Xah8ONEvzvkjGccYArGuvBek6PFKCqiPAI6D6Yr5+tvi/4lsQ9uhaQbeG2k9fxrB8XfEjxJqdu3mGRQ6YOAeOKr2k3okL2cTq/i7p+h+ZObWZVaNQeCD+FfP1xFE0p2yADOOaS8vrq5kZ55XYk85JqoTk80/e6lKKWxctZ3t3Jt5yuOfTNW1v55ifNlZvr6VjU9HZGDKeRQ0O51Md2ttYtNLg4+6M8n2rmbmdrieSV8bnOTSSzPKcuc1FQIWlQlWBHWm05AWYBRknpTA6LRbKe/QgqsaFdzSPwMfU96XVTHYAwW0293GJCDkE1b0Xw7ql5D+8EsUOA2GBAxWXq9immzSoZN7g4oYlZsxmRgTkGmkdKlaY5OB1GOeaizQMKO1JTlALAE4BPX0oASvVf2XP8Akuvhn/t6/wDSWWvK69U/Zc/5Lr4Z/wC3r/0lloGdV+2t/wAlT0r/ALAsX/o+evn+voD9tb/kqelf9gWL/wBHz18/0CCiiigAooooAKKKKAJFldejGjf+frUdFAGjYaleWmRaSum7g4PWuls/FeqQKBdSu6dNpPJrkobkxAbQCQc81pW1nqOoKkkEBkwcjacn+dJpMdz0/RPFnhq6V21G3lhkTGzaAcn16106ap4V+zS+VOMgAgNt6/nXg+o2F3ao3n20y5bJJTgGstncN/EPalZ9GRyI9Y8Q+IdOs5GFiyugUen6YrlrrxoZYXRbcZYd643JOe9GOeaaT6jsia7uTcys7ADJ6CoKDSUxi0lFFAC0qHa6kgHBzg96bRQAtdN4KvdMsLwy6lG0nBxxnB/z/OuYqzb2zyqzAHaOpxRr0B6no/ib4iG7gWK0QpGo2BRxxXm93cPczNJISSTmmTJ5blQc4qPtSSBK2wlLRSUwCiiigBa9V/Zc/wCS6+Gf+3n/ANJZa8qr1X9lz/kuvhn/ALev/SWWgDqv21v+Sp6V/wBgWL/0fPXgHavf/wBtb/kqelf9gWL/ANHz18/0AFFFFABRSng0lABRRRQAUUUUAFaOkavd6VcrNaSFSO1Z1FAHfL8RLiS1ht7m2jljV9zZA5rmtc1W31J3eKzWF2bO5T2+lY1FArIKXNJRQMKKKKAClAzSUooAUj3ptKTmlRSzACgDR0u3s3VpL2Yrj7qg9a2Rc6fLAlvC7Qx4OXPWseGythGryylm7ovX+VJHpV5dGVra1l8tcnp0FLcClchBKwjYsAcZ9ai71YuLWW3IEq4zUJU9qYDaKXB9KSgANJS0lADhxXqn7Lv/ACXXwz/28/8ApLLXlXavVf2Xf+S6+GP+3r/0lloGfW3xJ8PaLq2uQT6ro+nX062yoslzbJKwXcxwCwJxknj3Ncn/AMIV4V/6FnRP/ACL/wCJoooEH/CFeFf+hZ0T/wAAIv8A4mj/AIQrwr/0LOif+AEX/wATRRQAf8IV4V/6FnRP/ACL/wCJo/4Qrwr/ANCzon/gBF/8TRRQAf8ACFeFf+hZ0T/wAi/+Jo/4Qrwr/wBCzon/AIARf/E0UUAH/CFeFf8AoWdE/wDACL/4mj/hCvCv/Qs6J/4ARf8AxNFFAB/whXhX/oWdE/8AACL/AOJo/wCEK8K/9Czon/gBF/8AE0UUAH/CFeFf+hZ0T/wAi/8AiaP+EK8K/wDQs6J/4ARf/E0UUAH/AAhXhX/oWdE/8AIv/iaP+EK8K/8AQs6J/wCAEX/xNFFAB/whXhX/AKFnRP8AwAi/+Jo/4Qrwr/0LOif+AEX/AMTRRQAf8IV4V/6FnRP/AAAi/wDiaP8AhCvCv/Qs6J/4ARf/ABNFFAC/8IV4V/6FnRP/AAAi/wDiaVPBfhYHjw1og/7cIv8A4miigC3b+D/DKkbfDujDntYxf/E10w8P6MISBpGnAbMY+zJ0/KiikyWctdeDvDLykv4d0ZjnqbGI/wDstQnwX4X2j/im9E/8AIv/AImiihGiAeC/C3/QtaJ3/wCXCL/4mmt4K8K5/wCRa0T/AMAIv/iaKKYmN/4Qrwr/ANCzon/gBF/8TR/whXhX/oWdE/8AACL/AOJoooEL/wAIV4V/6FnRP/ACL/4mtzwP4X0DTvFFldafoelWt1Hv2TQWkaOuUYHDAZHBI/GiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the transducer at the suprasternal notch (panel A), the long axis of the aortic arch can be visualized (panel B). The circular right pulmonary artery (RPA) is seen under the arch just inferior to the air filled right bronchus (RB). Relative to the aorta, the RPA is one half the diameter.",
"    <div class=\"footnotes\">",
"     RSA: right subclavian artery; RCC: right common carotid artery; LCC: left common carotid artery; LSA: left subclavian artery; IN: inominate vein. The inominate artery is not labled.",
"    </div>",
"    <div class=\"reference\">",
"     Image courtesy of Dr. Norman Silverman",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21536=[""].join("\n");
var outline_f21_2_21536=null;
var title_f21_2_21537="Vaginal epithelium in menopause";
var content_f21_2_21537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Changes in the vaginal epithelium with menopause",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in the vaginal epithelium from the reproductive years (right) to menopause (left).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the Anatomical Chart Company. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21537=[""].join("\n");
var outline_f21_2_21537=null;
var title_f21_2_21538="Patient information: Daytime wetting (The Basics)";
var content_f21_2_21538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16325\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"         Anatomy of the urinary tract in children",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/39/37489\">",
"         Patient information: Bedwetting in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/2/43041\">",
"         Patient information: Constipation in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/47/20210\">",
"         Patient information: Urinary tract infections in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/9/7315\">",
"         Patient information: Bedwetting in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/7/15477\">",
"         Patient information: Constipation in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/45/43730\">",
"         Patient information: Toilet training (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/58/38818\">",
"         Patient information: Urinary tract infections in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Daytime wetting (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/daytime-wetting-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12826028\">",
"      <span class=\"h1\">",
"       Is daytime wetting normal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, it can be normal. By age 4, most children can control their bladder and stay dry during the day. But children ages 4 to 6&mdash;and even older&mdash;can still have &ldquo;accidents&rdquo; during the day and wet themselves.",
"     </p>",
"     <p>",
"      Daytime wetting can be very upsetting and stressful for children, especially when they go to school or daycare.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12826035\">",
"      <span class=\"h1\">",
"       What causes daytime wetting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different things can cause daytime wetting, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The child&rsquo;s behavior or habits &mdash; For example, children who are very active might wet themselves because they wait too long to use the toilet.",
"       </li>",
"       <li>",
"        Constipation, which is when children have trouble having a bowel movement",
"       </li>",
"       <li>",
"        Urinary tract problems or infections (",
"        <a class=\"graphic graphic_figure graphicRef65630 \" href=\"UTD.htm?14/27/14769\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Nervous system problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12826042\">",
"      <span class=\"h1\">",
"       Should my child see the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child should see the doctor or nurse if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Is upset or stressed by the daytime wetting",
"       </li>",
"       <li>",
"        Starts having daytime wetting after he or she was able to stay dry all day before",
"       </li>",
"       <li>",
"        Has pain when urinating or feels the need to urinate often",
"       </li>",
"       <li>",
"        Leaks urine after he or she has finished urinating",
"       </li>",
"       <li>",
"        Has many urinary tract infections, constipation, or another condition that could be causing daytime wetting",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The doctor or nurse will talk with you about your child&rsquo;s symptoms and do an exam. He or she might also do a urine test. Before the appointment, he or she might ask you to keep a record for a few days of:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How much your child drinks",
"       </li>",
"       <li>",
"        How often your child urinates and has bowel movements",
"       </li>",
"       <li>",
"        When the daytime wetting happens",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most of the time, daytime wetting is not caused by a medical problem. In some cases, though, it is. If your doctor finds a medical problem, he or she might treat the problem, order more tests, or have your child see a specialist.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12826049\">",
"      <span class=\"h1\">",
"       What can I do to try to stop my child&rsquo;s daytime wetting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can try different things at home to stop your child&rsquo;s daytime wetting.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Make a schedule and have your child urinate every 2 to 3 hours during the day. Give your child rewards for following the schedule. &nbsp;",
"       </li>",
"       <li>",
"        Have your child follow the doctor&rsquo;s advice about how to sit when urinating.",
"       </li>",
"       <li>",
"        Remind your child not to hold in urine and to urinate before he or she feels the urge to.",
"       </li>",
"       <li>",
"        Have your child sit for a few minutes after he or she urinates to let all the urine drain from the body.",
"       </li>",
"       <li>",
"        Avoid bubble baths or using soap on the genital area (in girls). These can irritate the genital area and worsen daytime wetting.",
"       </li>",
"       <li>",
"        Treat your child&rsquo;s constipation, if your child is constipated. Ask your doctor or nurse about ways to do this.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For any of these plans to work, both you and your child must want the daytime wetting to stop. Stopping daytime wetting can be very hard and can take a long time.",
"     </p>",
"     <p>",
"      Remember that children cannot help their daytime wetting. You should never punish, tease, or get mad at your child for it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12826056\">",
"      <span class=\"h1\">",
"       Are there other treatments for daytime wetting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child still has daytime wetting after trying the tips above, talk with the doctor or nurse. He or she might do other tests or suggest other treatments that could help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12826063\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/39/37489?source=see_link\">",
"       Patient information: Bedwetting in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/2/43041?source=see_link\">",
"       Patient information: Constipation in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20210?source=see_link\">",
"       Patient information: Urinary tract infections in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/45/43730?source=see_link\">",
"       Patient information: Toilet training (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/9/7315?source=see_link\">",
"       Patient information: Bedwetting in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=see_link\">",
"       Patient information: Urinary tract infections in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=see_link\">",
"       Patient information: Constipation in infants and children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/2/21538?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16325 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21538=[""].join("\n");
var outline_f21_2_21538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12826028\">",
"      Is daytime wetting normal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12826035\">",
"      What causes daytime wetting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12826042\">",
"      Should my child see the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12826049\">",
"      What can I do to try to stop my child&rsquo;s daytime wetting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12826056\">",
"      Are there other treatments for daytime wetting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12826063\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16325\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/27/14769\">",
"      Anatomy of the urinary tract in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/9/7315?source=related_link\">",
"      Patient information: Bedwetting in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/39/37489?source=related_link\">",
"      Patient information: Bedwetting in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/2/43041?source=related_link\">",
"      Patient information: Constipation in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=related_link\">",
"      Patient information: Constipation in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/45/43730?source=related_link\">",
"      Patient information: Toilet training (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20210?source=related_link\">",
"      Patient information: Urinary tract infections in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/58/38818?source=related_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_2_21539="Tenecteplase: Patient drug information";
var content_f21_2_21539=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tenecteplase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     see \"Tenecteplase: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      TNKase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      TNKase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691474",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop heart muscle problems during a heart attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tenecteplase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Aneurysm, arteriovenous malformations, bleeding problems, brain tumor, injury to the brain or spine in the last 2 months, stroke, surgery on the brain or spine in the last 2 months, or very high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had any recent surgery or dental care, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11075 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-3011E4F32C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21539=[""].join("\n");
var outline_f21_2_21539=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228480\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228481\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012440\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012439\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012444\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012445\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012447\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012442\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012449\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=related_link\">",
"      Tenecteplase: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_2_21540="Buspirone: Patient drug information";
var content_f21_2_21540=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Buspirone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     see \"Buspirone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/55/11126?source=see_link\">",
"     see \"Buspirone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Buspirone&reg;;",
"     </li>",
"     <li>",
"      BuSpar&reg;;",
"     </li>",
"     <li>",
"      Bustab&reg;;",
"     </li>",
"     <li>",
"      Dom-Buspirone;",
"     </li>",
"     <li>",
"      Novo-Buspirone;",
"     </li>",
"     <li>",
"      Nu-Buspirone;",
"     </li>",
"     <li>",
"      PMS-Buspirone;",
"     </li>",
"     <li>",
"      Riva-Buspirone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety. It may take 1 month to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to buspirone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11517 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-190.102.30.19-24BE664544-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21540=[""].join("\n");
var outline_f21_2_21540=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143295\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011605\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011607\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011606\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011611\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011612\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011614\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011609\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011610\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011615\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011616\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=related_link\">",
"      Buspirone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/55/11126?source=related_link\">",
"      Buspirone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_2_21541="Pathogenesis of obesity hypoventilation syndrome";
var content_f21_2_21541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of obesity hypoventilation syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/2/21541/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/2/21541/contributors\">",
"     Paul M Suratt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/2/21541/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/2/21541/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/2/21541/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/2/21541/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/2/21541/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity hypoventilation syndrome (OHS) is defined as obesity (body mass index [BMI] &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and chronic alveolar hypoventilation (arterial carbon dioxide tension [PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ] &gt;45 mmHg) during wakefulness, which occur in the absence of other conditions that cause hypoventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OHS is also known as Pickwickian syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/2\">",
"     2",
"    </a>",
"    ]. This alternative name is based upon a character in Charles Dickens' book, The Posthumous Papers of the Pickwick Club. The character, Joe, was a \"wonderfully fat boy, standing upright with his eyes closed\" (",
"    <a class=\"graphic graphic_figure graphicRef57135 \" href=\"UTD.htm?34/51/35633\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The pathogenesis of OHS and factors that contribute to it are reviewed here. Clinical manifestations, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=see_link\">",
"     \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=see_link\">",
"     \"Treatment of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alveolar hypoventilation in patients with obesity hypoventilation syndrome (OHS) is probably a consequence of several obesity-related physiologic abnormalities and conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/3\">",
"     3",
"    </a>",
"    ]. They include obstructive sleep apnea, increased work of breathing, respiratory muscle impairment, a depressed central ventilatory drive, and diminished effects of neurohumoral modulators (eg, leptin) due to decreased levels or resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/4\">",
"     4",
"    </a>",
"    ]. The importance of obesity in the pathogenesis of OHS is supported by the observation that weight loss alone decreases PaCO",
"    <sub>",
"     2",
"    </sub>",
"    during wakefulness in patients with OHS (",
"    <a class=\"graphic graphic_figure graphicRef80196 \" href=\"UTD.htm?32/11/32957\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is a syndrome characterized by episodic hypopnea or apnea due to recurrent partial or complete upper airway obstruction during sleep. It frequently coexists with OHS and may be one of the causes of OHS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with OSA, the arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) rises during each apnea or hypopnea. Those who develop OHS are unable to normalize their PaCO",
"    <sub>",
"     2",
"    </sub>",
"    between such respiratory events [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/6\">",
"     6",
"    </a>",
"    ]. As a result, the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    progressively rises during the night and causes the pH to decrease. The kidney decreases its bicarbonate excretion in order to buffer the falling pH [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/7\">",
"     7",
"    </a>",
"    ]. Serum bicarbonate will progressively increase if the bicarbonate retained during the night is not eliminated the following day [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/8\">",
"     8",
"    </a>",
"    ]. Eventually the serum bicarbonate level becomes high enough to depress ventilation, causing chronic hypoventilation and hypercapnia during both the day and night.",
"   </p>",
"   <p>",
"    Despite the proposed importance of sleep-related respiratory events, the association between the frequency of respiratory events (ie, the apnea hypopnea index) and the likelihood that a patient with OSA has coexisting OHS is not clear. Some studies support an association [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/9\">",
"     9",
"    </a>",
"    ], while others do not support an association [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, severe oxyhemoglobin desaturation during sleep in patients with OSA is associated with coexisting OHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OSA is probably a major contributor to the pathogenesis of OHS, as indicated by two observations. First, correction of OSA (with either positive airway pressure therapy or tracheostomy) eliminates OHS in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Second, OSA is present in 85 to 92 percent of patients who have OHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/10,11,16\">",
"     10,11,16",
"    </a>",
"    ]. The true prevalence of OSA in patients with OHS may be even higher, since OSA is sometimes not detected until after the patient with OHS has begun noninvasive positive pressure ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/17\">",
"     17",
"    </a>",
"    ]. OHS occurs in 4 to 20 percent of patients with OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/8,18,19\">",
"     8,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Work of breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity increases the work of breathing, which leads to hypoventilation if the individual is incapable of producing or sustaining the increased work. This was illustrated by a study that demonstrated that the work of breathing increased about 30 percent in obese patients without OHS and about 90 percent in patients with OHS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/20\">",
"     20",
"    </a>",
"    ]. Increased work of breathing related to obesity is due to decreased lung compliance and the increased effort required to move the rib cage and diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/21\">",
"     21",
"    </a>",
"    ]. The decreased lung compliance may be a result of closure of the small airways and the engorgement of pulmonary capillaries; the latter a consequence of increased pulmonary blood volume [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/21\">",
"     21",
"    </a>",
"    ]. It was hypothesized that the cause of the increased effort to move the rib cage and diaphragm is due to an increase in chest wall compliance; however, several studies indicate chest wall compliance is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This suggests that the increased effort is due to the force required to start the chest wall and diaphragm moving [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/4,24\">",
"     4,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Respiratory muscle function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory muscle impairment generally needs to be severe to cause hypoventilation, although modest impairment may be sufficient when other contributing factors are present. Patients with OHS often have a modest reduction in respiratory muscle strength and endurance that is accompanied by contributing factors, such as increased work of breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Central ventilatory drive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OHS have decreased ventilatory responsiveness to chemostimuli such as hypoxemia and hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. In contrast, obese individuals without OHS respond normally to these stimuli. This diminished ventilatory responsiveness appears to be an adaptation to the increased work of breathing that was described above, rather than a primary defect. Regardless of whether decreased ventilatory responsiveness is an adaptation or a primary defect, it almost certainly contributes to the sustained hypercapnia that defines OHS.",
"   </p>",
"   <p>",
"    The belief that decreased ventilatory responsiveness is a consequence rather than a cause of OHS is supported by two observations. First, treatment of OHS normalizes or improves ventilatory responsiveness to chemostimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/29\">",
"     29",
"    </a>",
"    ]. Second, a study of seven patients with OHS found no evidence of impaired chemosensitivity among 16 first degree relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Leptin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin is a neurohumoral modulator that has been implicated in the pathogenesis of OHS by preliminary research. Animal studies indicate that insufficient leptin or leptin resistance may contribute to OHS. Genetically obese leptin deficient mice hypoventilate and have an elevated PaCO",
"    <sub>",
"     2",
"    </sub>",
"    . Leptin replacement improves CO",
"    <sub>",
"     2",
"    </sub>",
"    chemosensitivity and increases minute ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obese humans have elevated leptin levels, particularly if they are hypercapnic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/32\">",
"     32",
"    </a>",
"    ]. The increased leptin levels may be a compensatory response to leptin resistance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an effort to maintain alveolar ventilation in the setting of a high ventilatory load due to obesity and increased upper airway resistance.",
"   </p>",
"   <p>",
"    The impact of OHS therapy on leptin levels is uncertain due to conflicting evidence. Some studies found that leptin levels decreased after treatment with nasal CPAP or noninvasive positive pressure ventilation, while others found that it did not change or that it increased:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study that followed 14 patients with OHS for a median of 2 years, leptin levels decreased among those who were treated with continuous positive airway pressure or noninvasive positive pressure ventilation and remained stable among those who did not receive positive airway pressure therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a randomized trial found that leptin levels did not change in either the 19 subjects with OHS who were treated with noninvasive ventilation for one month or the 18 control subjects who were treated with lifestyle modifications [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/34\">",
"       34",
"      </a>",
"      ]. However, the treatment group had improvement in their PaCO",
"      <sub>",
"       2",
"      </sub>",
"      , nocturnal oxyhemoglobin saturation, and apnea hypopnea index.",
"     </li>",
"     <li>",
"      Another study showed that leptin levels increased in six patients with OHS (but without OSA) after treatment with noninvasive positive pressure ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     V/Q mismatching",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese individuals poorly ventilate the lower lobes of their lungs. This is probably due to diminished lung compliance, difficulty moving the ribcage and diaphragm, and closure of some alveoli prior to the end of expiration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21541/abstract/21\">",
"     21",
"    </a>",
"    ]. Obese individuals also have increased lower lobe perfusion due to increased pulmonary blood volume. The combination of decreased ventilation and increased perfusion of the lower lobes can cause ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatching and hypoxemia in obese patients. This may be responsible for the modest increase in the alveolar to arterial gradient that occurs in some patients with OHS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity hypoventilation syndrome (OHS) is defined as obesity (body mass index [BMI] &ge;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and chronic alveolar hypoventilation (arterial carbon dioxide tension [PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ] &gt;45 mmHg) during wakefulness, which occur in the absence of other conditions that cause hypoventilation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoventilation in patients with OHS is probably the consequence of the interaction of several physiologic abnormalities and conditions, including obstructive sleep apnea (OSA, a disorder characterized by obstructive apneas and hypopneas), increased work of breathing, respiratory muscle impairment, ventilation-perfusion mismatching, a depressed central ventilatory drive, and diminished effects of neurohumoral modulators (eg, leptin). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/1\">",
"      Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med 2011; 183:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/2\">",
"      BICKELMANN AG, BURWELL CS, ROBIN ED, WHALEY RD. Extreme obesity associated with alveolar hypoventilation; a Pickwickian syndrome. Am J Med 1956; 21:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/3\">",
"      Piper AJ, Grunstein RR. Current perspectives on the obesity hypoventilation syndrome. Curr Opin Pulm Med 2007; 13:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/4\">",
"      Koenig SM. Pulmonary complications of obesity. Am J Med Sci 2001; 321:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/5\">",
"      Sugerman HJ, Baron PL, Fairman RP, et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 1988; 207:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/6\">",
"      Ayappa I, Berger KI, Norman RG, et al. Hypercapnia and ventilatory periodicity in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2002; 166:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/7\">",
"      Norman RG, Goldring RM, Clain JM, et al. Transition from acute to chronic hypercapnia in patients with periodic breathing: predictions from a computer model. J Appl Physiol 2006; 100:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/8\">",
"      Mokhlesi B, Tulaimat A, Faibussowitsch I, et al. Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea. Sleep Breath 2007; 11:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/9\">",
"      Kaw R, Hernandez AV, Walker E, et al. Determinants of hypercapnia in obese patients with obstructive sleep apnea: a systematic review and metaanalysis of cohort studies. Chest 2009; 136:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/10\">",
"      Banerjee D, Yee BJ, Piper AJ, et al. Obesity hypoventilation syndrome: hypoxemia during continuous positive airway pressure. Chest 2007; 131:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/11\">",
"      Kessler R, Chaouat A, Schinkewitch P, et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 2001; 120:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/12\">",
"      Jones JB, Wilhoit SC, Findley LJ, Suratt PM. Oxyhemoglobin saturation during sleep in subjects with and without the obesity-hypoventilation syndrome. Chest 1985; 88:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/13\">",
"      Chan CS, Grunstein RR, Bye PT, et al. Obstructive sleep apnea with severe chronic airflow limitation. Comparison of hypercapnic and eucapnic patients. Am Rev Respir Dis 1989; 140:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/14\">",
"      Berthon-Jones M, Sullivan CE. Time course of change in ventilatory response to CO2 with long-term CPAP therapy for obstructive sleep apnea. Am Rev Respir Dis 1987; 135:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/15\">",
"      Rapoport DM, Garay SM, Epstein H, Goldring RM. Hypercapnia in the obstructive sleep apnea syndrome. A reevaluation of the \"Pickwickian syndrome\". Chest 1986; 89:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/16\">",
"      P&eacute;rez de Llano LA, Golpe R, Ortiz Piquer M, et al. Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome. Chest 2005; 128:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/17\">",
"      Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc 2008; 5:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/18\">",
"      Laaban JP, Chailleux E. Daytime hypercapnia in adult patients with obstructive sleep apnea syndrome in France, before initiating nocturnal nasal continuous positive airway pressure therapy. Chest 2005; 127:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/19\">",
"      Verin E, Tardif C, Pasquis P. Prevalence of daytime hypercapnia or hypoxia in patients with OSAS and normal lung function. Respir Med 2001; 95:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/20\">",
"      SHARP JT, HENRY JP, SWEANY SK, et al. THE TOTAL WORK OF BREATHING IN NORMAL AND OBESE MEN. J Clin Invest 1964; 43:728.",
"     </a>",
"    </li>",
"    <li>",
"     Rochester DF, Arora NS. Respiratory failure from obesity. In: Medical Complications of obesity, Mancini M, Lewis B, Contaldo F (Eds), Academic Press, London 1980. p.183.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/22\">",
"      Suratt PM, Wilhoit SC, Hsiao HS, et al. Compliance of chest wall in obese subjects. J Appl Physiol 1984; 57:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/23\">",
"      Hedenstierna G, Santesson J. Breathing mechanics, dead space and gas exchange in the extremely obese, breathing spontaneously and during anaesthesia with intermittent positive pressure ventilation. Acta Anaesthesiol Scand 1976; 20:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/24\">",
"      SHARP JT, HENRY JP, SWEANY SK, et al. TOTAL RESPIRATORY INERTANCE AND ITS GAS AND TISSUE COMPONENTS IN NORMAL AND OBESE MEN. J Clin Invest 1964; 43:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/25\">",
"      Zwillich CW, Sutton FD, Pierson DJ, et al. Decreased hypoxic ventilatory drive in the obesity-hypoventilation syndrome. Am J Med 1975; 59:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/26\">",
"      Kronenberg RS, Gabel RA, Severinghaus JW. Normal chemoreceptor function in obesity before and after ileal bypass surgery to force weight reduction. Am J Med 1975; 59:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/27\">",
"      Sampson MG, Grassino K. Neuromechanical properties in obese patients during carbon dioxide rebreathing. Am J Med 1983; 75:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/28\">",
"      Kronenberg RS, Drage CW, Stevenson JE. Acute respiratory failure and obesity with normal ventilatory response to carbon dioxide and absent hypoxic ventilatory drive. Am J Med 1977; 62:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/29\">",
"      Redolfi S, Corda L, La Piana G, et al. Long-term non-invasive ventilation increases chemosensitivity and leptin in obesity-hypoventilation syndrome. Respir Med 2007; 101:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/30\">",
"      Jokic R, Zintel T, Sridhar G, et al. Ventilatory responses to hypercapnia and hypoxia in relatives of patients with the obesity hypoventilation syndrome. Thorax 2000; 55:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/31\">",
"      O'donnell CP, Schaub CD, Haines AS, et al. Leptin prevents respiratory depression in obesity. Am J Respir Crit Care Med 1999; 159:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/32\">",
"      Phipps PR, Starritt E, Caterson I, Grunstein RR. Association of serum leptin with hypoventilation in human obesity. Thorax 2002; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/33\">",
"      Yee BJ, Cheung J, Phipps P, et al. Treatment of obesity hypoventilation syndrome and serum leptin. Respiration 2006; 73:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21541/abstract/34\">",
"      Borel JC, Tamisier R, Gonzalez-Bermejo J, et al. Noninvasive ventilation in mild obesity hypoventilation syndrome: a randomized controlled trial. Chest 2012; 141:692.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7697 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-6F04F3F69B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21541=[""].join("\n");
var outline_f21_2_21541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Work of breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Respiratory muscle function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Central ventilatory drive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Leptin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      V/Q mismatching",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7697\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7697|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/51/35633\" title=\"figure 1\">",
"      Pickwickian syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/11/32957\" title=\"figure 2\">",
"      Effect of weight loss in OHS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=related_link\">",
"      Clinical manifestations and diagnosis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=related_link\">",
"      Treatment of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_2_21542="FAST stroke PI";
var content_f21_2_21542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Signs of stroke",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 673px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The letters in the word \"fast\" help you remember the signs of stroke. If a person shows any of these signs, call 9-1-1 right away.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21542=[""].join("\n");
var outline_f21_2_21542=null;
var title_f21_2_21543="Stellate lesions I";
var content_f21_2_21543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows stellate lesions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21543=[""].join("\n");
var outline_f21_2_21543=null;
var title_f21_2_21544="Ondansetron: Drug information";
var content_f21_2_21544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ondansetron: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/24/24965?source=see_link\">",
"    see \"Ondansetron: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"    see \"Ondansetron: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13246131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Premixed Ondansetron 32 mg I.V. Products to be Removed From Market",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is notifying healthcare providers that ondansetron hydrochloride (Zofran&reg;) 32 mg single premixed intravenous doses in a sodium chloride or dextrose solution will no longer be marketed because of the potential for QT prolongation, which can lead to torsade de pointes, a potentially fatal abnormal heart rhythm. The I.V. 32 mg dose has been removed from GlaxoSmithKline's ondansetron (Zofran&reg;) labeling. The FDA is working with the manufacturers of all ondansetron 32 mg, premixed single-dose injectable products to voluntarily recall them from the market. The FDA anticipates these products will be removed from the market through early 2013 and does not expect this recall to contribute to a drug shortage.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The approved labeling continues to recommend I.V. ondansetron for the prevention of chemotherapy induced nausea and vomiting at 0.15 mg/kg every 4 hours for 3 doses. No single I.V. dose should exceed 16 mg. Oral dosing labeling for ondansetron is unchanged.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm330772.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm330772.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      QT Prolongation with Ondansetron",
"     </span>",
"     <span class=\"collapsible-date\">",
"      June 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Previously, in September 2011, the U.S. Food and Drug Administration (FDA) notified healthcare professionals about an ongoing safety review of the risk of QT prolongation with ondansetron. At that time, the FDA required GlaxoSmithKline (manufacturer of Zofran&reg;) to conduct an in-depth study on the effects of ondansetron on the QT interval. Recent preliminary study results suggest that a single intravenous dose of ondansetron (Zofran&reg;) 32 mg may prolong the QT interval, which could predispose patients to development of torsade de pointes. Those most at risk include patients with congenital long QT syndrome, heart failure, bradyarrhythmias, electrolyte abnormalities (ie, hypokalemia, hypomagnesemia), and concomitant use of other QT-prolonging medications. GlaxoSmithKline has announced changes to ondansetron labeling to remove the 32 mg single intravenous dose. Updated labeling will also state that ondansetron 0.15 mg/kg can be administered to patients with chemotherapy-induced nausea and vomiting every 4 hours for 3 doses, but no single intravenous dose should exceed 16 mg. The labeling for oral ondansetron will not be changed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm310219.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm310219.htm?source=govdelivery",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zofran&reg;;",
"     </li>",
"     <li>",
"      Zofran&reg; ODT;",
"     </li>",
"     <li>",
"      Zuplenz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ondansetron&reg;;",
"     </li>",
"     <li>",
"      CO Ondansetron;",
"     </li>",
"     <li>",
"      Dom-Ondansetron;",
"     </li>",
"     <li>",
"      JAMP-Ondansetron;",
"     </li>",
"     <li>",
"      Mint-Ondansetron;",
"     </li>",
"     <li>",
"      Mylan-Ondansetron;",
"     </li>",
"     <li>",
"      Ondansetron Injection;",
"     </li>",
"     <li>",
"      Ondansetron Injection USP;",
"     </li>",
"     <li>",
"      Ondansetron-Odan;",
"     </li>",
"     <li>",
"      Ondansetron-Omega;",
"     </li>",
"     <li>",
"      PHL-Ondansetron;",
"     </li>",
"     <li>",
"      PMS-Ondansetron;",
"     </li>",
"     <li>",
"      RAN&trade;-Ondansetron;",
"     </li>",
"     <li>",
"      ratio-Ondansetron;",
"     </li>",
"     <li>",
"      Sandoz-Ondansetron;",
"     </li>",
"     <li>",
"      Teva-Ondansetron;",
"     </li>",
"     <li>",
"      Zofran&reg;;",
"     </li>",
"     <li>",
"      Zofran&reg; ODT;",
"     </li>",
"     <li>",
"      ZYM-Ondansetron",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F203757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Selective 5-HT",
"      <sub>",
"       3",
"      </sub>",
"      Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F203710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of nausea and vomiting associated with emetogenic chemotherapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 0.15 mg/kg/dose (maximum: 16 mg/dose) over 15 minutes for 3 doses, beginning 30 minutes prior to chemotherapy, followed by subsequent doses 4 and 8 hours after the first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Highly-emetogenic agents/single-day therapy:",
"     </i>",
"     Oral: 24 mg given as three 8 mg tablets 30 minutes prior to the start of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Moderately-emetogenic agents:",
"     </i>",
"     Oral: 8 mg beginning 30 minutes before chemotherapy; repeat dose 8 hours after initial dose, then 8 mg every 12 hours for 1-2 days after chemotherapy completed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     American Society of Clinical Oncology Antiemetic Guideline recommendations (Basch, 2011): High emetic risk: Day(s) chemotherapy is administered:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 8 mg or 0.15 mg/kg.",
"     <b>",
"      Note:",
"     </b>",
"     Single I.V. doses &gt;16 mg are no longer recommended by the manufacturer due to the potential for QT prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 8 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of nausea and vomiting associated with radiation therapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Total body irradiation:",
"     </i>",
"     Oral: 8 mg 1-2 hours before each daily fraction of radiotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Single high-dose fraction radiotherapy to abdomen:",
"     </i>",
"     Oral: 8 mg 1-2 hours before irradiation, then 8 mg every 8 hours after first dose for 1-2 days after completion of radiotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Daily fractionated radiotherapy to abdomen:",
"     </i>",
"     Oral: 8 mg 1-2 hours before irradiation, then 8 mg every 8 hours after first dose for each day of radiotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     American Society of Clinical Oncology Antiemetic Guideline recommendations (Basch, 2011): Give before each fraction throughout radiation therapy for high emetic risk (continue for at least 24 hours after completion) and for moderate emetic risk; for low emetic risk, may give either as prevention or rescue; for minimal emetic risk, give as rescue (if rescue used for either low or minimal emetic risk, then prophylaxis should be given until the end of radiation therapy):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. (unlabeled route/dosing): 8 mg or 0.15 mg/kg.",
"     <b>",
"      Note:",
"     </b>",
"     Single I.V. doses &gt;16 mg are no longer recommended by the manufacturer due to the potential for QT prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 8 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postoperative nausea and vomiting (PONV):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 16 mg given 1 hour prior to induction of anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 4 mg as a single dose (over 2-5 minutes if giving I.V.) administered ~30 minutes before the end of anesthesia (see Note below) or as treatment if vomiting occurs after surgery (Gan, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer recommends administration immediately before induction of anesthesia; however, this has been shown not to be as effective as administration at the end of surgery (Sun, 1997). Repeat doses given in response to inadequate control of nausea/vomiting from preoperative doses are generally ineffective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of severe or refractory hyperemesis gravidum (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Oral: 8 mg every 12 hours (Levichek, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: 8 mg administered over 15 minutes every 12 hours (ACOG, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F203733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"      see \"Ondansetron: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of nausea and vomiting associated with emetogenic chemotherapy:",
"     </b>",
"     I.V.: Children 6 months to 18 years: 0.15 mg/kg/dose (maximum: 16 mg/dose) over 15 minutes for 3 doses, beginning with the first dose administered 30 minutes prior to chemotherapy, followed by subsequent doses administered 4 and 8 hours after the first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of nausea and vomiting associated with moderately-emetogenic chemotherapy:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-11 years: 4 mg 30 minutes before chemotherapy; repeat 4 and 8 hours after initial dose, then 4 mg every 8 hours for 1-2 days after chemotherapy completed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of postoperative nausea and vomiting (PONV):",
"     </b>",
"     I.V.: Children 1 month to 12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;40 kg: 0.1 mg/kg as a single dose over 2-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;40 kg: 4 mg as a single dose over 2-5 minutes",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F203711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F203712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary (there is no experience for oral ondansetron beyond day 1)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F203713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe impairment (Child-Pugh C):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Day 1: Maximum dose: 8 mg (there is no experience beyond day 1)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Maximum daily dose: 8 mg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Film, soluble, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zuplenz&reg;: 4 mg (10s); 8 mg (10s) [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W [preservative free]: 32 mg (50 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg;: 32 mg (50 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS [preservative free]: 32 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 2 mg/mL (2 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg;: 2 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 2 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 4 mg/5 mL (5 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg;: 4 mg/5 mL (50 mL) [contains sodium benzoate; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg;: 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zofran&reg; ODT: 4 mg, 8 mg [contains phenylalanine &lt;0.03 mg/tablet; strawberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral soluble film",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F203683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Oral dosage forms should be administered 30 minutes prior to chemotherapy; 1-2 hours before radiotherapy; 1 hour prior to the induction of anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orally-disintegrating tablets: Do not remove from blister until needed. Peel backing off the blister, do not push tablet through. Using dry hands, place tablet on tongue and allow to dissolve. Swallow with saliva.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral soluble film: Do not remove from pouch until immediately before use. Using dry hands, place film on top of tongue and allow to dissolve (4-20 seconds). Swallow with or without liquid. If using more than one film, each film should be allowed to dissolve completely before administering the next film.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Should be administered undiluted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     IVPB: Infuse diluted solution over 15-30 minutes; 24-hour continuous infusions have been reported, but are rarely used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chemotherapy-induced nausea and vomiting: Give first dose 30 minutes prior to beginning chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. push: Prevention of postoperative nausea and vomiting: Single doses may be administered I.V. injection over 2-5 minutes as undiluted solution.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F203763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, mannitol 10%, LR, NS; do not mix injection with alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aldesleukin, amifostine, amikacin, azithromycin, aztreonam, bleomycin, carboplatin, carmustine, caspofungin, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, cisatracurium, cisplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, dexamethasone sodium phosphate, dexmedetomidine, diphenhydramine, docetaxel, dopamine, doripenem, doxorubicin, doxorubicin liposome, doxycycline, droperidol, etoposide, etoposide phosphate, famotidine, fenoldopam, filgrastim, floxuridine, fluconazole, fludarabine, gallium nitrate, gemcitabine, gentamicin, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ifosfamide, imipenem/cilastatin, linezolid, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, metoclopramide, mitomycin, mitoxantrone, morphine, oxaliplatin, paclitaxel, paclitaxel with ranitidine, pentostatin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, remifentanil, sodium acetate, streptozocin, telavancin, teniposide, thiotepa, ticarcillin/clavulanate, topotecan, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, allopurinol, aminophylline, amphotericin B, amphotericin B cholesteryl sulfate complex, ampicillin, ampicillin/sulbactam, amsacrine, cefepime, furosemide, ganciclovir, lorazepam, methylprednisolone sodium succinate, micafungin, pemetrexed, sargramostim, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cyclosporine, fluorouracil, fosaprepitant, meropenem, piperacillin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Alfentanil, atropine, fentanyl, glycopyrrolate, meperidine, metoclopramide, midazolam, morphine, naloxone, neostigmine, propofol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dexamethasone sodium phosphate, droperidol.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F203682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy (including high-dose cisplatin); prevention of postoperative nausea and/or vomiting (PONV); treatment of PONV if no prophylactic dose of ondansetron received",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy (including high-dose cisplatin); prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy; prevention of nausea and vomiting associated with radiotherapy (either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen); prevention of PONV",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F203753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperemesis gravidarum (severe or refractory); breakthrough treatment of nausea and vomiting associated with chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F203765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ondansetron may be confused with dolasetron, granisetron, palonosetron",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zofran&reg; may be confused with Zantac&reg;, Zosyn&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F203755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages reported in adult patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (9% to 27%), malaise/fatigue (9% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (8%), fever (2% to 8%), dizziness (7%), anxiety (6%), cold sensation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (2% to 5%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (2% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Gynecological disorder (7%), urinary retention (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (&gt;2 times ULN: 1% to 5%), AST increased (&gt;2 times ULN: 1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (4%; pain, redness, burning)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Hypoxia (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal hepatic function, anaphylactoid reactions, anaphylaxis, angina, angioedema, arrhythmia, atrial fibrillation, AV block, blindness (transient/following infusion; lasting &le;48 hours), blurred vision (transient/following infusion), bradycardia, cardiopulmonary arrest, dystonic reaction, electrocardiographic alterations (second-degree heart block and ST-segment depression), extrapyramidal symptoms, hepatic failure, hepatic necrosis, hepatitis, hypersensitivity reaction, hypokalemia, hypotension, oculogyric crisis, premature ventricular contractions (PVC), QT interval increased, seizure, shock, supraventricular tachycardia, syncope, tachycardia, torsade de pointes, vascular occlusive events, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F203687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ondansetron or any component of the formulation; concomitant use of apomorphine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F203670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Use with caution in patients allergic to other 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists; cross-reactivity has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: Dose-dependent QT interval prolongation occurs with ondansetron use. Cases of torsade de pointes have also been reported to the manufacturer. Selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists, including ondansetron, have been associated with a number of dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QT",
"     <sub>",
"      c",
"     </sub>",
"     , JT), usually occurring 1-2 hours after I.V. administration. Single doses &gt;16 mg ondansetron I.V. are no longer recommended due to the potential for an increased risk of QT prolongation. In most patients, these changes are not clinically relevant; however, when used in conjunction with other agents that prolong these intervals or in those at risk for QT prolongation, arrhythmia may occur. When used with agents that prolong the QT interval (eg, Class I and III antiarrhythmics) or in patients with cardiovascular disease, clinically relevant QT interval prolongation may occur resulting in torsade de pointes. A number of trials have shown that 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists produce QT interval prolongation to variable degrees. Avoid ondansetron use in patients with congenital long QT syndrome. Use caution and monitor ECG in patients with other risk factors for QT prolongation (eg, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomagnesemia], heart failure, bradyarrhythmias, and cumulative high-dose anthracycline therapy). Reduction in heart rate may also occur with the 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists. I.V. formulations of 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists have more association with ECG interval changes, compared to oral formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Dose limitations are recommended for patients with severe hepatic impairment (Child-Pugh class C); use with caution in mild-moderate hepatic impairment; clearance is decreased and half-life increased in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Orally-disintegrating tablets contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chemotherapy-associated emesis:",
"     <b>",
"      For chemotherapy, should be used on a scheduled basis, not on an &ldquo;as needed&rdquo; (PRN) basis,",
"     </b>",
"     since data support the use of this drug only in the prevention of nausea and vomiting (due to antineoplastic therapy) and not in the rescue of nausea and vomiting. Should only be used in the first 24-48 hours of chemotherapy. Data does not support any increased efficacy in delayed nausea and vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ileus or gastric distention: Does not stimulate gastric or intestinal peristalsis; may mask progressive ileus and/or gastric distension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F203750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Antiemetics (5HT3 Antagonists).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F203703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Tablet: Food slightly increases the extent of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease ondansetron levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F203690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Ondansetron readily crosses the human placenta in the first trimester of pregnancy and can be detected in fetal tissue (Siu, 2006). The use of ondansetron for the treatment of nausea and vomiting of pregnancy (NVP) has been evaluated. Although a significant increase in birth defects has not been described in case reports and some studies (Ferreira, 2012; Pasternak, 2013), other studies have shown a possible association with ondansetron exposure and adverse fetal events (Anderka, 2012; Einarson, 2004). Additional studies are needed to determine safety to the fetus, particularly during the first trimester. Based on available data, use is generally reserved for severe NVP (hyperemesis gravidarum) or when conventional treatments are not effective (ACOG, 2004; Koren, 2012; Levicheck, 2002; Tan, 2011). Because a dose-dependent QT-interval prolongation occurs with use, the manufacturer recommends ECG monitoring in patients with electrolyte abnormalities (which can be associated with some cases of NVP; Koren, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F203719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16565637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if ondansetron is excreted into breast milk. The manufacturer recommends caution be used if administered to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F203691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take without regard to meals. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F203689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Film",
"     </b>",
"     (Zuplenz Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (1): $15.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (1): $15.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ondansetron HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/2 mL (2 mL): $1.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/20 mL (20 mL): $24.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ondansetron HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/5 mL (50 mL): $239.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ondansetron HCl-NaCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32 mg/50 mL (50 mL): $43.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zofran Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/20 mL (20 mL): $256.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zofran Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/5 mL (50 mL): $269.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Ondansetron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $668.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $1113.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Zofran ODT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $752.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $1252.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ondansetron HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $735.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $1217.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     24 mg (1): $105.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zofran Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (3): $79.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $1328.09",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F554062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG (if applicable in high risk patients); potassium, magnesium",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F203692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avessa (LU);",
"     </li>",
"     <li>",
"      Cedantron (ID);",
"     </li>",
"     <li>",
"      Cetron (AR);",
"     </li>",
"     <li>",
"      Danac (MX);",
"     </li>",
"     <li>",
"      Dantron (TH, ZA);",
"     </li>",
"     <li>",
"      Danzetron (AU);",
"     </li>",
"     <li>",
"      Emeset (IN);",
"     </li>",
"     <li>",
"      Emetron (HU);",
"     </li>",
"     <li>",
"      Emistop (PH);",
"     </li>",
"     <li>",
"      Emodan (PH);",
"     </li>",
"     <li>",
"      Frazon (ID);",
"     </li>",
"     <li>",
"      Glotron (ID);",
"     </li>",
"     <li>",
"      Invomit (ID);",
"     </li>",
"     <li>",
"      Izofran (CN, UY);",
"     </li>",
"     <li>",
"      Lartron (MX);",
"     </li>",
"     <li>",
"      Modifical (CO);",
"     </li>",
"     <li>",
"      Narfoz (ID);",
"     </li>",
"     <li>",
"      Nausedron (BR);",
"     </li>",
"     <li>",
"      Ondak (CO);",
"     </li>",
"     <li>",
"      Ondant (KP);",
"     </li>",
"     <li>",
"      Ondavell (ID);",
"     </li>",
"     <li>",
"      Ondaz (AU);",
"     </li>",
"     <li>",
"      Onetic (ID);",
"     </li>",
"     <li>",
"      Onset-8 (PH);",
"     </li>",
"     <li>",
"      Onsetron (KP);",
"     </li>",
"     <li>",
"      Onsia (TH);",
"     </li>",
"     <li>",
"      Onzod (TW);",
"     </li>",
"     <li>",
"      Osetron (AU);",
"     </li>",
"     <li>",
"      Setronax (HK, MY, SG);",
"     </li>",
"     <li>",
"      Vomceran (ID);",
"     </li>",
"     <li>",
"      Vometron (ID);",
"     </li>",
"     <li>",
"      Vomiof (IN);",
"     </li>",
"     <li>",
"      Vomiz (TW);",
"     </li>",
"     <li>",
"      Zetron (TH);",
"     </li>",
"     <li>",
"      Zofran (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, GB, GH, GM, GN, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Zofran Zydis (CR, DO, GT, KP, NI, NZ, PA, SV, TH);",
"     </li>",
"     <li>",
"      Zofron (GR);",
"     </li>",
"     <li>",
"      Zophren (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F203669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     -receptor antagonist, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F203686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 1.7-3.7 L/kg; Adults: 2.2-2.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 70% to 76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via hydroxylation, followed by glucuronide or sulfate conjugation; CYP1A2, CYP2D6, and CYP3A4 substrate; some demethylation occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 56% to 71% (some first pass metabolism); Rectal: 58% to 74%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children &lt;15 years: 2-7 hours; Adults: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh classes A and B): Adults: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh class C): Adults: 20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: ~2 hours; Oral soluble film: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (44% to 60% as metabolites, ~5% as unchanged drug); feces (~25%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetrics and Gynecology, ACOG (American College of Obstetricians and Gynecologists) Practice Bulletin: &ldquo;Nausea and Vomiting of Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 103(4):803-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/15051578/pubmed\" id=\"15051578\" target=\"_blank\">",
"        15051578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderka M, Mitchell AA, Louik C, et al, \"Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects,\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2012, 94(1):22-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/22102545/pubmed\" id=\"22102545\" target=\"_blank\">",
"        22102545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Basch E, Prestrud AA, Hesketh PJ, et al, \"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(31):4189-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/21947834/pubmed\" id=\"21947834\" target=\"_blank\">",
"        21947834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einarson A, Maltepe C, Navioz Y, et al, \"The Safety of Ondansetron for Nausea and Vomiting of Pregnancy: A Prospective Comparative Study,\"",
"      <i>",
"       BJOG",
"      </i>",
"      , 2004, 111(9):940-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/15327608/pubmed\" id=\"15327608\" target=\"_blank\">",
"        15327608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferreira E, Gillet M, Leli&egrave;vre J, et al, \"Ondansetron Use During Pregnancy: A Case Series,\"",
"      <i>",
"       J Popul Ther Clin Pharmacol",
"      </i>",
"      ,  2012, 19(1):e1-e10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/22267256/pubmed\" id=\"22267256\" target=\"_blank\">",
"        22267256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Meyer TA, Apfel CC, et al, \"Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 105(6):1615-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/18042859/pubmed\" id=\"18042859\" target=\"_blank\">",
"        18042859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, \"Motherisk Update. Is Ondansetron Safe for Use During Pregnancy?\"",
"      <i>",
"       Can Fam Physician",
"      </i>",
"      , 2012, 58(10):1092-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/23064917/pubmed\" id=\"23064917\" target=\"_blank\">",
"        23064917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kris MG, Hesketh PJ, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2932-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/16717289/pubmed\" id=\"16717289\" target=\"_blank\">",
"        16717289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levichek Z, Atanackovic G, Oepkes D, et al, &ldquo;Nausea and Vomiting of Pregnancy. Evidence-Based Treatment Algorithm,&rdquo;",
"      <i>",
"       Can Fam Physician",
"      </i>",
"      , 2002, 48:267-8, 277.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/11889884/pubmed\" id=\"11889884\" target=\"_blank\">",
"        11889884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Navari RM and Koeller JM, &ldquo;Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine",
"      <sub>",
"       3",
"      </sub>",
"      Receptor Antagonists,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(9):1276-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/12921512/pubmed\" id=\"12921512\" target=\"_blank\">",
"        12921512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak B, Svanstr&ouml;m H, and Hviid A, \"Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2013, 368(9):814-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/23445092/pubmed\" id=\"23445092\" target=\"_blank\">",
"        23445092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roila F and Del Favero A, &ldquo;Ondansetron Clinical Pharmacokinetics,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 29(2):95-109.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/7586904/pubmed\" id=\"7586904\" target=\"_blank\">",
"        7586904",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siu SS, Chan MT, and Lau TK, \"Placental Transfer of Ondansetron During Early Human Pregnancy,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2006, 45(4):419-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/16584287/pubmed\" id=\"16584287\" target=\"_blank\">",
"        16584287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sun R, Klein KW, and White PF, \"The Effect of Timing of Ondansetron Administration in Outpatients Undergoing Otolaryngologic Surgery,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 84(2):331-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/9024023/pubmed\" id=\"9024023\" target=\"_blank\">",
"        9024023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tan PC and Omar SZ, \"Contemporary Approaches to Hyperemesis During Pregnancy,\"",
"      <i>",
"       Curr Opin Obstet Gynecol",
"      </i>",
"      , 2011, 23(2):87-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/21297474/pubmed\" id=\"21297474\" target=\"_blank\">",
"        21297474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tramer MR, Moore RA, Reynolds DJ, et al, &ldquo;A Quantitative Systematic Review of Ondansetron in Treatment of Established Postoperative Nausea and Vomiting,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1997, 314(7087):1088-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/9133892/pubmed\" id=\"9133892\" target=\"_blank\">",
"        9133892",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilde MI and Markham A, &ldquo;Ondansetron. A Review of Its Pharmacology and Preliminary Clinical Findings in Novel Application,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 52(5):773-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/2/21544/abstract-text/9118822/pubmed\" id=\"9118822\" target=\"_blank\">",
"        9118822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9719 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21544=[""].join("\n");
var outline_f21_2_21544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13246131\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203706\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203707\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203757\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203710\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203733\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203711\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203712\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203713\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203680\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203666\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203683\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203763\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203682\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203753\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203765\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203755\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203687\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203670\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203750\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203675\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203703\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203677\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203719\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565637\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203691\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203689\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554062\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203692\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203669\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203686\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9719\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9719|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/24/24965?source=related_link\">",
"      Ondansetron: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=related_link\">",
"      Ondansetron: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_2_21545="Clinical manifestations and causes of nephrogenic diabetes insipidus";
var content_f21_2_21545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and causes of nephrogenic diabetes insipidus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/2/21545/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/2/21545/contributors\">",
"     Daniel G Bichet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/2/21545/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/2/21545/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/2/21545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/2/21545/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/2/21545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrogenic diabetes insipidus (DI) refers to a decrease in urinary concentrating ability that results from resistance to the action of antidiuretic hormone (ADH). This problem can reflect resistance at the ADH site of action in the collecting tubules, or interference with the countercurrent mechanism due, for example, to medullary injury or to decreased sodium chloride reabsorption in the medullary aspect of the thick ascending limb of the loop of Henle (",
"    <a class=\"graphic graphic_figure graphicRef51077 \" href=\"UTD.htm?1/18/1317\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nephrogenic DI, in its mild form, is relatively common, since almost all patients who are elderly, sick, or have acute or chronic kidney disease have a reduction in maximum concentrating ability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, the maximum urine osmolality that can be achieved may fall from the normal value of 800 to 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    down to 350 to 600",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/1\">",
"     1",
"    </a>",
"    ]. In chronic kidney disease, this defect is due in part to increased solute excretion per functioning nephron and to decreased expression of mRNA for the V2 vasopressin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and causes of nephrogenic DI will be reviewed here. The treatment of nephrogenic DI, the diagnostic approach to polyuria and diabetes insipidus, and the clinical manifestations and causes of central DI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141708491\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate to severe nephrogenic or central DI typically present with polyuria, nocturia, and polydipsia. Polyuria is arbitrarily defined as a urine output exceeding 3",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    in adults or 2",
"    <span class=\"nowrap\">",
"     L/m2",
"    </span>",
"    in children. Causes of polyuria other than DI include primary polydipsia and increased solute excretion due to one or more of the following: glucosuria in uncontrolled diabetes mellitus, urea with a high protein diet, or sodium chloride and urea in a postobstructive diuresis. In addition, glucosuria can contribute to polyuria in patients with severe DI when hyperglycemia is induced by the administration of large volumes of intravenous dextrose in water. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis of polyuria and diabetes insipidus\", section on 'Solute diuresis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urine is normally most concentrated in the morning due to lack of fluid ingestion overnight and increased vasopressin secretion during the late sleep period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, the first manifestation of a mild to moderate loss of concentrating ability is often nocturia. However, nocturia is not diagnostic of a defect in concentrating ability since it can also be caused by other factors such as drinking before going to bed or, in men, by prostatic hypertrophy, which is characterized by urinary frequency rather than polyuria.",
"   </p>",
"   <p>",
"    The serum sodium in untreated patients with DI is often in the high normal range to provide the stimulus for thirst to replace the urinary water losses. Moderate to severe hypernatremia can develop when thirst is impaired or cannot be expressed. This can occur in patients with central nervous system lesions who also have hypodipsia or adipsia, in infants, young children, and neurologically impaired adults who cannot independently access free water, and in the postoperative period in patients with unrecognized DI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H92106445#H92106445\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'Adipsic diabetes insipidus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with nephrogenic DI may also have manifestations related to the underlying cause, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    toxicity, hypercalcemia, and hypokalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of ADH resistance severe enough to produce polyuria are hereditary nephrogenic DI in children, and chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ingestion and hypercalcemia in adults. Acquired causes are often at least partially reversible with cessation of the offending drug or correction of hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hereditary nephrogenic DI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary nephrogenic DI is an uncommon disorder resulting in variable degrees of resistance to ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. There are two different receptors for ADH: the V1 (AVPR1) and V2 (AVPR2) receptors. The AVPR2 gene is located on the X-chromosome (Xq-28).",
"   </p>",
"   <p>",
"    Activation of the V1 receptors induces vasoconstriction and enhancement of prostaglandin release [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/1\">",
"     1",
"    </a>",
"    ], while the V2 receptors mediate the antidiuretic response as well as peripheral vasodilation and the release of factor VIIIc and von Willebrand's factor from endothelial cells (",
"    <a class=\"graphic graphic_figure graphicRef79887 \" href=\"UTD.htm?19/7/19571\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also several congenital polyuric-polydipsic Bartter-like syndromes associated with urinary concentrating defects of varying severity. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Other inherited disorders'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"     \"Bartter and Gitelman syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Vasopressin V2 receptor gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of cases of hereditary nephrogenic DI have X-linked inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. They are due to mutations in the AVPR2 gene, which encodes for a dysfunctional vasopressin V2 receptor (V2R).",
"   </p>",
"   <p>",
"    Several hundred putative disease-causing AVPR2 mutations have been identified in ancestrally independent families. Most of these mutant proteins are misfolded, trapped in the endoplasmic reticulum and unable to reach the basolateral cell surface of the principal cells of the collecting ducts to engage circulating vasopressin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/6\">",
"     6",
"    </a>",
"    ]. In patients with AVPR2 mutations, the antidiuretic, vasodilator, and coagulation factor responses to ADH are impaired, while the vasoconstrictor and prostaglandin effects are intact [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The X-linked inheritance means that males tend to have more pronounced polyuria. Female carriers are usually asymptomatic because they have a normal gene on the second X chromosome. However, occasional females have severe polyuria. The presumed mechanism is that X chromosome inactivation is skewed in such a way that the normal X chromosome is preferentially inactivated, leaving the mutant X chromosome dominantly expressed in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although heterozygous female individuals may be asymptomatic most of the time, they may develop polyuria during pregnancy when vasopressinases released from the placenta markedly increase the clearance of endogenous ADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link&amp;anchor=H22#H22\">",
"     \"Renal and urinary tract physiology in normal pregnancy\", section on 'Polyuria and diabetes insipidus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no specific therapy for X-linked nephrogenic DI due to mutations in the AVPR2 gene. However, studies in a mouse model in which the V2 vasopressin receptors were deleted showed that activation of renal EP4 prostaglandin E2 receptors with a selective agonist could compensate for the lack of functional V2 receptors and could markedly reduce all of the manifestations of the disease, including the polyuria and alterations in renal morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/14\">",
"     14",
"    </a>",
"    ]. Nonpeptide vasopressin receptor agonists have been identified that can activate the mutant V2R receptors at their intracellular sites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/15\">",
"     15",
"    </a>",
"    ]. These and other treatment issues in patients with nephrogenic DI are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of nephrogenic diabetes insipidus\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Aquaporin-2 gene mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second form of hereditary nephrogenic DI is caused by a defect in the aquaporin-2 gene that encodes the ADH-sensitive water channels in the collecting tubule cells. This variant may have autosomal recessive or autosomal dominant modes of inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/7,10,12,16-24\">",
"     7,10,12,16-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aquaporin-2 channels are normally stored in the cytosol. Under the influence of ADH, the aquaporin-2 water channels are phosphorylated at Ser-256 and Ser-264 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/25\">",
"     25",
"    </a>",
"    ] and redistributed to the apical (luminal) membrane, thereby allowing water to be reabsorbed down the favorable concentration gradient from the tubular fluid into the hypertonic medullary interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/20,21,26\">",
"     20,21,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link&amp;anchor=H2#H2\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\", section on 'Actions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one kindred, the autosomal dominant form of nephrogenic DI was mediated by lack of phosphorylation of the aquaporin-2 water channel [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/27\">",
"     27",
"    </a>",
"    ]. Such defects impair trafficking of the water channels, preventing their fusion with the luminal membrane, and decrease channel function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/7,10,17,23\">",
"     7,10,17,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inherited defects of the aquaporin-2 water channel can be distinguished clinically from the more common V2 receptor defect by evaluating, in male patients, the extrarenal responses to ADH: vasodilation and release of factor VIIIc and von Willebrand's factor from endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/23,28\">",
"     23,28",
"    </a>",
"    ]. These responses are intact in patients with defective water channels and impaired in patients with defective V2 receptors. Molecular genetic testing is also available [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lithium toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyuria due to impaired urinary concentrating ability occurs in up to 20 percent of patients treated with chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    therapy; an additional 30 percent have a subclinical impairment in concentrating ability. These adverse effects are mediated by lithium entry into the principal cells in the collecting tubule via the epithelial sodium channel (ENaC) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/29\">",
"     29",
"    </a>",
"    ]. At cytotoxic concentrations, lithium inhibits signaling pathways that involve glycogen synthase kinase type 3, resulting in dysfunction of the aquaporin-2 water channel [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal toxicity of lithium\", section on 'Nephrogenic diabetes insipidus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal concentrating defect may become clinically apparent if the plasma calcium concentration is persistently above 11",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.75",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/1\">",
"     1",
"    </a>",
"    ]. This defect, which is generally reversible with correction of the hypercalcemia, may be associated with reductions both in sodium chloride reabsorption in the thick ascending limb of the loop of Henle, thereby interfering with the countercurrent mechanism, and in the ability of ADH to increase collecting tubule water permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of hypercalcemia\", section on 'Nephrogenic diabetes insipidus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism by which these changes occur is incompletely understood. Calcium deposition in the medulla with secondary tubulointerstitial injury may play an important role [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, activation of the calcium-sensing receptor can directly impair concentrating ability by affecting both the loop of Henle and the collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium-sensing receptors are expressed on the",
"      <strong>",
"       basolateral",
"      </strong>",
"      membrane in the thick ascending limb of the loop of Henle. Activation of these receptors by calcium reduces sodium chloride and calcium reabsorption in the thick ascending limb, an effect that appears to be mediated by the generation of a P450 arachidonic acid metabolite (possibly 20-HETE) which then induces closure of the luminal potassium channel [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/34\">",
"       34",
"      </a>",
"      ]. Inhibition of loop sodium chloride reabsorption impairs generation of the medullary osmotic gradient that is essential for urinary concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=see_link\">",
"       \"Chapter 4A: Cell model for loop of Henle transport\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=see_link\">",
"       \"Chapter 4B: Countercurrent mechanism\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Hypercalcemia also enhances the generation of prostaglandin E2, which can contribute to the impairment in sodium chloride reabsorption in the thick ascending limb [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/31,35\">",
"       31,35",
"      </a>",
"      ]. This response may be mediated by angiotensin II-induced activation of phospholipase A2 and prostaglandin H synthase-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/35\">",
"       35",
"      </a>",
"      ]. In hypercalcemic rats, the associated polyuria can be abolished by the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      , an angiotensin II receptor blocker [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcium-sensing receptors are also expressed on the",
"      <strong>",
"       luminal",
"      </strong>",
"      membrane of the cells of the inner medullary collecting duct (IMCD). By reducing calcium and sodium reabsorption in the loop of Henle, hypercalcemia is associated with an increase in calcium delivery to the luminal IMCD calcium-sensing receptors; their activation reduces the antidiuretic hormone-induced increase in water permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies in patients with familial hypocalciuric hypercalcemia have demonstrated the importance of hypercalciuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the calcium-sensing receptor in the concentrating defect associated with hypercalcemia. The primary defect in this disorder is an inactivating mutation of the calcium-sensing receptors leading to a reduction in urinary calcium excretion. Affected patients have normal concentrating ability despite persistent hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypercalcemia may also impair water reabsorption by decreasing the number of water channels in the collecting tubules. In a rodent study, a large decrease in aquaporin-2 expression was observed in the inner medulla and cortex of hypercalcemic rats compared to control animals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/38\">",
"     38",
"    </a>",
"    ]. This was associated with an increase in urine output and a reduction in urine osmolality.",
"   </p>",
"   <p>",
"    The concentrating defect induced by hypercalcemia is generally reversible with restoration of a normal serum calcium concentration. However, the defect may persist in patients in whom interstitial nephritis has induced permanent medullary damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent severe hypokalemia (plasma potassium concentration usually below 3",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    can impair urinary concentrating ability. As with hypercalcemia, both decreased collecting tubule responsiveness to ADH (which may be mediated by decreased expression of aquaporin-2) and diminished sodium chloride reabsorption in the thick ascending limb have been demonstrated in experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypokalemia-induced renal dysfunction\", section on 'Impaired urinary concentrating ability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The concentrating defect is generally less severe than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    toxicity or hypercalcemia, and symptomatic polyuria and polydipsia are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/1\">",
"     1",
"    </a>",
"    ]. When these symptoms do occur, direct stimulation of thirst (via an unknown mechanism) may play a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrogenic DI has been described in a number of other clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic nephrogenic DI can be seen in a variety of renal diseases, including release of bilateral urinary tract obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/43\">",
"     43",
"    </a>",
"    ], sickle cell disease or trait, autosomal dominant polycystic kidney disease and medullary cystic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], renal amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/46\">",
"     46",
"    </a>",
"    ], and Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/47\">",
"     47",
"    </a>",
"    ]. In the last two conditions, amyloid deposits in and lymphocytic infiltration around the collecting tubules are presumably responsible for the decline in ADH responsiveness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=see_link\">",
"     \"Urine output in urinary tract obstruction and postobstructive diuresis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link\">",
"     \"Renal manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\", section on 'Concentrating defect'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=see_link\">",
"     \"Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=see_link\">",
"     \"Renal disease in Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A decline in urinary concentrating ability is also common in patients with acute or chronic kidney disease. A variety of factors contribute including decreased tubular responsiveness to ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], and interference with the countercurrent mechanism in diseases affecting the renal medulla, such as chronic pyelonephritis and analgesic abuse nephropathy. In addition, the decrease in the number of functioning nephrons in patients with acute or chronic kidney disease means that each remaining nephron must excrete a larger proportion of the total solute load. The net result is an osmotic diuresis that limits the ability to concentrate the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Despite the impairment in concentrating ability, patients with acute or chronic kidney disease do",
"    <strong>",
"     not",
"    </strong>",
"    usually develop polyuria for at least two reasons: the glomerular filtration rate, and therefore the filtered fluid load, is substantially reduced; and the urine osmolality is usually isosmotic or only slightly hypoosmotic to plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrogenic DI can be caused by a number of drugs other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    which are used to treat cytomegalovirus infection in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], and vasopressin V2 receptor antagonists, which induce a transient state of nephrogenic DI that can be used to treat hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/54,55\">",
"     54,55",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     demeclocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/4,56\">",
"     4,56",
"    </a>",
"    ]. Drug-induced nephrogenic DI is typically reversible, at least in part [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unusual form of transient ADH-resistance occurs in selected women during the second half of pregnancy, a disorder that has been called gestational diabetes insipidus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Craniopharyngioma surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniopharyngioma has been associated with central DI both before surgery and particularly after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\", section on 'Neurosurgery or trauma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A different mechanism is responsible in at least some patients who develop early polyuria following transfrontal surgery for craniopharyngioma. In this setting, the increase in urine output may result from the release of an ADH precursor from the hypothalamus that competes for but does not activate the antidiuretic vasopressin V2 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/60\">",
"     60",
"    </a>",
"    ]. These patients initially have high ADH levels by immunoassay, but little or no biological activity and a diminished response to exogenous hormone replacement. Thus, they behave as if they have nephrogenic DI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Bardet-Biedl syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bardet-Biedl syndrome is an autosomal recessive disorder that is characterized by obesity and a number of other abnormalities, including hypogenitalism in men, mental retardation, retinal dystrophy, polydactyly, renal malformations (particularly calyceal abnormalities), hypertension and, over time, progressive chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polyuria and polydipsia are among the most common and earliest symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/61\">",
"     61",
"    </a>",
"    ]. A urinary concentration defect can be detected when kidney function is near normal and in the absence of major cyst formation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/63\">",
"     63",
"    </a>",
"    ]. Bardet-Biedl derived renal epithelial cells are nonciliated and the vasopressin V2 receptor, which is activated by ADH in normal individuals, is localized in the primary cilium [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/63\">",
"     63",
"    </a>",
"    ]. In in vitro studies, these cells did not respond to luminal vasopressin and did not activate luminal aquaporin-2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bartter syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several congenital polyuric-polydipsic Bartter syndromes associated with nephrogenic DI of varying severity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/10,64,65\">",
"     10,64,65",
"    </a>",
"    ]. These patients have various degrees of polyuria that may be poorly investigated and confused with \"pure\" hereditary nephrogenic DI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/8\">",
"     8",
"    </a>",
"    ]. However, patients with \"pure\" nephrogenic DI handle sodium and potassium normally in contrast to patients with Bartter syndrome who have renal sodium and potassium wasting. In addition, Bartter syndrome may start prenatally, with polyhydramnios frequently leading to prematurity. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Hereditary nephrogenic DI'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link&amp;anchor=H3869725#H3869725\">",
"     \"Bartter and Gitelman syndromes\", section on 'Bartter syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of Bartter syndrome can also be distinguished from \"pure\" hereditary nephrogenic DI in part by sequencing the carboxyl terminus or the last exons of SLC12A1 and KCNJ1 (which are two of the five genes underlying Bartter syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/8\">",
"     8",
"    </a>",
"    ]. This approach may be informative because most mutations in SLC12A1 and KCNJ1 are found in the carboxyl terminus or in the last exon, and, as a consequence, are amenable to rapid DNA sequencing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other inherited disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other inherited disorders with a mild, moderate, or severe inability to concentrate the urine include nephronophthisis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], cystinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/68\">",
"     68",
"    </a>",
"    ], familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/69\">",
"     69",
"    </a>",
"    ], and the syndrome of apparent mineralocorticoid excess in which the polyuria is presumed to be due to chronic hypokalemia, as described above [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16744?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis, and treatment of nephronophthisis\", section on 'Renal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link&amp;anchor=H8#H8\">",
"     \"Cystinosis\", section on 'Renal symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=see_link\">",
"     \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Hypokalemia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link&amp;anchor=H8658123#H8658123\">",
"     \"Causes of hypomagnesemia\", section on 'Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .) The ARC syndrome (arthrogryposis-renal dysfunction-cholestasis), a rare autosomal recessive multisystem disorder caused by mutations in VPS33B [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/72\">",
"     72",
"    </a>",
"    ] and VIPAR [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21545/abstract/73\">",
"     73",
"    </a>",
"    ], is also associated with renal tubular dysfunction, medullary nephrocalcinosis, and nephrogenic diabetes insipidus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=see_link\">",
"       \"Patient information: Diabetes insipidus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578595\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrogenic diabetes insipidus (DI) refers to a decrease in urinary concentrating ability that results from resistance to the action of antidiuretic hormone (ADH). This problem can reflect resistance at the ADH site of action in the collecting tubules, or interference with the countercurrent mechanism due, for example, to medullary injury or to decreased sodium chloride reabsorption in the medullary aspect of the thick ascending limb of the loop of Henle (",
"      <a class=\"graphic graphic_figure graphicRef51077 \" href=\"UTD.htm?1/18/1317\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with moderate to severe nephrogenic or central DI typically present with polyuria, nocturia, and polydipsia. The first manifestation of a mild to moderate loss of concentrating ability is often nocturia. (See",
"      <a class=\"local\" href=\"#H141708491\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of nephrogenic DI in children are genetic mutations; in adults, nephrogenic DI is most often due to drugs, hypercalcemia, and hypokalemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutations in the vasopressin V2 receptor gene, which is X-linked, and the aquaporin-2 gene, which is autosomal, are the two most frequent causes of hereditary nephrogenic DI. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hereditary nephrogenic DI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired symptomatic nephrogenic DI occurring in adults is usually due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      toxicity or hypercalcemia. The polyuria in these settings is at least partially reversible with cessation of lithium or correction of the hypercalcemia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lithium toxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less frequent causes of nephrogenic DI include a variety of genetic and acquired conditions, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Renal diseases such as bilateral urinary tract obstruction, sickle cell disease or trait, renal amyloidosis, and Sj&ouml;gren's syndrome. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      , vasopressin V2 receptor antagonists,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"       demeclocycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"       orlistat",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy, which is associated with release of a vasopressinase from the placenta. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Craniopharyngioma surgery. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Craniopharyngioma surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bardet-Biedl syndrome, Bartter syndrome, nephronophthisis, cystinosis, familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), and the syndrome of apparent mineralocorticoid excess. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bardet-Biedl syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Bartter syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Other inherited disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.754.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/2\">",
"      Teitelbaum I, McGuinness S. Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA. J Clin Invest 1995; 96:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/3\">",
"      Trudel E, Bourque CW. Central clock excites vasopressin neurons by waking osmosensory afferents during late sleep. Nat Neurosci 2010; 13:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/4\">",
"      Garofeanu CG, Weir M, Rosas-Arellano MP, et al. Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis 2005; 45:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/5\">",
"      van Lieburg AF, Knoers NV, Monnens LA. Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1999; 10:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/6\">",
"      Morello JP, Salahpour A, Laperri&egrave;re A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000; 105:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/7\">",
"      Devonald MA, Karet FE. Renal epithelial traffic jams and one-way streets. J Am Soc Nephrol 2004; 15:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/8\">",
"      Bichet DG. Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol 2006; 26:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/9\">",
"      Bichet DG, Razi M, Lonergan M, et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988; 318:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/10\">",
"      Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005; 16:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/11\">",
"      Bichet DG. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008; 28:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/12\">",
"      Sasaki S. Nephrogenic diabetes insipidus: update of genetic and clinical aspects. Nephrol Dial Transplant 2004; 19:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/13\">",
"      Nomura Y, Onigata K, Nagashima T, et al. Detection of skewed X-inactivation in two female carriers of vasopressin type 2 receptor gene mutation. J Clin Endocrinol Metab 1997; 82:3434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/14\">",
"      Li JH, Chou CL, Li B, et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest 2009; 119:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/15\">",
"      Robben JH, Kortenoeven ML, Sze M, et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci U S A 2009; 106:12195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/16\">",
"      Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol 2012; 27:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/17\">",
"      Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/18\">",
"      Deen PM, Croes H, van Aubel RA, et al. Water channels encoded by mutant aquaporin-2 genes in nephrogenic diabetes insipidus are impaired in their cellular routing. J Clin Invest 1995; 95:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/19\">",
"      Asai T, Kuwahara M, Kurihara H, et al. Pathogenesis of nephrogenic diabetes insipidus by aquaporin-2 C-terminus mutations. Kidney Int 2003; 64:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/20\">",
"      Yamamoto T, Sasaki S. Aquaporins in the kidney: emerging new aspects. Kidney Int 1998; 54:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/21\">",
"      Kozono D, Yasui M, King LS, Agre P. Aquaporin water channels: atomic structure molecular dynamics meet clinical medicine. J Clin Invest 2002; 109:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/22\">",
"      Oksche A, M&ouml;ller A, Dickson J, et al. Two novel mutations in the aquaporin-2 and the vasopressin V2 receptor genes in patients with congenital nephrogenic diabetes insipidus. Hum Genet 1996; 98:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/23\">",
"      Hochberg Z, Van Lieburg A, Even L, et al. Autosomal recessive nephrogenic diabetes insipidus caused by an aquaporin-2 mutation. J Clin Endocrinol Metab 1997; 82:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/24\">",
"      Loonen AJ, Knoers NV, van Os CH, Deen PM. Aquaporin 2 mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008; 28:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/25\">",
"      Fenton RA, Moeller HB, Hoffert JD, et al. Acute regulation of aquaporin-2 phosphorylation at Ser-264 by vasopressin. Proc Natl Acad Sci U S A 2008; 105:3134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/26\">",
"      Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/27\">",
"      de Mattia F, Savelkoul PJ, Kamsteeg EJ, et al. Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus. J Am Soc Nephrol 2005; 16:2872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/28\">",
"      Bichet DG, Oksche A, Rosenthal W. Congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1997; 8:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/29\">",
"      Gr&uuml;nfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/30\">",
"      Berl T. The cAMP system in vasopressin-sensitive nephron segments of the vitamin D-treated rat. Kidney Int 1987; 31:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/31\">",
"      Peterson LN, McKay AJ, Borzecki JS. Endogenous prostaglandin E2 mediates inhibition of rat thick ascending limb Cl reabsorption in chronic hypercalcemia. J Clin Invest 1993; 91:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/32\">",
"      Rosen S, Greenfeld Z, Bernheim J, et al. Hypercalcemic nephropathy: chronic disease with predominant medullary inner stripe injury. Kidney Int 1990; 37:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/33\">",
"      Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996; 50:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/34\">",
"      Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 1996; 271:C103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/35\">",
"      Mangat H, Peterson LN, Burns KD. Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. Role of angiotensin II AT1 receptors. J Clin Invest 1997; 100:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/36\">",
"      Sands JM, Naruse M, Baum M, et al. Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J Clin Invest 1997; 99:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/37\">",
"      Brown EM, Hebert SC. A cloned Ca(2+)-sensing receptor: a mediator of direct effects of extracellular Ca2+ on renal function? J Am Soc Nephrol 1995; 6:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/38\">",
"      Earm JH, Christensen BM, Fr&oslash;kiaer J, et al. Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol 1998; 9:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/39\">",
"      Marples D, Fr&oslash;kiaer J, D&oslash;rup J, et al. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest 1996; 97:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/40\">",
"      Luke RG, Booker BB, Galla JH. Effect of potassium depletion on chloride transport in the loop of Henle in the rat. Am J Physiol 1985; 248:F682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/41\">",
"      Elkjaer ML, Kwon TH, Wang W, et al. Altered expression of renal NHE3, TSC, BSC-1, and ENaC subunits in potassium-depleted rats. Am J Physiol Renal Physiol 2002; 283:F1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/42\">",
"      Berl T, Linas SL, Aisenbrey GA, Anderson RJ. On the mechanism of polyuria in potassium depletion. The role of polydipsia. J Clin Invest 1977; 60:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/43\">",
"      Fr&oslash;kiaer J, Marples D, Knepper MA, Nielsen S. Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney. Am J Physiol 1996; 270:F657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/44\">",
"      Gabow PA, Kaehny WD, Johnson AM, et al. The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 1989; 35:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/45\">",
"      Scolari F, Caridi G, Rampoldi L, et al. Uromodulin storage diseases: clinical aspects and mechanisms. Am J Kidney Dis 2004; 44:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/46\">",
"      CARONE FA, EPSTEIN FH. Nephrogenic diabetes insipidus caused by amyloid disease. Evidence in man of the role of the collecting ducts in concentrating urine. Am J Med 1960; 29:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/47\">",
"      SHEARN MA, TU WH. NEPHROGENIC DIABETIC INSIPIDUS AND OTHER DEFECTS OF RENAL TUBULAR FUNCTION IN SJOERGREN'S SYNDROME. Am J Med 1965; 39:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/48\">",
"      Fine LG, Schlondorff D, Trizna W, et al. Functional profile of the isolated uremic nephron. Impaired water permeability and adenylate cyclase responsiveness of the cortical collecting tubule to vasopressin. J Clin Invest 1978; 61:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/49\">",
"      Tannen RL, Regal EM, Dunn MJ, Schrier RW. Vasopressin-resistant hyposthenuria in advanced chronic renal disease. N Engl J Med 1969; 280:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/50\">",
"      KLEEMAN CR, ADAMS DA, MAXWELL MH. An evaluation of maximal water diuresis in chronic renal disease. I. Normal solute intake. J Lab Clin Med 1961; 58:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/51\">",
"      DORHOUT MEES EJ. Relation between maximal urine concentration, maximal water reabsorption capacity, and mannitol clearance in patients with renal disease. Br Med J 1959; 1:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/52\">",
"      Schliefer K, Rockstroh JK, Spengler U, Sauerbruch T. Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet 1997; 350:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/53\">",
"      Navarro JF, Quereda C, Quereda C, et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 1996; 27:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/54\">",
"      Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/55\">",
"      Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/56\">",
"      D'Ythurbide G, Goujard C, M&eacute;cha&iuml; F, et al. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrol Dial Transplant 2007; 22:3656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/57\">",
"      Brewster UC, Hayslett JP. Diabetes insipidus in the third trimester of pregnancy. Obstet Gynecol 2005; 105:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/58\">",
"      Aleksandrov N, Audibert F, Bedard MJ, et al. Gestational diabetes insipidus: a review of an underdiagnosed condition. J Obstet Gynaecol Can 2010; 32:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/59\">",
"      Ghirardello S, Hopper N, Albanese A, Maghnie M. Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. J Pediatr Endocrinol Metab 2006; 19 Suppl 1:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/60\">",
"      Seckl JR, Dunger DB, Bevan JS, et al. Vasopressin antagonist in early postoperative diabetes insipidus. Lancet 1990; 335:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/61\">",
"      Anadoliiska A, Roussinov D. Clinical aspects of renal involvement in Bardet-Biedl syndrome. Int Urol Nephrol 1993; 25:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/62\">",
"      Parfrey PS, Davidson WS, Green JS. Clinical and genetic epidemiology of inherited renal disease in Newfoundland. Kidney Int 2002; 61:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/63\">",
"      Marion V, Schlicht D, Mockel A, et al. Bardet-Biedl syndrome highlights the major role of the primary cilium in efficient water reabsorption. Kidney Int 2011; 79:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/64\">",
"      Peters M, Jeck N, Reinalter S, et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 2002; 112:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/65\">",
"      Jeck N, Schlingmann KP, Reinalter SC, et al. Salt handling in the distal nephron: lessons learned from inherited human disorders. Am J Physiol Regul Integr Comp Physiol 2005; 288:R782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/66\">",
"      Hildebrandt F, Attanasio M, Otto E. Nephronophthisis: disease mechanisms of a ciliopathy. J Am Soc Nephrol 2009; 20:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/67\">",
"      Bodaghi E, Honarmand MT, Ahmadi M. Infantile nephronophthisis. Int J Pediatr Nephrol 1987; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/68\">",
"      Knoepfelmacher M, Rocha R, Salgado LR, et al. [Nephropathic cystinosis: report of 2 cases and review of the literature]. Rev Assoc Med Bras 1994; 40:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/69\">",
"      Praga M, Vara J, Gonz&aacute;lez-Parra E, et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney Int 1995; 47:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/70\">",
"      Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1998; 83:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/71\">",
"      Bockenhauer D, van't Hoff W, Dattani M, et al. Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases. Nephron Physiol 2010; 116:p23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/72\">",
"      Gissen P, Johnson CA, Morgan NV, et al. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet 2004; 36:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21545/abstract/73\">",
"      Cullinane AR, Straatman-Iwanowska A, Zaucker A, et al. Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. Nat Genet 2010; 42:303.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2289 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21545=[""].join("\n");
var outline_f21_2_21545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H578595\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141708491\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hereditary nephrogenic DI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Vasopressin V2 receptor gene mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Aquaporin-2 gene mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lithium toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Craniopharyngioma surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Bardet-Biedl syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bartter syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other inherited disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H578595\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2289\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2289|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/18/1317\" title=\"figure 1\">",
"      Urinary concentrating mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/7/19571\" title=\"figure 2\">",
"      AVP and AVP receptor 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33721?source=related_link\">",
"      Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=related_link\">",
"      Chapter 4A: Cell model for loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=related_link\">",
"      Chapter 4B: Countercurrent mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16744?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=related_link\">",
"      Hypokalemia-induced renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=related_link\">",
"      Patient information: Diabetes insipidus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=related_link\">",
"      Renal disease in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=related_link\">",
"      Treatment of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=related_link\">",
"      Urine output in urinary tract obstruction and postobstructive diuresis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_2_21546="The global human immunodeficiency virus pandemic";
var content_f21_2_21546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The global human immunodeficiency virus pandemic",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/2/21546/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/2/21546/contributors\">",
"     Thomas C Quinn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/2/21546/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/2/21546/contributors\">",
"     John A Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/2/21546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/2/21546/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/2/21546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acquired immunodeficiency syndrome (AIDS) was first recognized among homosexual men in the United States in 1981 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. While initially limited, infection with the human immunodeficiency virus (HIV) has literally exploded over the past three decades to become the worst epidemic of the twentieth century. With more than 35 million fatalities, the AIDS epidemic now ranks alongside the influenza pandemic of the early 1900s and the Bubonic plague of the fourteenth century in terms of fatalities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/3\">",
"     3",
"    </a>",
"    ]. The impact of this disease on human suffering, cultures, demographics, economics, and even politics has been felt in nearly every society across the globe.",
"   </p>",
"   <p>",
"    Unfortunately, the epidemic continues to spread relentlessly into new areas and to consolidate in many other locations. In some countries in sub-Saharan Africa, the AIDS epidemic has caused a dramatic effect on depopulation and decreased fertility.",
"   </p>",
"   <p>",
"    The most recent statistics on estimates of",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    by region, past and present trends, and future projections of the epidemic will be reviewed here. Updated information on global statistics is available on the Joint United Nations Programme on",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    (UNAIDS) and on the United States Centers for Disease Control and Prevention (CDC) websites:",
"    <a class=\"external\" href=\"file://www.unaids.org/\">",
"     www.unaids.org",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.cdc.gov/\">",
"     www.cdc.gov",
"    </a>",
"    , respectively.",
"   </p>",
"   <p>",
"    This topic reviews worldwide statistics on the global HIV epidemic, modes of transmission, and the introduction of antiretroviral therapy (ART) into resource-limited settings. The clinical impact of ART on morbidity and mortality is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=see_link\">",
"     \"The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ORIGIN OF THE HIV EPIDEMIC",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Zoonotic transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular phylogenetic studies suggest that HIV evolved from a lentivirus, simian immunodeficiency virus (SIV), which has been found in some subspecies of monkeys from Bioko (an island off the East African coast) and some subspecies of chimpanzees in the Cameroon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Researchers believe that all the SIV strains infecting the monkeys across Africa diverged from a common ancestor between 32,000 and 78,000 years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Several lines of evidence support zoonotic transmission of primate lentiviruses into humans [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similarities in viral genome between SIV and HIV",
"     </li>",
"     <li>",
"      Prevalence in the natural host",
"     </li>",
"     <li>",
"      Geographic association between the animal reservoir and emergence of human cases",
"     </li>",
"     <li>",
"      Plausible route of transmission",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HIV has evolved into groups M, N, O, and P; M (\"Main\") is considered the pandemic strain and comprises the vast majority of strains of HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Viruses from group M are subsequently divided into ten distinct subtypes or clades (A to J). Group O (\"Outlier\") represents far fewer strains from Cameroon, Gabon, and Equatorial Guinea. Group N",
"    <span class=\"nowrap\">",
"     (\"non-M/non-O\")",
"    </span>",
"    is represented by very few isolates and has only been documented in Cameroon. In 2009, a novel HIV virus that is closely related to SIV strains found in gorillas was isolated from a woman in the Cameroon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/8\">",
"     8",
"    </a>",
"    ]. This virus is distinct from HIV groups M, N, and O and has been designated as a prototype of a new lineage of HIV viruses named \"group P\".",
"   </p>",
"   <p>",
"    Studies have been performed to ascertain the origins of HIV infection. In an extensive field study, SIV-specific antibodies and nucleic acids were assayed in urine and fecal samples collected from the forest floor in the Cameroon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/9\">",
"     9",
"    </a>",
"    ]. Through sequence analysis, the origins of pandemic (group M) and nonpandemic (group N) HIV could be traced to distinct, geographically isolated chimpanzee communities. The origin of group O HIV is still unknown.",
"   </p>",
"   <p>",
"    Direct evidence of simian-to-human transmission is still missing, but is inferred by the known practice of hunting chimpanzees for food (\"bushmeat\"), particularly in western Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/6\">",
"     6",
"    </a>",
"    ]. Unlike other more readily transmitted zoonoses, important viral adaptations may have been required for HIV to infect humans. These adaptations may have included the acquisition of viral regulatory genes such as vpu, vif, nef, and tat, and structural genes, gag and env [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical implications of SIV infection in natural hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was generally believed that unlike HIV, SIV infection did not lead to acquired immunodeficiency syndrome (AIDS) in their natural hosts. However, one study demonstrated that SIVcpz is pathogenic in free-ranging chimpanzees [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/10\">",
"     10",
"    </a>",
"    ]. During a nine-year follow-up of 94 members of two chimpanzee communities in Gombe National Park, Tanzania, a 10- to 16-fold higher death hazard was demonstrated for SIVcpz-infected (n = 17) compared to uninfected (n = 77) chimpanzees, after adjusting for age. They also found that SIVcpz-infected females were less likely to give birth and had a higher infant mortality rate than uninfected females.",
"   </p>",
"   <p>",
"    Immunohistochemistry and in situ hybridization of post-mortem spleen and lymph node samples from three infected and two uninfected chimpanzees revealed significant CD4(+) T-cell depletion in all infected individuals, with evidence of high viral replication and extensive follicular dendritic cell virus trapping in one of them. One female, who died within three years of acquiring SIVcpz, had histopathological findings consistent with end-stage AIDS.",
"   </p>",
"   <p>",
"    These results indicate that SIVcpz, like HIV-1, is associated with progressive CD4(+) T-cell loss, lymphatic tissue destruction, and premature death. These findings challenge the former prevailing view that all natural SIV infections are non-pathogenic and suggest that SIVcpz has a substantial negative impact on the health, reproduction and lifespan of chimpanzees in the wild [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/10\">",
"     10",
"    </a>",
"    ]. Similarly, SIV can cause AIDS after cross-species transmission from asymptomatic African sooty mangabeys (SIVsm) to Asian macaques [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     WORLDWIDE STATISTICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General statistics",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of December 2011, 34 million people were estimated to be living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    and more than 35 million had died since the beginning of the epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/12\">",
"     12",
"    </a>",
"    ]. Of the 34 million, 23.5 million were living in sub-Saharan Africa alone, where the adult prevalence rate is 4.9 percent; the prevalence in sub-Saharan Africa appears to have stabilized mainly due to a slowing in the incidence and increasing number of infected people accessing treatment. More than half of those living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    are women. It is estimated that 25 million children have been orphaned by the premature death of both parents due to AIDS, placing enormous responsibilities on communities, and 2.5 million children are living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    terms of the recent growth of the epidemic, an estimated 2.5 million people became newly infected with HIV in 2011, including 330,000 children, many of whom became infected by perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. An additional 1.7 million people died due to AIDS in 2011, including 260,000 children. Each day, 7000 people become newly infected with HIV, with increasing numbers among young adults, women, and children.",
"   </p>",
"   <p>",
"    Of the 330,000 infants and children infected with HIV in year 2011, 70 percent were born in sub-Saharan Africa, 25 percent in Southeast Asia, and the remainder in Latin America and the Caribbean [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/12\">",
"     12",
"    </a>",
"    ]. With escalation of the epidemic in Southeast Asia and Eastern Europe, these numbers are only likely to increase, unless more aggressive prevention campaigns and interventions programs intercede to slow the pace of the epidemic.",
"   </p>",
"   <p>",
"    Countries in sub-Saharan Africa and the Caribbean currently have the highest national rates of adult HIV prevalence. In the year 2011, the adult HIV prevalence ranged from 0.1 percent in East Asia to 7.2 percent in sub-Saharan Africa overall and to &gt;35 percent in some countries, such as Botswana and Swaziland [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Part of this disparity can be attributed to the maturity of the epidemics in Africa and the more recent introduction of HIV into some other areas of the world. Unfortunately, data regarding the incidence or current spread of HIV are scarce.",
"   </p>",
"   <p>",
"    The following figures for HIV infection globally by the end of year 2008 are among the most distressing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      34 million adults and children were living with",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"     </li>",
"     <li>",
"      2.5 million people had been newly infected with HIV in 2008",
"     </li>",
"     <li>",
"      1.7 million people died of AIDS in 2008",
"     </li>",
"     <li>",
"      The prevalence of HIV appears to have stabilized, or increased in some countries due to increased survival of infected people due to treatment with antiretroviral drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sub-Saharan Africa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of the world population lives in sub-Saharan Africa, but the region is home to approximately 64 percent of the world population living with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/3\">",
"     3",
"    </a>",
"    ]. All countries in this region have an HIV seroprevalence rate that is above 5 percent, with some as high as 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/3\">",
"     3",
"    </a>",
"    ]. In 33 countries though, HIV incidence has fallen by more than 25 percent between 2001 and 2009. Of these countries 22 are in sub-Saharan Africa. The biggest epidemics in sub-Saharan Africa (Ethiopia, Nigeria, South Africa, Zambia and Zimbabwe) have either stabilized or are showing signs of decline.",
"   </p>",
"   <p>",
"    Sub-Saharan Africa has a high rate of HIV infection, mostly related to heterosexual transmission. A study was performed of more than 4000 men and women from Rwanda and Zambia who underwent voluntary counseling and testing for HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/14\">",
"     14",
"    </a>",
"    ]. An estimated 55 to 93 percent of new heterosexually acquired HIV infections among adults occurred within serodiscordant marital or cohabiting relationships.",
"   </p>",
"   <p>",
"    Little is known about the overall prevalence of male same-sex behaviors in African societies, although there has been a surge in research in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Asia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the 4.8 million HIV-infected persons living in Asia, more than half live in India [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/3\">",
"     3",
"    </a>",
"    ]. The estimates for India are based primarily on anonymous testing data from public clinics for prenatal care and for patients with other STDs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/16\">",
"     16",
"    </a>",
"    ]. Approximately 85 percent of HIV transmission in India is thought to be through sexual contact. Barriers to control of the epidemiologic include the lack of social acceptance of condoms and laws making homosexuality illegal and punishable by imprisonment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In China, the government estimates that over one million people are infected with HIV, which represents an HIV prevalence of approximately 0.05 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/17\">",
"     17",
"    </a>",
"    ]. Most cases are concentrated in five provinces: Guangdong, Guangxi, Xinjiang, Yunnan, and Henan, where residents became infected through contaminated equipment at a plasma donation center. Among new HIV infections in China, 49 percent are caused by drug use and approximately 50 percent by sexual transmission. In 2007, MSM accounted for 12 percent of the 50,000 estimated new HIV infections in China; a significant association has also been found with an increasing prevalence of syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high HIV prevalence has also been found among MSM in other Asian countries including Cambodia (9 percent), Thailand (15 percent), and India (18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Americas",
"    </span>",
"    &nbsp;&mdash;&nbsp;After sub-Saharan Africa, the Caribbean has the second highest HIV seroprevalence rates in the world [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the end of 2009, an estimated 1.2 million persons in the United States were living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/19\">",
"     19",
"    </a>",
"    ]. In 2010, there were an estimated 47,230 new diagnoses, or 16.1 diagnoses per 100,000 persons, among the 46 states with confidential name-based reporting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/20\">",
"     20",
"    </a>",
"    ]. The rate of new HIV diagnoses was higher than average among certain racial and ethnic minorities, particularly African-Americans, Latinos, and Pacific Islanders (62, 20, and 19 infections per 100,000 persons, respectively). Over three quarters of the",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    diagnoses among adolescents and adults were in men, primarily in men who have sex with men (MSM), followed by persons infected through high-risk heterosexual contact. In fact, approximately 64 percent of all newly diagnosed HIV infections in the United States in 2009 were in MSM; this proportion represents a continual rise from previous years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) developed an innovative system designed to estimate the number of new HIV infections (or incidence, as opposed to new diagnoses) in the United States in a given year [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/22\">",
"     22",
"    </a>",
"    ]. This system estimates duration of infection based on results of the BED HIV-1 capture enzyme immunoassay, which distinguishes recent infection (approximately 150 days after seroconversion) from chronic infection. Remnant serum specimens from patients who were diagnosed with HIV infection in 2006 from 22 states were tested with this assay, and infections were classified as recent or long standing. Based on these data, coupled with extrapolations for the entire country, the estimated incidence of infections was 56,300 in 2006; 45 percent of these infections were among black individuals and 53 percent were among MSM. Among women, the predominant HIV transmission category was high-risk heterosexual contact, which accounted for 80 percent of new infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some debate over the reliability of the BED assay, since false positive results can occur in the setting of low anti-HIV antibody levels due to antiretroviral therapy, advanced disease, and immune response variability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/24\">",
"     24",
"    </a>",
"    ]. The use of other tests (specifically an antibody avidity assay, HIV viral load measurement, and CD4 cell count) to supplement results from the BED immunoassay in a multi-assay algorithm can more accurately detect recent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a study of 2099 at-risk, predominantly black women living in urban areas of high HIV prevalence and poverty rates, the incidence of HIV infection was assessed through testing for acute and recent infection at enrollment (using a fourth generation serologic test and the multi-assay algorithm, respectively) in addition to longitudinal serologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/27\">",
"     27",
"    </a>",
"    ]. Four acute or recent HIV infections were detected at enrollment, and an additional four infections occurred over the following year, yielding an overall annual incidence of 0.32 percent, which substantially exceeds the general estimated incidence in the US. Establishing accurate estimations of HIV incidence through the use of such assays is critical to identifying populations still at greatest risk of infection, which can help target public health efforts for testing, treatment, and prevention.",
"   </p>",
"   <p>",
"    During the mid-to-late 1990s, advances in HIV treatments slowed the progression of HIV infection to AIDS and led to dramatic decreases in deaths among persons with AIDS living in the 50 states and the District of Columbia. In general, the trend in the estimated numbers of new AIDS diagnoses remained stable from 2007 through 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the number of deaths of any cause among persons with HIV infection rose slightly over that time. It is unclear what has driven this trend or whether it will continue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MODES OF TRANSMISSION AND DYNAMICS OF THE EPIDEMIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major modes of acquiring HIV infection are [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexual transmission, including via heterosexual and homosexual contact",
"     </li>",
"     <li>",
"      Parenteral transmission, predominantly among injection drug users (IDU)",
"     </li>",
"     <li>",
"      Perinatal transmission",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Men who have sex with men (MSM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the initial description of the disease mainly among men who have sex with men (MSM) in the United States, more than 80 percent of infections occur through heterosexual transmission, and over 50 percent of all HIV-infected people in the world are women [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link\">",
"     \"HIV and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mother-to-child transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the level of HIV infection is so high among women, the potential exists for large numbers of infected children, since infants can become infected with HIV in utero, at birth, or during breastfeeding. Mother-to-child transmission accounts for 90 percent of infection among children worldwide. In the worst-affected countries in the world, such as sub-Saharan Africa between 20 and 40 percent of pregnant women are HIV-infected, and one-third of their babies are infected [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/13\">",
"     13",
"    </a>",
"    ] despite data that antiretroviral drugs given at the time of delivery and to the infant after birth can largely prevent this [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/31\">",
"     31",
"    </a>",
"    ]. Unfortunately, antiretroviral prophylaxis to prevent mother-to-child transmission reaches only 10 percent or less of affected mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Injection drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection drug use (IDU) is fueling epidemics in central and eastern Europe and in some countries of Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/32\">",
"     32",
"    </a>",
"    ]. It is also a major concern in industrialized nations and the Middle East.",
"   </p>",
"   <p>",
"    A meta-analysis in 2008 examined the role of IDU as a cause of HIV transmission worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/33\">",
"     33",
"    </a>",
"    ]. Prevalence estimates of injecting drug use could be ascertained for 61 countries containing an estimated 77 percent of the world's population. Estimates suggest that 15.9 million people might inject drugs worldwide; the largest numbers of injectors were found in China, the United States, and Russia, where mid-estimates of HIV prevalence among injectors were 12, 16, and 37 percent, respectively. Furthermore, HIV prevalence among injecting drug users was 20 to 40 percent in five countries and over 40 percent in nine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EFFECT OF OTHER STDS ON HIV TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined whether reduction in the incidence of other sexually transmitted infections (STIs) might decrease the transmission of HIV. In one such study, monthly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    administration to 230 HIV-negative female sex workers in Nairobi, Kenya significantly decreased the number of cases of gonococcal and chlamydial infections but failed to affect the acquisition of HIV compared to placebo recipients (4 versus 3.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/34\">",
"     34",
"    </a>",
"    ]. The investigators speculated that the high rate of concomitant herpes simplex type 2 infection may have played a role. An earlier study in Uganda using azithromycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    to prevent a larger array of STIs also failed to impact HIV acquisition rates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INTRODUCTION OF ANTIRETROVIRAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     ART coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"3 by 5\" initiative, launched by UNAIDS and WHO in 2003, was a global strategy to provide antiretroviral therapy to three million people living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    in 50 developing countries by the end of 2005. By December 2005, 18 countries had met their \"3 by 5\" target and the number of persons receiving ART had increased from 400,000 in 2003 to 1.6 million in July 2006, representing about 20 percent of those in need of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/36\">",
"     36",
"    </a>",
"    ]. In 2009 alone, 1.2 million people received HIV antiretroviral therapy for the first time, an increase of 30 percent in a single year. Overall, the number of people receiving therapy has grown 13-fold representing more than five million people in low-and middle-income countries since 2004. By the end of 2009, ART coverage in low-income and middle-income countries stood at 35 percent of an estimated total of 15 million people in need [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/12,37\">",
"     12,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This program was subsequently replaced by The Global Fund for AIDS, Tuberculosis and Malaria as well as bilateral support like the President's Emergency Plan for AIDS Relief (PEPFAR). By the end of 2009, over 20 billion dollars had been donated and disbursed for the HIV pandemic in developing countries. One analysis demonstrated that PEPFAR was associated with a decline in all-cause mortality rates in the African countries where it operated most intensively with the greatest antiretroviral therapy coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of generic medications has been an important advance in making ART available in resource-poor countries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/39\">",
"     39",
"    </a>",
"    ]. In Zambia, for example, 21,755 adults were enrolled into HIV treatment programs at 18 primary care facilities over 19 months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/40\">",
"     40",
"    </a>",
"    ]. Adherence and adverse events on ART were comparable to that seen in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors attributed the success of this program to four factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Zambian government eliminated medical fees for all patients seeking HIV care and treatment.",
"     </li>",
"     <li>",
"      The use of nurses and other health care personnel allowed the program to proceed despite the critical physician shortage.",
"     </li>",
"     <li>",
"      Use of an electronic patient tracking system generated data critical for effective patient management.",
"     </li>",
"     <li>",
"      PEPFAR (US President's Emergency Plan for AIDS Relief) provided large scale funding, which supported this complex care system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Access to ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late access to ART has been associated with high early mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/42\">",
"     42",
"    </a>",
"    ]. In the Zambia study cited above, most mortality occurred within the first three months of starting therapy, consistent with the advanced stage of disease at presentation (mean CD4 cell count 143",
"    <span class=\"nowrap\">",
"     cells/mm3)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/40\">",
"     40",
"    </a>",
"    ]. In another community-based antiretroviral treatment program in 1340 HIV-infected patients in South Africa, more than 46 percent of the total mortality occurred after enrollment, but prior to the initiation of ART [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even transportation costs can be a major barrier for patients trying to access ART. However, one study in Uganda demonstrated that home-based care can be less costly and as efficacious as clinic-based care in attaining viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LABORATORY MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions about the initiation of ART require knowledge of the patient's CD4+ T cell counts.",
"   </p>",
"   <p>",
"    Alternatives to expensive methods, such as standard flow cytometry, have been investigated for use in resource-poor areas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study demonstrated that microcapillary flow cytometry (EasyCD4 assay) correctly identified those individuals with a CD4+ T cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      (95 percent sensitivity and 100 percent specificity) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/45\">",
"       45",
"      </a>",
"      ]. Although this technology is easier to use, requires little training of personnel, and is less expensive than flow cytometry, it still requires significant initial capital investment for the instrument.",
"     </li>",
"     <li>",
"      Manual immunobead-based methods have the advantage of only requiring routine light microscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/46\">",
"       46",
"      </a>",
"      ]. However, the results with this technique may be less reproducible.",
"     </li>",
"     <li>",
"      The \"CD4 Select\" method, which utilizes only an automatic hematoanalyzer to assess both CD4 absolute counts and percentages, was found to have greater than 90 percent correlation with standard flow cytometry [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an observational study conducted in Mozambique, CD4 testing at the point-of-care facilitated immunologic staging at the initial clinic visit, thus enabling prompt initiation of ART when needed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/48\">",
"     48",
"    </a>",
"    ]. Information about the use and interpretation of CD4 cell counts is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Monitoring treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is controversy about the best way to monitor treatment responses in resource-poor settings. In resource-rich settings, laboratory monitoring can alert the clinician to drug toxicities, the emergence of resistance, and declines of CD4+ T-cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Assessment of toxicity and clinical progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two trials conducted in Africa have suggested that routine CD4 cell count monitoring results in a survival benefit over clinical monitoring alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In one trial, 1094 Ugandan HIV-infected adults with a CD4 cell count &lt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    were offered ART and randomly assigned to one of three monitoring arms: a viral load arm (ie, clinical monitoring, quarterly CD4 cell counts and viral load testing), a CD4 arm (ie, clinical monitoring with quarterly CD4 cell counts) and a clinical arm (ie, clinical monitoring alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients in the clinical arm were more likely to have at least one serious morbid event or die than participants in the viral load arm (7.6 versus 4.8 per 100 person years; aHR 1.83, 95% CI 1.25-2.69) and the CD4 arm (6.5 versus 6 per 100 person years; aHR 1.49, 95% CI 1.03-2.13). There was no significant difference in serious events or mortality between the CD4 arm and the viral load arm. Another study in Uganda also found that CD4 cell count monitoring was cost-effective by WHO standards [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Assessment of virologic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial World Health Organization (WHO) guidelines recommended that CD4 cell counts may be used to monitor clinical response to therapy in programs in which viral load testing is not available. However, some studies demonstrated that these criteria perform poorly in the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/52-57\">",
"     52-57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 20,113 patients, including 6,369 patients who had access to viral load monitoring, 576 patients eventually switched therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/58\">",
"       58",
"      </a>",
"      ]. Switching therapy occurred earlier and at higher CD4 cell counts in patients who had access to viral load testing.",
"     </li>",
"     <li>",
"      A logistic regression analysis in 674 patients in British Columbia demonstrated that using immunologic criteria alone to predict which patients did not achieved viral suppression resulted in significant misclassification of therapeutic response [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These, and other data, prompted revision of the WHO guidelines in 2006, which suggest viral load testing as an important component of treatment failure criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/53,59-61\">",
"     53,59-61",
"    </a>",
"    ]. Where viral load testing is available in resource-poor countries, WHO does not recommend switching antiretroviral therapy unless the viral load is greater than 10,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/59\">",
"     59",
"    </a>",
"    ]. However, the rationale for this conservative approach has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, sustained viremia in the presence of drug pressure increases the risk of transmission of drug-resistant virus to others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other modalities for monitoring viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nucleic acid amplification studies for HIV RNA generally use plasma, there has been interest in alternative samples, such as dried blood spots (DBS), which can be stored at ambient temperatures without degradation of RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. One study in Tanzania conducted parallel HIV RNA testing using plasma and dried blood spots and found 100 percent concordance in samples with &gt;3000 copies; however, sensitivity declined dramatically in samples with lower levels of viremia (eg, 60 percent in samples with 1000 to 2999",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    use of pooled HIV RNA testing to identify virologic failure has also been proposed as a cost-saving measure that maintains a similar level of accuracy as individual viral load monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ADHERENCE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Managing patients on ART is complex due to the need for high rates of adherence to avoid the onset of drug resistance. This challenge is even more daunting in resource-poor nations where clinics are often understaffed and poorly funded [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/65\">",
"     65",
"    </a>",
"    ]. However, a meta-analysis of 31 studies from North America and 27 studies from sub-Saharan Africa suggest that comparable levels of adherence can be achieved in resource-poor countries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As demonstrated in prior studies in Europe and the US, adherence is strongly correlated with viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/67\">",
"     67",
"    </a>",
"    ]. One large study of 2821 adults who began NNRTI-based therapy in South Africa demonstrated that adherence (as assessed by monthly pharmacy claims) was directly related to viral suppression in a linear dose-response manner [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/68\">",
"     68",
"    </a>",
"    ]. One cohort study of 6833 HIV-infected patients in South Africa, who started ART between 2000 and 2006, found that high ART adherence was associated with reduced hospitalization costs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various adherence strategies are being studied including simple measures, such as pill counts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In rural Uganda, the efficacy of adherence interventions was evaluated in a home-based ART trial of 987 adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/70\">",
"     70",
"    </a>",
"    ]. The median CD4 cell count was 124",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and the median HIV RNA level was 217,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    Each week, a team of 25 to 30 field officers delivered medications in pill boxes directly to the homes of patients. More than 96 percent of the participants achieved a viral load &lt;1000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are emerging from resource-poor countries that confirm the remarkable effectiveness of ART in reducing mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated the efficacy of ART in decreasing morbidity and mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 416 patients in Cambodia who initiated ART, estimates of survival at 24 months were 86 percent. Furthermore, 74 percent had attained a CD4 cell count greater than 200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and 88 percent had a non-detectable viral load [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/72\">",
"       72",
"      </a>",
"      ]. This is remarkable since the baseline median CD4 cell count in this patient population was 11",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and 49 percent had advanced stage IV disease by the WHO criteria.",
"     </li>",
"     <li>",
"      In Peru, an observational database was established in 1996 to review clinical outcomes of 564 antiretroviral-naive patients who received combination therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/73\">",
"       73",
"      </a>",
"      ]. The overall survival rate was 96, 94 and 91 percent at years 2, 4, and 5, respectively. Opportunistic infections occurred in 20 percent of the study participants.",
"     </li>",
"     <li>",
"      In Uganda, a prospective study enrolling 466 HIV-infected adults and 1481 seronegative household members demonstrated that introduction of ART and co-trimoxazole was associated with a 95 percent reduction in mortality in HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/74\">",
"       74",
"      </a>",
"      ]. Furthermore, an 81 percent reduction in mortality was demonstrated in their uninfected children younger than 10 years.",
"     </li>",
"     <li>",
"      In Botswana, a prospective study of 693 patients with a median CD4 cell count of 67",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      were initiated on NNRTI-based combination ART and followed for a median of 42 months [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/75\">",
"       75",
"      </a>",
"      ]. The median CD4 cell count increases were 169,302, and 337",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      at one, three, and five years, respectively. Rates of viral suppression exceeded 90 percent at all time points measured. At one year follow-up there was a 2.3-fold higher mortality rate among patients initiating ART with a baseline CD4 cell count of less than 50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      compared with those initiating ART with a CD4 cell count of 51 to 200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"     <li>",
"      In an observational cohort based in South Africa, 179 patients died during the 3155 person-years of follow-up on ART [",
"      <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/76\">",
"       76",
"      </a>",
"      ]. Despite rapid immune recovery, high mortality in the first year of ART was related to the large proportion of person-time accrued within the CD4 cell strata of &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data demonstrate that antiretroviral therapy is very effective in the developing world, with overall mortality rates comparable to that seen in European and US cohorts after the initiation of ART. However, early mortality rates in sub-Saharan Africa during the first few months remain high secondary to tuberculosis, acute sepsis, cryptococcal meningitis, malignancy, and wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/77\">",
"     77",
"    </a>",
"    ]. This is mainly due to the presence of advanced AIDS and severe immunosuppression. &nbsp;",
"   </p>",
"   <p>",
"    In 2006, the WHO recommended ART in HIV-infected patients with CD4 cell counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Based on emerging evidence that ART also leads to marked declines in mortality among patients with higher CD4 counts, WHO revised its treatment guidelines in 2010; it is now recommended that HIV-infected asymptomatic patients with a CD4 cell count of &lt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    initiate ART [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/78\">",
"     78",
"    </a>",
"    ]. The impact of ART on morbidity and mortality in resource-limited settings is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=see_link\">",
"     \"The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Virologic outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most first-line regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -based therapy. One observational cohort of 2817 HIV-infected patients taking either NVP or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based ART suggested that patients taking efavirenz had superior virologic outcomes than those taking NVP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/79\">",
"     79",
"    </a>",
"    ]. However, the higher cost of efavirenz and its potential teratogenicity are important barriers to more generalized usage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Immunologic outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of nearly 20,000 patients from a network of cohorts in sub-Saharan Africa, Latin America, and Asia with sufficient follow-up, ART led to increases in the median baseline CD4 cell count of 114",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    to 395",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    after five years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/80\">",
"     80",
"    </a>",
"    ]. As noted in other studies, the baseline CD4 cell count was the most important determinant of subsequent CD4 cell count trajectories. Regression models of these data suggested that after several years of treatment, only those patients initiating ART at 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or higher achieved immunologic recovery characterized by CD4 cell counts near or above 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    a study of long-term outcomes within the China National Free Antiretroviral Treatment Program, mortality rates declined dramatically after six months of treatment from 22.6 deaths to 4 deaths per 100 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/81\">",
"     81",
"    </a>",
"    ]. However, a cumulative immunologic treatment failure rate of 50 percent occurred after five years due to the limited availability of second-line agents, emphasizing the need for expanded therapeutic options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31116112\">",
"    <span class=\"h2\">",
"     Risk factors for poor outcomes after initiating ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognostic models suggest that mortality among patients initiating ART is associated with low total lymphocyte count, advanced age, anemia, low bodyweight, low pretreatment CD4 cell count, and an advanced stage of clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS FOR PCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower early mortality rates in Malawi have been observed among patients receiving ART at clinics which also offer cotrimoxazole prophylaxis compared to clinics not offering prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/83\">",
"     83",
"    </a>",
"    ]. These retrospective data suggest that cotrimoxazole prophylaxis, which is relatively inexpensive, should also be incorporated into ART delivery programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     TOLERABILITY OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data are available on the tolerability of first-line ART regimens in developing countries. A longitudinal observational study was performed in 1286 patients in Nairobi, Kenya who were initiating ART, which was primarily composed of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/84\">",
"     84",
"    </a>",
"    ]. Although ART led to significant clinical and immunologic benefit, the cumulative incidence of an ART switch at 12 months was 78 percent. The most common reasons for alternative therapy included onset of peripheral neuropathy and drug interactions with TB medications. A subsequent study estimated the cost-effectiveness of switching from d4T to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in South Africa and found that savings on d4T-related toxicities would offset only 20 percent of the higher price of tenofovir [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the significant concerns regarding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    use in developing countries is hepatotoxicity, specifically in men with a CD4 count &gt;400",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and women with a CD4 count &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    who are initiating ART. However, two studies in treatment-experienced patients have demonstrated that switching to nevirapine from another regimen is safe, even after immune reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance is a major contributing cause of treatment failure. Mutations accumulate in the setting of incomplete viral suppression. The genetic barrier to resistance varies depending on the antiretroviral agents being administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A fixed-dose combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    is used extensively as the first-line ART regimen in many developing countries since it is widely available and inexpensive. However, one study of 98 Thai patients who experienced treatment failure on this treatment regimen demonstrated that high levels of resistance to lamivudine (89 percent) and non-nucleoside reverse transcriptase inhibitors (92 percent) were present by genotypic analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/88\">",
"     88",
"    </a>",
"    ]. These findings are most likely due to the low genetic barrier to resistance exhibited by both lamivudine and nevirapine. Furthermore, 37 percent had developed a thymidine analogue mutation associated with cross-resistance to other nucleoside analogues. Cross-resistance may be even higher in other countries where genotypic and viral load testing are not available.",
"   </p>",
"   <p>",
"    Choices of second-line therapies are limited by cost and availability. Some have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    should be considered as a alternate first-line agent since it does not select for thymidine analogue mutations and is associated with hypersusceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , which can then serve as part of a second-line option for therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/89\">",
"     89",
"    </a>",
"    ]. One study of 141 patients with virologic failure demonstrated viral suppression on a",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir-containing",
"    </span>",
"    regimen in 65 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/90\">",
"     90",
"    </a>",
"    ]. At least one major resistance mutation was documented in 87 percent of the patients at baseline.",
"   </p>",
"   <p>",
"    Also concerning are several data showing the emergence of HIV drug resistance in untreated HIV-infected patients, particularly in sub-Saharan Africa with marked increases in NNRTI drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/91\">",
"     91",
"    </a>",
"    ]. Many strategies are being implemented to curtail the development of drug resistance in the developing world including monitoring of early warning indicators, surveys to assess both acquired and transmitted drug resistance, and creation of an accredited genotyping laboratory network to support testing in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS OF HIV TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of ART has led to a significant decline in morbidity and mortality, similar to that in developed nations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/93\">",
"     93",
"    </a>",
"    ]. The World Health Organization (WHO) has proposed ART guidelines based upon available efficacy and safety data from clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/94\">",
"     94",
"    </a>",
"    ]. A rise in global funding for AIDS initiatives and reduced drug costs has improved the feasibility of offering treatment in resource-limited settings.",
"   </p>",
"   <p>",
"    A decision analysis was conducted to estimate the clinical and economic outcomes associated with different treatment strategies, with or without CD4 testing, in HIV-infected patients in Cote d'Ivoire [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/95\">",
"     95",
"    </a>",
"    ]. The incremental cost per year of life gained was $240 for prophylaxis alone, $620 for ART and prophylaxis combined without CD4 testing, and $1180 for ART and prophylaxis with CD4 testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H644143\">",
"    <span class=\"h1\">",
"     COINFECTIONS WITH HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several important coinfections need to be considered when addressing the morbidity and mortality of HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The global burden of tuberculosis (TB) and HIV are focused in many of the same resource-poor regions of the world. In Zimbabwe, for example, the number of patients treated for tuberculosis each year has increased 10-fold since the 1980s and the emergence of the HIV epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/96\">",
"     96",
"    </a>",
"    ]. In South Africa, 400,000 cases occur annually and public health concerns have continued to rise due to the emergence of extensively drug-resistant TB (XDR-TB) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=see_link\">",
"     \"Epidemiology and molecular mechanisms of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concomitant HIV infection also dramatically increases the risk of progression of TB and mortality rates are dramatically higher in those patients with advanced immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. In one study from Uganda, TB incidence and TB-associated mortality were highest within the first six months of ART, but declined significantly within 7 to 18 months of treatment initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/100\">",
"     100",
"    </a>",
"    ]. A similar decline in TB incidence was also noted after six months of ART in a study of 26,000 patients from both resource-rich and resource-poor countries [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of HIV and TB therapies in patients with CD4 cell counts less than 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    improves survival, but can also be complicated by the immune reconstitution inflammatory syndrome (IRIS) and drug toxicity or treatment interruption [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/102\">",
"     102",
"    </a>",
"    ]. A decision analysis, based on published data, was conducted in hypothetical cohorts of patients in which HAART was initiated at various timepoints: during the first two months of tuberculosis therapy (early); during months two through six of TB therapy (deferred); or administered after TB therapy (no HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/103\">",
"     103",
"    </a>",
"    ]. A sensitivity analysis demonstrated that mortality rates were lowest with \"early\" HAART, even when including the highest reported rates of IRIS and severe drug toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one autopsy study of 47 HIV-infected patients with TB from Soweto, 68 percent had disseminated TB [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/104\">",
"     104",
"    </a>",
"    ]. In addition, severe bacterial infections were identified as important comorbid conditions (eg, bacterial pneumonia and salmonellosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV and malaria infections often coexist in patients in many parts of the world due to geographic overlap of these two diseases. This is particularly true in sub-Saharan Africa, where an estimated 40 million people are living with HIV and more than 350 million episodes of malaria occur yearly. There is also evidence of a negative interaction between these two infections. HIV increases the risk of malaria infection and the development of clinical malaria. Conversely, malaria increases HIV replication. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/8/3209?source=see_link\">",
"     \"HIV and malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Cryptococcal meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcal meningitis is a leading cause of death in patients with AIDS and contributes to high early mortality rates in ART programs within resource-limited settings.",
"   </p>",
"   <p>",
"    A retrospective study in South Africa examined the value of measuring cryptococcal antigen from stored plasma samples in participants who enrolled in an ART program [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/105\">",
"     105",
"    </a>",
"    ]. Of 707 study patients, 46 (7 percent) were positive for cryptococcal antigen. Antigenemia was 100 percent sensitive for predicting development of cryptococcal meningitis during the first year of ART, suggesting that screening in patients with advanced immunosuppression might permit targeted preemptive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H644207\">",
"    <span class=\"h2\">",
"     Viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus (HBV) is highly prevalent in resource-limited settings, and hepatitis C infection is highly prevalent in select countries (eg, Egypt). Both infections can lead to cirrhosis, decompensated liver disease, and hepatocellular carcinoma.",
"   </p>",
"   <p>",
"    An estimated 400 million people are infected with HBV, with the majority of cases occurring in regions of Asia and Africa; HBV is often acquired via perinatal transmission or through medical or traditional scarification procedures (predominant in Africa) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/106\">",
"     106",
"    </a>",
"    ]. Hepatitis B is also transmitted efficiently through sex and injection drug use among adults, although these modes of acquisition are more common in resource-rich settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of transmitting hepatitis C perinatally is higher in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients than among women with HCV alone (25 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/2/21546/abstract/107\">",
"     107",
"    </a>",
"    ]. Acquisition of hepatitis C has also been associated with medical procedures; the sexual transmission of hepatitis C is less efficient than with hepatitis B virus. In resource-rich settings, the predominant mode of acquisition is injection drug use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the third decade of AIDS, it is evident that the global HIV epidemic is quite different from that first recognized among a small number of homosexual men in 1981. The epidemic has reached every country and nearly all populations throughout the world. Spread of the disease has been particularly alarming in developing countries, especially sub-Saharan Africa and southeast Asia, but continues to threaten other populations in eastern Europe, Latin America, and the Caribbean. In the more developed countries, which have also witnessed dramatic increases in",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    over the past two decades, marked advances in HIV antiretroviral therapy have resulted in significant changes in the survival rate and quality of life of HIV-infected individuals. Current treatments are effective, allowing HIV-infected individuals to live longer, healthier lives, but at the same time have resulted in complacency and a resurgence in high-risk behavior among some populations. This recidivism has resulted in a resurgence of STDs and a recent increase in HIV incidence among populations where HIV prevention had been so effective in past years.",
"   </p>",
"   <p>",
"    The AIDS epidemic is undermining the very social fabric of many cultures in developing countries. The demographics, economy, cultures, and political structures of many countries have been dramatically affected by the spread of",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"    The challenges to controlling the epidemic throughout the world are enormous but must be overcome today and in the very near future. To meet these challenges, the development and worldwide distribution of inexpensive antiretroviral drugs must be supported, and the accelerated development and distribution of a safe and efficacious vaccine promoted. There is no doubt that the clinical science of HIV research has made and will continue to make a dramatic difference in this epidemic, but the initial optimism that followed the discovery of HIV, the development of diagnostic assays to help monitor the epidemic, the prophylaxis of opportunistic infections, the identification of effective antiretroviral drugs, and the prevention of perinatal transmission has been tempered by the stark reality and magnitude of the global HIV pandemic. A concerted effort must be made from all international health agencies, philanthropic foundations, and governments from the national down to the community level to implement immediate prevention programs based upon education, behavioral modification, and treatment of those infected with HIV.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/1\">",
"      Centers for Disease Control (CDC). Pneumocystis pneumonia--Los Angeles. MMWR Morb Mortal Wkly Rep 1981; 30:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/2\">",
"      Centers for Disease Control (CDC). Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California. MMWR Morb Mortal Wkly Rep 1981; 30:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). The Global HIV/AIDS pandemic, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/4\">",
"      Heeney JL, Dalgleish AG, Weiss RA. Origins of HIV and the evolution of resistance to AIDS. Science 2006; 313:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/5\">",
"      Worobey M, Telfer P, Souqui&egrave;re S, et al. Island biogeography reveals the deep history of SIV. Science 2010; 329:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/6\">",
"      Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/7\">",
"      Archer J, Robertson DL. Understanding the diversification of HIV-1 groups M and O. AIDS 2007; 21:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/8\">",
"      Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009; 15:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/9\">",
"      Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006; 313:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/10\">",
"      Keele BF, Jones JH, Terio KA, et al. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 2009; 460:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/11\">",
"      Murphey-Corb M, Martin LN, Rangan SR, et al. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 1986; 321:435.",
"     </a>",
"    </li>",
"    <li>",
"     UNAIDS Report on the Global AIDS Epidemic, 2012. Joint United Nations Programme on HIV/AIDS And World Health Organization, December 2012.",
"    </li>",
"    <li>",
"     UNAIDS: 2009 AIDS epidemic update. UNAIDS/09.36E/JC1700E. Geneva, Joint United Nations Programme on HIV/AIDS AND World Health Organization, November 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/14\">",
"      Dunkle KL, Stephenson R, Karita E, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008; 371:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/15\">",
"      Smith AD, Tapsoba P, Peshu N, et al. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet 2009; 374:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/16\">",
"      Steinbrook R. HIV in India--a complex epidemic. N Engl J Med 2007; 356:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/17\">",
"      Gill B, Okie S. China and HIV - a window of opportunity. N Engl J Med 2007; 356:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/18\">",
"      Feng TJ, Liu XL, Cai YM, et al. Prevalence of syphilis and human immunodeficiency virus infections among men who have sex with men in Shenzhen, China: 2005 to 2007. Sex Transm Dis 2008; 35:1022.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data&mdash;United States and 6 U.S. dependent areas&mdash;2010. HIV Surveillance Supplemental Report 2012;17(No. 3, part A). file://www.cdc.gov/hiv/surveillance/resources/reports/2010supp_vol17no3/pdf/hssr_vol_17_no_3.pdf (Accessed on December 12, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. HIV Surveillance Report, 2010; vol. 22. file://www.cdc.gov/hiv/surveillance/resources/reports/2010report/pdf/2010_HIV_Surveillance_Report_vol_22.pdf (Accessed on December 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). HIV infections attributed to male-to-male sexual contact - metropolitan statistical areas, United States and Puerto Rico, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/22\">",
"      Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Subpopulation estimates from the HIV incidence surveillance system--United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/24\">",
"      Mastro TD. Determining HIV incidence in populations: moving in the right direction. J Infect Dis 2013; 207:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/25\">",
"      Laeyendecker O, Brookmeyer R, Cousins MM, et al. HIV incidence determination in the United States: a multiassay approach. J Infect Dis 2013; 207:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/26\">",
"      Eshleman SH, Hughes JP, Laeyendecker O, et al. Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis 2013; 207:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/27\">",
"      Hodder SL, Justman J, Hughes JP, et al. HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med 2013; 158:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/28\">",
"      Piot P. AIDS: from crisis management to sustained strategic response. Lancet 2006; 368:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/29\">",
"      Quinn TC. Global burden of the HIV pandemic. Lancet 1996; 348:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/30\">",
"      Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts--16th International AIDS Conference epidemiology plenary. Clin Infect Dis 2007; 44:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/31\">",
"      Schwartl&auml;nder B, Grubb I, Perri&euml;ns J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet 2006; 368:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/32\">",
"      Arasteh K, Des Jarlais DC. Injecting drug use, HIV, and what to do about it. Lancet 2008; 372:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/33\">",
"      Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/34\">",
"      Kaul R, Kimani J, Nagelkerke NJ, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/35\">",
"      Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/36\">",
"      Vekemans M, John L, Colebunders R. When to switch for antiretroviral treatment failure in resource-limited settings? AIDS 2007; 21:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/37\">",
"      Korenromp EL, Viisainen KM. ART in rural Uganda--efficient scale-up with home-based care? Lancet 2009; 374:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/38\">",
"      Bendavid E, Holmes CB, Bhattacharya J, Miller G. HIV development assistance and adult mortality in Africa. JAMA 2012; 307:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/39\">",
"      Kim JY, Farmer P. AIDS in 2006--moving toward one world, one hope? N Engl J Med 2006; 355:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/40\">",
"      Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/41\">",
"      Sow PS, Otieno LF, Bissagnene E, et al. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr 2007; 44:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/42\">",
"      Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006; 368:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/43\">",
"      Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/44\">",
"      Jaffar S, Amuron B, Foster S, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet 2009; 374:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/45\">",
"      Balakrishnan P, Solomon S, Mohanakrishnan J, et al. A reliable and inexpensive EasyCD4 assay for monitoring HIV-infected individuals in resource-limited settings. J Acquir Immune Defic Syndr 2006; 43:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/46\">",
"      Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis 2003; 37:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/47\">",
"      Srithanaviboonchai K, Rungruengthanakit K, Nouanthong P, et al. Novel low-cost assay for the monitoring of CD4 counts in HIV-infected individuals. J Acquir Immune Defic Syndr 2008; 47:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/48\">",
"      Jani IV, Sitoe NE, Alfai ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 2011; 378:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/49\">",
"      DART Trial Team, Mugyenyi P, Walker AS, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/50\">",
"      Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011; 343:d6792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/51\">",
"      Kahn JG, Marseille E, Moore D, et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ 2011; 343:d6884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/52\">",
"      Moore DM, Mermin J, Awor A, et al. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 2006; 43:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/53\">",
"      Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/54\">",
"      Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/55\">",
"      Moore DM, Awor A, Downing R, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/56\">",
"      Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/57\">",
"      Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/58\">",
"      ART-LINC of IeDEA Study Group, Keiser O, Tweya H, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23:1867.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Geneva: World Health Organization, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/60\">",
"      Bagchi S, Kempf MC, Westfall AO, et al. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis 2007; 44:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/61\">",
"      Schooley RT. Viral load testing in resource-limited settings. Clin Infect Dis 2007; 44:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/62\">",
"      Johannessen A, Garrido C, Zahonero N, et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis 2009; 49:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/63\">",
"      Rottinghaus EK, Ugbena R, Diallo K, et al. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin Infect Dis 2012; 54:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/64\">",
"      Smith DM, May SJ, P&eacute;rez-Santiago J, et al. The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS 2009; 23:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/65\">",
"      Gill CJ. Antiretroviral programme in rural Uganda. Lancet 2006; 368:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/66\">",
"      Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/67\">",
"      Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/68\">",
"      Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/69\">",
"      Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med 2010; 152:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/70\">",
"      Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006; 368:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/71\">",
"      San Lio MM, Carbini R, Germano P, et al. Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique. Clin Infect Dis 2008; 46:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/72\">",
"      Madec Y, Laureillard D, Pinoges L, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 2007; 21:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/73\">",
"      Corey DM, Kim HW, Salazar R, et al. Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr 2007; 44:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/74\">",
"      Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008; 371:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/75\">",
"      Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008; 22:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/76\">",
"      Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/77\">",
"      Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897.",
"     </a>",
"    </li>",
"    <li>",
"     file://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (Accessed on October 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/79\">",
"      Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008; 22:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/80\">",
"      Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/81\">",
"      Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009; 151:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/82\">",
"      May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010; 376:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/83\">",
"      Lowrance D, Makombe S, Harries A, et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 2007; 46:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/84\">",
"      Hawkins C, Achenbach C, Fryda W, et al. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr 2007; 45:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/85\">",
"      Rosen S, Long L, Fox M, Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr 2008; 48:334.",
"     </a>",
"    </li>",
"    <li>",
"     Mocroft A, Lacombe K, Rockstroh J, et al. Risk of discontinuation of nevirapine due to toxicity in antiretroviral naive and experienced patients with high and low CD4 counts. IAS Toronto 2006 Abstract #THAB0104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/87\">",
"      Kumarasamy N, Venkatesh KK, Devaleenal B, et al. Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. J Acquir Immune Defic Syndr 2007; 45:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/88\">",
"      Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/89\">",
"      Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis 2007; 44:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/90\">",
"      Murphy RA, Sunpath H, Lu Z, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/91\">",
"      Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/92\">",
"      Jordan MR, Bennett DE, Wainberg MA, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis 2012; 54 Suppl 4:S245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/93\">",
"      Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29.",
"     </a>",
"    </li>",
"    <li>",
"     Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach &mdash; 2003 revision. Geneva: World Health Organization, 2003. file://www.who.int/3by5/publications/documents/arv_guidelines/en/ (Accessed on August 18, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/95\">",
"      Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings--the case of C&ocirc;te d'Ivoire. N Engl J Med 2006; 355:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/96\">",
"      Corbett EL, Muzangwa J, Chaka K, et al. Nursing and community rates of Mycobacterium tuberculosis infection among students in Harare, Zimbabwe. Clin Infect Dis 2007; 44:317.",
"     </a>",
"    </li>",
"    <li>",
"     Weyer K. In Programs and abstracts:14th Conference on Retroviruses and Opportunistic Infections, February 25-28, 2007, Los Angeles, CA; Abstract # 8.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/98\">",
"      Perri&euml;ns JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/99\">",
"      Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, C&ocirc;te d'Ivoire. Lancet 1995; 345:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/100\">",
"      Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/101\">",
"      Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA), ART Cohort Collaboration, Brinkhof MW, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/102\">",
"      Messou E, Anglaret X, Duvignac J, et al. Antiretroviral treatment changes in adults from C&ocirc;te d'Ivoire: the roles of tuberculosis and pregnancy. AIDS 2010; 24:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/103\">",
"      Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/104\">",
"      Martinson NA, Karstaedt A, Venter WD, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007; 21:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/105\">",
"      Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/106\">",
"      Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection--a global challenge. N Engl J Med 2012; 366:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/2/21546/abstract/107\">",
"      Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192:1880.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3036 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-5480875BC6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21546=[""].join("\n");
var outline_f21_2_21546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ORIGIN OF THE HIV EPIDEMIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Zoonotic transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical implications of SIV infection in natural hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WORLDWIDE STATISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General statistics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sub-Saharan Africa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Asia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Americas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MODES OF TRANSMISSION AND DYNAMICS OF THE EPIDEMIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Men who have sex with men (MSM)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mother-to-child transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Injection drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EFFECT OF OTHER STDS ON HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INTRODUCTION OF ANTIRETROVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ART coverage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Access to ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LABORATORY MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Monitoring treatment response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Assessment of toxicity and clinical progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Assessment of virologic failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other modalities for monitoring viral load",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ADHERENCE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      EFFECTIVENESS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Virologic outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Immunologic outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31116112\">",
"      Risk factors for poor outcomes after initiating ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROPHYLAXIS FOR PCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      TOLERABILITY OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      COST-EFFECTIVENESS OF HIV TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H644143\">",
"      COINFECTIONS WITH HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Cryptococcal meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H644207\">",
"      Viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=related_link\">",
"      Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/8/3209?source=related_link\">",
"      HIV and malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39018?source=related_link\">",
"      The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_2_21547="Chest tube size in children";
var content_f21_2_21547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chest tube sizes for pediatric trauma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weight (kg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chest tube (French)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant (up to 1 year)",
"       </td>",
"       <td>",
"        3 to 9",
"       </td>",
"       <td>",
"        10 to 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toddler (1 to 3 years)",
"       </td>",
"       <td>",
"        10&nbsp;to 11",
"       </td>",
"       <td>",
"        16 to 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preschool child (3 to 5 years)",
"       </td>",
"       <td>",
"        12 to 18",
"       </td>",
"       <td>",
"        20 to 24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        School-aged child (5 to 12 years)",
"       </td>",
"       <td>",
"        19 to 29",
"       </td>",
"       <td>",
"        24 to 32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Over 12 years",
"       </td>",
"       <td>",
"        &ge;30",
"       </td>",
"       <td>",
"        32 to 38",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *In addition to considering age and weight, the clinician should evaluate the distance between the ribs to arrive at the correctly sized chest tube for placement.",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Data from: Hazinski MF, Samson R, Schexnayder S (Eds). 2010 Handbook of Emergency Cardiovascular Care for Healthcare Providers. American Heart Association 2010.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21547=[""].join("\n");
var outline_f21_2_21547=null;
var title_f21_2_21548="Outcome of placebo group NINDS trial";
var content_f21_2_21548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stroke outcome at three months in the placebo group of the NINDS trial",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Baseline NIHSS score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent with favorable outcome",
"        <br/>",
"        (three-month NIHSS score = 0 or 1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Age &lt;60 y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-9",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-14",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-20",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;20",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Age 61-68 y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-9",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-14",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-20",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;20",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Age 69-75 y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-9",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-14",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-20",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;20",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Age &gt;75 y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-9",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-14",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15-20",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;20",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NIHSS: National Institutes of Health Stroke Scale.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: NINDS t-PA Stroke Study Group, Stroke 1997; 28:2119.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21548=[""].join("\n");
var outline_f21_2_21548=null;
var title_f21_2_21549="Guidelines playground equipment";
var content_f21_2_21549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for playground equipment*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Type of access",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Age of intended user",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       2 to 5 years",
"      </td>",
"      <td class=\"subtitle2\">",
"       5 to 12 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Rung ladder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Slope",
"      </td>",
"      <td>",
"       75 to 90 degrees",
"      </td>",
"      <td>",
"       75 to 90 degrees",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rung width",
"      </td>",
"      <td>",
"       &ge;12 inches",
"      </td>",
"      <td>",
"       &ge;16 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vertical rise (tread to tread)",
"      </td>",
"      <td>",
"       &le;12 inches&bull;",
"      </td>",
"      <td>",
"       &le;12 inches&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rung diameter",
"      </td>",
"      <td>",
"       0.95 to 1.55 inches",
"      </td>",
"      <td>",
"       0.95 to 1.55 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Stepladders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Slope",
"      </td>",
"      <td>",
"       50 to 75 degrees",
"      </td>",
"      <td>",
"       50 to 75 degrees",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\" rowspan=\"1\">",
"       Tread width",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Single file",
"      </td>",
"      <td class=\"sublist_other\">",
"       12 to 21 inches",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;16 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Two abreast",
"      </td>",
"      <td class=\"sublist_other\">",
"       Not recommended for preschool-age children",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;36 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\" rowspan=\"1\">",
"       Tread depth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Open riser",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;7 inches",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;3 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Closed riser",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;7 inches",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;6 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vertical rise (tread to tread)",
"      </td>",
"      <td>",
"       &le;9 inches&bull;",
"      </td>",
"      <td>",
"       &le;12 inches&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Stairways",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Slope",
"      </td>",
"      <td>",
"       &le;35 degrees",
"      </td>",
"      <td>",
"       &le;35 degrees",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\" rowspan=\"1\">",
"       Tread width",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Single file",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;12 inches",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;16 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Two abreast",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;30 inches",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;36 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\" rowspan=\"1\">",
"       Tread depth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Open riser",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;7 inches",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;8 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Closed riser",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;7 inches",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;8 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vertical rise (tread to tread)",
"      </td>",
"      <td>",
"       &le;9 inches",
"      </td>",
"      <td>",
"       &le;12 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Ramps&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Slope (Vertical:horizontal)",
"      </td>",
"      <td>",
"       &le;1:8",
"      </td>",
"      <td>",
"       &le;1:8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\" rowspan=\"1\">",
"       Width",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Single file",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;12 inches",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;16 inches",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Two abreast",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;30 inches",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;36 inches",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Recommended dimensions for access slope, tread or rung width, tread depth, rung diameter, and vertical rise for rung ladders, stepladders, stairways, and ramps.",
"     <br>",
"      &bull; Entrapment provisions apply.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from US Consumer Product Safety Commission. Handbook for public playground safety. U.S. Government Printing Office, Washington, DC, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21549=[""].join("\n");
var outline_f21_2_21549=null;
var title_f21_2_21550="Tropocollagen synthesis";
var content_f21_2_21550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Tropocollagen synthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 269px; background-image: url(data:image/gif;base64,R0lGODlhAgINAeYAAP///wAAAICZzICAgKCz2f+AgEBAQCBNpgAzmVBzufDz+cDAwP+goBBAn5Cm08DN5rDA3/8AAP9QUGCAvxAQEP8gINDZ7DBZrP/w8P+wsP8QECAgIKCgoHBwcNDQ0FBQULCwsEBms/+QkGBgYPDw8DAwMODg4ODm8/8wMP/AwJCQkP/Q0HCNxv9wcP/g4P9gYP9AQE8jaX8ZTB8shZ8yWZ8TOa+AoO+DiX85bKBzmY9Wg6CDqSA8lYBJfK8wT+/j6Y82Yu9DSa+Pr6CjyV8fX++TmZ8jSQ8vj5+Tub9shoApXN+Wo79cdq9gf0A1gj8mcp9DaS8pfAAcVs+JnM+pvM8ZLD9Gk1Biqe/DyX9pnODW4++jqVBTma9wj59jie9zeu+zua8/X98GE19fn49mk492o78MJrCwz1AzeWAwcCAyWd+Gkz8gIL9gYGBpfDBTmRAsZYCDiQAZTBA5jAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAACAg0BAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4e6MjCASJGcAgIOLNhjEKFChQwVQ267mABBggQNGiQgIC9DhIkMNEjAILKmNJImCSgYZMHBgQMs3xVoMQiDBA0gbSpVBqHkyp2ICPyE4K5AgUIZZNJcynUYiwY6HRFQCVWdVUNGkXZd2+vEhQsn/yIpQElVHQMJiDhOZMvX1oMGLCpBqJsOQ4SthvT2XRzrBFiCEvYeUsy48qoLgQneVZSVqOXPpVhcMGgY8SEXKFC4AM3609i4BiMzaqG2tW1MBBAQLniWEeXbwCPlDnqwt++XwZM3Gq7Q+HHJyqMTYk4IxIABIAQyqAAp60zp4KkLIlEigIHyAwRWgM4obVLwwBU4QEBc0IAAHQR5yB5wcyTvpsHHGAECCODUboJwEIB5A3gwUGmSpMWegEpdVKAAPxUYFiIDULBgABwMJIEIlGTg0YQUQoRTAhfWlwgJ+nVg3kApaEXJduulmE9PFxaY0SMEOLUhJAMYwMECIwSQ3v+DRzEQ4CM4vqfjOTz2eCFKKlmJZQIOPIBITz8NKckCBiy4wZIFZSBBBBJICYkIyE35jYVXpsSilT5q9KUDE1yAwAUT1KmSi5ZhACeKjfwmZzB0XtjlcgU61eOPmTzggKN6BscAoo0AiIkLKVhlFaeMXETpISuIQCoAPZ0qiKmZMiDqrKsOYmmLZZ1A4AOwAYCBrLMG6+QiFvI6SKMCGItICiKIkIIkt7YIALItbhGsqMMi0pRJVvb55wSuCiLVARqWhYwJKgyggglsuScJsy/AEEEEMLwgqkduHouRl/o6tSUBv1p1lEweWSVlkHZuGalJW+IgQxjXnqitt4BeaZL/aCpNEAICCIQwRg1BXDvrmrINAoHFCWjMcQgb3ymAyh1PQAAWIryAQgQovGAzzvaOashFFAd6IQIHcNtjDzLEgEAMNFxLMntzgWVuIZZumdG4hCaj4AYGePhOldKa4ukiGeyccwEprGbIoYSsGLSQZVmgwwwzGGGVCCsMImsLyI17am4sFB0CVAxUAYQALNCXGL6EnBDCAY9Oh9IFRQelphhMGJjT1EXh+Czg5Q4yLoYh9CqIFkkkvTQUYBjC7L0fCWLBBA1cELnJGU6ldwQiYHBRmIX8yjgAYyXAeSI9NcDxY88sCCMAaKbTlJ1WAl+Ku4ik5awjHIEU5ObHHlB7/wMTZAoARyJgnVcN1g8yX1DjCiGxuAg4cAjbCgiAgABTYw3buDbgHWJWhCBCFKAC7zMEBKyXv/0p4Fckw9uKsjYIONngAuQz36tQQpwEKop4uiuEBUPoiN8BBUxAccYGArCBEXDgeeiIWrhEF6bjeeKDghjbI9aghNqJCQAQIAuraHcBnbBNXO0TxAN+UgPoLPAACJqPDhSYREFwxAYHKF3b1GcIHSAgB4j4nRYNQYAZ8KCAubFfIU7ghAOALFtbrOKxuHAELxyveP1DQBniZIgEFiIHCCDDIyZYiHEV0BgeKNOCSgDDcgTReIz4XgIO2Qn0IQZ7j3jABBCQhiT8jP8uhVDAEKJwBCJMgYztI9f5eDctDh6iAD74Cb+mQ0IAnMAKM+gCIWbnw0OYqAI7qJ8NG8g/Gh5gB3wUhB8J8UshwC0qSbyISorASlpCERFNMCMliSfMV80nB9VMxARtSDwhJgNGJADBChdgjqht8xDyUVwkKdgpklnFRkDCoABOkIKC3e0MQkyVqEhGBSL+0G8YGkQGzAAEcxLCcwBI6CHm4wAFEJOaS3iAADBYvrxUc1tPOYTjyMVFxZiwgOjrF/hQSdID5fBEP+Bi8KKER235yyRU+SXeQinJH4YRlMigQAcWAAIKUKCRW8TTLKPxF0hKQjyHeGItIxGwAuQrESf/EEAvHyoqGiDACBIYmASwNcCemmssCMiYnwDlgwpELEeDOECgfqhVoiFgAjB7AhFocIO8DUKgQ0nmtCSJpwIJrmhZZIEAkHYFBKBhCH8VgVX4hqIVFbauG4tZj3CgNKaJrABPOxZKcMUTnxxAUhdymAyUkIWFMe0LotopIx5JTl+MYIUB+ICDDMHLCyiVGpCzBFSnUz9xOVQUmrzrUslIn1TJlliENSwUW7VUYNHKEBrVXAJY8DiihUCxF+JVBgaqAZmIVVRXfRWBCjskC2S3QEi4AcnOazDoXnZDJ3hvi35g3WvBkRAnW9hJ7BQUauEpvk4r71hH9aRWMs8ZF+Go/watIRXcyBPAF3bwO3GjT9MdYriQaBQ9J1GsCSvCuX69HgOe6wtYcQKwoGXTVZ/oU2KMsxsFysRwg8vcEVMiq1tdBIgXZYpfacAzZJSUshhlVnDkWMfdjOgBEpHGTSR3AsulcoaJrArUqCaMBIBZCAL1ABPTorc15kaQNgFSWSqCxpVw70YbsE8gbZnLq6DNf0WqUe4i9rvJMnMqLPUGKcjBDeyyCAJqK4mL+NiYt0NEfhHX3cQ+unEhaMCG8Sw2FGjgBSluhJz97F0WpNkTlqIYHFjYtQCYg0uvCPNahXYhMZNZ0IvQKgsYzWlUrOAFGkBBekWtUQl7QgGpnnXknP9nH3NA4M6siFaPllyJB7wly72GhZGvconeCoAAD8C2qE/W3TFHehArbOELzzFkZSjgKwLIdi5WgILvXMJCLCuad0Nw2R6pLIsCgACu9aPIADCS3dA+hjTHKG9cGAUFobbyA9bbbwF0ideFQKc6A8DOc9A2GQRseC8KoIFa1UKoRDUqUi0C1GHcWOS++KXJZXHbBemWHe3WBZoxTo0F+LzjmUhkiAyQn37gaOaWIcClG1PsDJLjQwGgwG4vsQAlAWBG/zj6Q7K7aWWkOrNjPnU3FgQAFeQWehzwQHpI0AEDjGC3JFCBAQygAgB4YAREh1HV0zMjE+A97/Yh+gBCBAD/Dsy97ibATtujNw6tM6TPxX1Gsr+VLA+bg+xVN8DVPeTqElBgAJ5nV5k60AEKmIACJehQCQCw96trnkwDSNIIACCjD9xH8zLqwAcCoIKqm8dDhDeH4xkCZ2FMulvKFnc6FgR6EF199XbHDwBAwHsPBGD2AEBXALIjIw+0HuscwPuMWCiIGVHgTLdvPfUZX47hL0SmuQAa2GntI+W3Y0FzJzzWW7/31tuH49DDcd+He/iRea5XfprHQtcxePxndevAAJ5WAGrzflM1C95GbfxAdoSAdQBwfguwew5iVCAAAiVgfR+wABtAAaxndTNSJiCgIJpXHi84I7s3AAvAATZo/3X+xw4p8AIR8ALPsgrWgR3dMB9dhwoEYGwDoYGDwIEeUB4bQHgesHszwgErVIIryHea5wEeUiZbuEJeCAAkMAIe8nkNyH7q4AIkhwJoM4GjQB7mgR7doFiXoF/fVglYw3OsQVQLcB9Fl3UtAAMagDNjxQBB6Al+qB/8sQ1PVgnc1SNuBgnFpyMKEnUjsHIAkQKyIgE3owEw0AJtmAmVaAAN4g2NOAnPhiASJRaRBxrXYRmgMhSCSIgFYIiU0CEfEnzacIqSgDiHoErLkXCL8Yq3oYmg1YmfyGIvEiMcqA1BpIeGwItKFIlatnRdQYzREYsSUAGeiDaJUCRHkiRoeP8NJ1EJKYQIqzhRwsgY2CggLsAALXAzKNACGeCGZGIm43gNCqBpjZaOv6hGhVSBrpiP4IEBoSIvFfACDOCG4rBmJSRJ9gdEGQZ/t9GOXJYqa4ICyugNCrBojLBzrMgSFAkcFslpGFA2GlABLXCI3gBriGApSggJuSFHwVGS8pYCLcCNL5ABDWYNTQUVPRE0YrcIEGCNn2GTIpcqN1My2hA1VhORMGcfBCly7zg/zjhDUakISJmVVuQRLMmV57CVYAkAIqABDDmW4yCWYxmPaBmWUzmW89iW5aCWAYEug4eJomgAU7cIQscILlBycpmWb/kPlYh/htCMlNCHicYIO8j/GYIVmNxAl/5gAlHHTmpXCFszAOxieHRnH2mXHjgIAnmHdw6imGgnd5dYeHP3AdnRmIqAQ5CZDZLZD2b3h4YgIxSgl7m3e3UXdWRXJhuwQrlJfvfBTou0QrP3AR0wACtkAq75mhEwbOHgc+i0AIvZCX3pCERHELPJD/cRPb7HgprXgeg3ftAHAGWShejpasV5gCTQd0WyTs/5mma5fGf3nOl5CYkHdIyAmP/QnfsAg4NgAiTwc+yCdQp4HSHCgenZeunZnghqAKdXAuEngA74CGyJDh/icxcqCCioJOz0gYCHg+jinNjxAR9AAuCYfTZYeCd6cyLamQc4EAC6D2A4/wAfMJ4buAHWWYM3qIWD0KBW96AAGKFVd4JlwqGDWQhxeQ4Gd37rh5ldyAHUp5xnVyYe0odRVx6o5yHOOaQsBIXQMwJF4nz+6Q81qg8mQIUbUHeFcB8B4AFjWIZAKghCmh5EapzjOSNJgnoWuqSE8JfSOXZGYh4saJj5WYPM6Wpl8jwQqnnF6aCuBgDlIYYq8AFyeKb9kKZjmQGDyg0tyHys53MOkp9lsoB4OqkBqKerKql22nkUoAJmV6cCwamxKQ4z4nvs54IeYHYnCAKzl5+reoCRCqavenU8KiO0GhC22hfbSQjPShBYJ46GUFS8Bz249QHrOQiP2qrGuq2jKP+e3AmofeF/g1cImnqr8NCsA5F4INB2/OF3bleaNoiiDpIkpIh2gYevCXJ4+oF3H6CL6moO7CoQVXcm5eEBE9ohKnh7DEuprHaAtXd7tIcfvEmZqTcC2jqw6FCwAaF+SmJ2ZJqk7SkjSoqA5Imy53cd5mF9G9ABKoCXHAsOHgsQZ3gfZHodiQeAxbok47enCYh+5yqaHnKeDxGtdmqbXFGz/1B1I7AACWt9JQACC9ABasd7RaWCR5odoTqDmuejOIgkVGtUDWGuApuuIsG0/nCwUUd4JLhIO5tuu4WlB+gBYDgjcxp1mlkeBreX9OCu8CoI8vp2rFevN4ev6XGu0OP/duDnr3YHsAK7EGrbD/NJCO1pEwfbfAqLeg/rsGQLhQlIgLY3I7vJexgbexvrEJPLD5XLrQCIuVa3fiJbplrKTibrf+a3ASpbnnrJQjArswexujMrDTd7fQu4s+zUsygboci6gCFCtAYHEcLLDKIpsNvZdo7Ql2NIdNhLCIbnt4XQl91rCNnJCOIrofngtFAbp1JLtVZ7HyqQtSvImgfoggIKtjY4AmOrgg8xvcpAArl5mJqHg47QeknSARxAwJb7uojQegpsCK1bCK1HAlyTvizUtoLwtgYXtyw0t1FXt3ereXn7eSbAt1jYv+QqmwGwmEXCrwosd0RnouyimP23/0KaqcBTOHcAOLh76cDp0YfAagCtGbulKKIdgE4A64AKwp/0EMHDKh3+mwwloKMTG6oAcMCgV7veOnhdmEiudnqfl6QLS7aD4Kr3MZwr3H/XN325VXsQ2wHUWn5KOw9OfLnREcXIcKHnh7LpuXu2l7w8+6fbuq1mFyLFObtJWsbGWrIWWnoHp6grZH2zt4NzN7wEm8LYcKHMm55jyLfWEcgna6rsCco4e7yKnKrDWqxGdVTriapnGKQ6asnigMfHsAGpa79WPAK9JyOyanCLGsqTKqRIynHtW7VTZ8agXHUwe3a+SlSX6IHKOggUgH2yPMuYfA1k+Dx2a6ia96BlmP8fJFAmJbB7wHysFeun7KTBJbCYyAzIwFx3i3p2HNCFDlh1kVvN3UDLxkCZczwNBqC7+GzN6nAf9wwNScLEAZ3P15zQDM0L+tzQEH0KDx3RFC0KE13RGN0JF53RHI0JG93RID0JHx3SJO0II13SKP2NC53SLL0JJ93SMP3SMM3SMj3TKF3TNk3SOJ3TIL3TPM3RPv3TGB3UQk3RRF3UEH3USM3QSr3UAd3UTl3NUB3VljzVVD2zVn3VA5vVWn2rXN3VkPnVYC2XYj3WaFnWZg2WaJ3WWbnWbA1zbv3WDRfXcp1tdF3XnHbXeM1ler3Xi9LXfj0lgB3YKTLYhC0ghn3/2OCR2Ip9xyvd2ED92JA91JI92UZd2Zad1Jid2Uy92Zz91J792VId2qJd1aRd2lh92qh9q7i1IPy72iWdJB+SurAd0oV5rbVN0pT5IeCb2xnNtwDt250gEWApI2uc0C6GDRwxPDBHfc5XzSvyL9XgEjCBTyK3INc5sC/HKqZllMMwFEVxFJ86JecxvCB1aoYUDc4BADrUawPQz4H5FUMpOse1DOvtK+Itb/sxsG4BF3LRcsvgH4nxmMLtDn+RGah4hMAAIZNB4BThfT+3AL0NCtv5vQ3nGN5tDUw54EiHEAVnmKYwI3bca5iBDgLuS0dmE94nexLehx5wJNOXo27a/4cfeHMxLqOFl6NHXHYGQL/ECoBtN68Z7HbEaMQwEpr2+hmiURiHoQhedpbS64BnrCRVmnsBSIpkW+XSdx+2l6wWu30/zk5nUnq6S32pt0JsbKXaCpxiWhmvoQ4bjgi0Md4I8Z3/xx+7ByOeN6wmm+eUqoJ7LIYAvHrvqa0iDoBV22rrKXquBsmMOqmVOiC6sQ733eAdzp1S/rqinMoct+nNyLyHTlS59baDnJ6nuoClrqp8kXPjUOmWHhJ2/sSzWqUBGL9kO+tnx5sf+IHbB79h/p0bV7HYgebNDKypvhis3urcligOrhCxbsell1swch9yKwjRnqJiSIYsRKC7J/9UKFuccBicrhbOLITm2Gpzx77q60gO29Ed1t0XIx4KJnAk82y0tgFVQ7iI5QBXjoBJfBHvoMCFNjfhlRFPxAGH59GhjYcX//HuBT4N6+VSrlt0+20ODA4JEvLwz9AoGfJtnDOKpYgOI1IiVqnxxmBZGsIIuLggBQ0ONWJvkuB+Jo8KYJMnQPJMj6DNMhLL5SAhPekbzD3zonZu2HVZCtMjT7knNSTSRoIkCm8OaiJjlHBEQp9UgpIAEWmHmII8fDJrV5/hhHCPCugOhtLsiwCbeE0tRP9hAjYpA8cJ0oaVCLEpldDelBCLX5kIoeIzlJDcqKIqi9AqGuT3/YUtjiD/bUOiK5XXOZ/FYPa1ZMiCgYTALNsTCdJ2hwb2bdYiMnsGYKhVa8o2YaPj8RHt744AL/JCL0B4+rCTXtS1Rf5CYFUlVv50MFty9LGvEg4DMcFS8gAWNCiDMSkDdh8TMo0fWiaDMmLWMrU2fzNTM/KoM9Fv+DwF/ENTNC5TIEjTWU0TLMgvWlKTCFVjJ1dDk9Rgl+tCDTV/h2Lj8L5kNvaSNpdA9T2xJW+zUqwyN3VzNykGCAwFLREMAAQHBw4WAI0ECCwHCCEKjQxVQAIsCASNngAMFRUZnychig+fhwkNF5KdABkSYkwCCQgJBJWqjRihFSmHkAICup6IBwIHISeq/1pJMjEIMVBgvCkiBdqipAAWE60OqZ8QicoHEJ4MESIYCsiwnr7cjg0Ju7z5Fg4NCAgN8fIJHEiwoMGDCD9xCLDBAIUACSNKnJgQAit7xDImCkgxIQYJGrrl+6hBRLCOA9ftuJhg0ScFB1o1mMBIHTt4AhnU2KjKASdHiYSIMuQIgYN8IgoBUCAAgQB8QA8QaHYokQ12GDy9u5UgncACFXxyBFBOaiOmThX4khBBgogVW3GN/ZTUxoWZNV+yiicWlNJPyLzSjWAjkeCD7zbu44mysePGAQKQaDTgseXLehu4zAcPKmZe64iqyqBBQtbPx3jM2KwKgr1K31rpSioa5/+nB4lqiCZruCcCHbzKjl1XmNlL26p0IMghMLFxXgRm8Dhc9KiqE04O1AjC4PRxxrwUcDnixXO9e6oelfnLq6+qHAjIJIybK31v1Pgxb2A4gsPk/AAi5Bp6BRHAFXX5rdOOPCCJhJpwFRQQHivUKTBEFEcQMQV04CXjlwhL7ZVPAT4kMg5g9zVyghUzdPFJbBfMlYEoOxhl3llNPXVMIjuw14h7n8xYgRBcGcMZeEsRYE8R7NiHjkBNSIfgMTae5VMOTRJEn5GcvRbglxN5YEBkAZTwH5honkVhRAoASRABcyEkS1valObdZ6aYBUAKomhTgAhneLlCNtqwJQEV4MT/6BkyDijjSQZmAOGlKr8E42g+PjmgAFoCMLnEAwLcRVNOWVok1415FsNYaEmmaBOIZxl46pHJyNpVI0Iy8ANyn8wzipIEBsfVgbGI8pYqW944YQNTpulsI5ORAMJ+C2hJQEYZnfjsQQ9MKtEjcTZSlqsS+aKNg5hx6pkg2tCAgBESgFSan91pZSuXh/RjzwQXIHDBBD5E6Oc2Fex2wATFeCZAP5JMMEEI/jxBBA03rPDJoNoQsluSXGGLrSSnILAMCwL0IMMVCKAxhCcYD+KjvR17TEw/EE+CcEY4SBMDDQMPbKhoCrCSEZeLHRAzMTjIIIMSWRBzy85f+HmsQQMq/7vtlxR0sAAIFFBwpiowyqzt1QQp0hi4Aj1iHbBWf/bO2AOV81zanAw6dUH0aYTOPuJ8wu7AGwMAqi24sBDyyNg+cEIGfsobrwbznjvQOzITQ/TgxCBxg6GO+4lueNdWbuQJmA/9w989F1BvcBkN24A9sFBeeUaap965NqsjKyLZzo6wXwAfeAC6qHnxHhEij6Hd2k9arRkgjHALBEGzVIZrkOzFuH3tA8UbZLfFzvpyt/ETvcOaZS0XYOjnvEnVNvkAJgv/RMRYprwnZkPHvPbEf3b//AAMoADx4wsNtCBtXInebQSguAGy6V7vc+An6me/KgHgUpwxCmZghK8KWv9PgiAMoQgb4QIUoMAFzSGAAj3xgIf5IwQI494IG8HBCM7QQJgxVQJMRBDhoMQCoOoffv43wyIa0YEt0EDuUEI6TRwuBCSTIQAf4AAhHlFLCLDhfOCEEEatUEWgMpwkRtbBy5iCWVdMoxrhlwEUaOAF4NtgGJ/IgjICiIr8QsAcpKCGOJhgjQRpyfwIkMd/ecyFNmNg9/KzMBZoEZCQjKRjVvACDaCAfXIMFV7wowA89utf4lhIQx4iyeDsb35UFBtVnPWAC1zgi6WMpSwpUkDToClsKoTlQCwAAQGEDIZ9+0Rk/lOZWRblg8a8HgsaIIBkOvOZEyEJJlFDuRCETGT/1pwdtly4DAFAYJGf2M8G+vO1WRIRmgXpZQPmhs52uhM0L3vWAx4QOm0KQByPFBOZzPTMqhmTirosCguo986CQpNVBMlA4EYYrWkFoFrPDBoaIfmOQk4goIdApkE3akwGLDRIQzli1rbWtXIm85xFhFEwOcrSlmLmF9MUoO8iE7x3cvGIVLSiS3fK08aEAgYo7ClKBkdQZ3rSXxOwo1CXytSBYKAAESjAnZpqkDBqEJ1HBSVGqcrVproABgWbalfjhqQ0NvGQn5zASsfK1rbyoo1vjKNbaaXR+VW0ZjD02Frnyte+UtKSS+xrVIpKvrA1ULCITSwvfOFGOCr2Rwgg/+zVCKDTx1r2sX9FQQFSEFQ0gWAAAwABJEnmmNJlryOduaxqV+uLFsBAAxFAgQRUd5LPkKAEATAAboupRgqixHAfO8BWxVXW1Rp3tSkQhARQEAENwKAFm+1sRwYQgA40wgOiXaNvKQKByKoCgwdR23HHS15VuCAFg3htbGfLgNoiZCG5HYDwALld+rEgHx4K7ynLy9/+Jld9zHVuC8YnkAE8JDIcAKRrHsmL+jYCN8It0H77S+EKn1d9FXDuZvPxHw90ILeQTEACUKKnfIC3PROusIpV7AIGtIC5KGhBBoI6AANwYAEjCABv1aiAibLpxLzIn5Mku+IikxcD6IVBBP8q8II2sCEyG9jxGnGIEPrAsrsB4ZWRt8xlAAyKLSgg8BoVkEWD1LCLP9Fyl9e8ZQxkoJIVaIF71ShIgeR0k98SWYnZzGc2p6AFGX5BBsQ6w24RaB8WVepBIFDXPjuawoNirgQ+GkKJsmSvj860pjvS4pBeEQLn27SoR02RSpH61Khupwg0IN1Uu/rVkHwxrGdN6zTGuNa4zrUEXaBEXfv618bLQDyBTexiowahxk62sh+zjpgu+9nQzgcDWB3taltbILK+tra1fettexvavHb2t8dd6wyIm9zoTre6183udrv73fCOt7znTe962/ve+M63vvfN7377+98AD7jAB04X8IIb/OAIT7jCF87whjv84RCPuMSLGAgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The first step in the synthesis of type I collagen in bone is the production of alpha-1 and alpha-2 polypeptides. After many of the prolines and lysines in the collagen chains are hydroxylated to hydroxyproline and hydroxylysine, one alpha-2 (shown in red) and two alpha-1 polypeptides (shown in blue) wind around each other to form a helical structure known as procollagen (top). Amino- and carboxy-terminal propeptides of type I collagen are cleaved off the procollagen molecule, resulting in the formation of tropocollagen (bottom).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21550=[""].join("\n");
var outline_f21_2_21550=null;
var title_f21_2_21551="Hypercoagulability";
var content_f21_2_21551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Hypercoagulability",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Citrated rapid-TEG reflecting hypercoagulability. The red tracing indicates a normal study.",
"    <br>",
"     This study shows a shortened to normal ACT, R time, and K time, reflecting enzymatic hypercoagulability; high alpha angle, MA, and G, reflecting platelet hypercoagulability and/or excessive fibrin deposition; normal LY30. To distinguish the relative contribution of platelet hypercoagulability and excessive fibrin deposition, one would need to perform TEG platelet mapping or RoTEM&reg; fibrin function testing.",
"     <div class=\"footnotes\">",
"      R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_2_21551=[""].join("\n");
var outline_f21_2_21551=null;
